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Tumour metastasis initially requires invasion through the basement membrane and tissue 
migration towards the vascular system. During these stages cancer cells are thought to use actin 
rich protrusions called invadopodia to facilitate matrix and basement membrane degradation. 
p21-activated kinases (PAKs), a family of six serine/threonine protein kinases, have been linked 
to cell invasion and are found to be  amplified/overexpressed in a wide variety of human invasive 
cancer cell lines and tissue. PAK1 localises in invadopodia, and PAK4 in podosomes (a closely 
related structure). This study looks at the role of these two PAK isoforms in invadopodia 
formation and cellular invasion in melanoma. 
In this study a significant increase in the level of PAK1 and PAK4 expression in melanoma cell 
lines was demonstrated and both proteins were expressed in cell strains derived from patient 
samples. PAK1 overexpression correlated with melanoma cell line invasive potential, while both 
PAK1 and PAK4 overexpression occurred in cell lines and cell strains that formed invadopodia. 
Depletion of PAK1 and/or PAK4 expression resulted in a significant decrease in invasive capacity 
in melanoma cell lines and in an in vivo zebrafish invasion assay.  
Protein depletion experiments point to differential roles for PAK1 and PAK4 during the 
invadopodia lifecycle. The data suggest that PAK1 promotes the formation of this protrusion 
while PAK4 is more important for the maturation and matrix degradation activity of 
invadopodia. This is the first time that PAK4 has been shown to be involved in invadopodia 
activity. Furthermore, this study has identified a signalling pathway, unique to PAK4, which 
suggests that this protein inhibits the function of PDZ-RhoGEF to promote the formation and 
degradation of invadopodia.  
In conclusion, the data obtained from this study indicate that PAK1 and PAK4 play an important 
role in invadopodia activity and cellular invasion in melanoma. Distinct functions for each of 
these PAK isoforms in the invadopodia lifecycle has been established, with the identification of 
a novel PAK4 pathway involving the localised inhibition of PDZ-RhoGEF. PAK1 and PAK4 







I owe my sincerest and deepest gratitude to my supervisor, Dr. Claire Wells, for her unwavering 
guidance and encouragement. I learnt and grew so much as a researcher in your lab and would 
not have been able to complete this project without your help, support and infinite wisdom. I 
cannot thank you enough. I am also grateful to my second supervisor, Dr. Katie Lacy for all the 
advice and suggestions throughout my PhD and for access to patient melanoma samples. 
I am extraordinarily appreciative of all those who provided technical assistance and taught me 
a range of new research techniques. In particular, Simon Ameer-Beg for FRET, Joanna Richardson 
for zebrafish, Penny Morton for help with the RhoA biosensor, Panagiotis Karagiannis and Isioma 
Egbuniwe for patient tissue and for general help in the dermatology lab and finally the Hurlstone 
lab in Manchester for assistance with zebrafish xenografting and the spheroid assay. 
I would like to say a big thank you to everyone in the Wells lab both past and present. In 
particular, Fahim, Katerina and Nouf, thank you for making the lab a fun environment, for your 
friendship, your support and for being there through the ups and downs of my PhD. I will 
certainly miss our lunches. I would also like to acknowledge Mario, Sally, Fariesha, Helen and 
Anna.   
I am extremely grateful to all those in the office who have made the past three years a 
meaningful and enjoyable experience. In particular Yoli, thank you for being a good friend, for 
your help and support and for being there for a laugh and a chat. Ritu, I am forever grateful for 
your kindness, your encouraging words and for your absolute belief in my abilities. Jez, your 
guidance, technical support and advice were invaluable. Thank you for all your help and for being 
a smiling face in the lab. 
I heartily thank all those who have shared their knowledge, advised, taught and guided me in 
the biological research field over the years - in particular, Dr. Philippa Darbre, Dr. Simon Scott, 
Dr. Vadim Sumbayev, Professor Shaun Thomas, Dr. David Fear and Professor Anne Ridley. 
Lastly, and above all, I am extraordinarily grateful to my family. Mum, Janine and Beccy, thank 
you for your love and encouragement throughout my life. Sally, thank you for the past six years 
- for encouraging me, for believing in me, for showing me that anything is possible and for the 
steadfast help and support in all aspects of my life. Without you, none of this would have been 
possible.   
3 
 
Table of Contents 
 
Abstract .................................................................................................................... 2 
Acknowledgements .................................................................................................. 3 
Table of Contents ..................................................................................................... 4 
List of Figures ........................................................................................................... 8 
List of Tables ........................................................................................................... 10 
Abbreviations ......................................................................................................... 11 
1 Chapter 1 - Introduction ................................................................................... 13 
1.1 The Skin ............................................................................................................. 13 
1.2 Cutaneous Melanoma......................................................................................... 15 
1.2.1 Diagnosis of Melanoma....................................................................................... 17 
1.2.2 Breslow Thickness ............................................................................................... 17 
1.2.3 Staging - American Joint Committee on Cancer (AJCC) TNM Staging System .... 18 
1.2.4 Treatment ........................................................................................................... 20 
1.3 The Metastatic Cascade ...................................................................................... 20 
1.3.1 Mechanisms of Cell Invasion ............................................................................... 22 
1.3.2 Intravasation, Extravasation and Colonisation at Secondary Sites ..................... 25 
1.4 The Rho GTPase Family ....................................................................................... 25 
1.4.1 Rho GTPases are Major Regulators of Cell Motility ............................................ 27 
1.4.2 Rho GTPases are Central to Cancer Cell Invasion ............................................... 30 
1.5 Invadopodia ....................................................................................................... 31 
1.5.1 Invadopodia Formation ....................................................................................... 34 
1.5.2 Invadopodia Maturation ..................................................................................... 37 
1.6 p21-Activated Kinases ........................................................................................ 38 
1.6.1 PAK Domain Structure and Regulation of Activity .............................................. 40 
1.6.2 PAK Expression in Cancer .................................................................................... 43 
1.6.3 PAK1 and PAK4 in Invasion ................................................................................. 44 
1.6.4 Expression and Localisation of PAK1 and PAK4 .................................................. 46 
1.6.5 PAK1 and PAK4 Substrates .................................................................................. 47 
1.6.6 PAK1 and PAK4 in Invadopodia ........................................................................... 48 
1.7 Aims .................................................................................................................. 50 
2 Chapter 2 - Materials and Methods .................................................................. 51 
2.1 Materials............................................................................................................ 51 
2.1.1 General Materials................................................................................................ 51 
4 
 
2.1.2 Cell lines .............................................................................................................. 54 
2.1.3 Antibodies ........................................................................................................... 54 
2.1.4 Plasmids .............................................................................................................. 55 
2.1.5 Buffers ................................................................................................................. 56 
2.2 Methods ............................................................................................................ 56 
2.2.1 Cell Line Culture .................................................................................................. 56 
2.2.2 Thawing and Freezing Cells ................................................................................. 57 
2.2.3 Preparation of Ethanol Washed Coverslips ........................................................ 57 
2.2.4 Immunofluorescent Staining ............................................................................... 57 
2.2.5 Establishment and Isolation of Patient Derived Cell Strains ............................... 58 
2.2.6 Fluorescence Activated Cell Sorting (FACS) ........................................................ 59 
2.2.7 MTT Assay ........................................................................................................... 59 
2.2.8 Adhesion Assay ................................................................................................... 59 
2.2.9 Cell Morphology Analysis .................................................................................... 60 
2.2.10 Invadopodia Assay .............................................................................................. 60 
2.2.11 Gelatin Degradation Analysis .............................................................................. 61 
2.2.12 Fluorescence Intensity Co-Localisation Analysis ................................................. 61 
2.2.13 3D Spheroid Invasion Assay ................................................................................ 61 
2.2.14 Transfection ........................................................................................................ 62 
2.2.15 RNA Interference (RNAi) ..................................................................................... 62 
2.2.16 Cell Lysates .......................................................................................................... 63 
2.2.17 Western Blotting ................................................................................................. 63 
2.2.18 Fluorescence Resonance Energy Transfer (FRET) ............................................... 64 
2.2.19 Polymerase Chain Reaction................................................................................. 64 
2.2.20 Site Directed Mutagenesis .................................................................................. 66 
2.2.21 Zebrafish Embryo Maintenance .......................................................................... 67 
2.2.22 Zebrafish Yolk Invasion Assay ............................................................................. 67 
2.2.23 Imaging of Zebrafish Embryos ............................................................................. 68 
2.2.24 Statistical Analysis ............................................................................................... 68 
3 Chapter 3 – Characterisation of Melanoma Invasion ......................................... 69 
3.1 Introduction ....................................................................................................... 69 
3.2 Results ............................................................................................................... 70 
3.2.1 Characterisation of Melanoma Cell Lines ........................................................... 70 
3.2.1.1 Cell Morphology .............................................................................................. 70 
3.2.1.2 Invadopodia Assay as a Measure of Cell Invasiveness .................................... 73 
5 
 
3.2.1.3 Characterisation of Cellular Adhesion ............................................................ 76 
3.2.1.4 3D Spheroid Invasion Assay using Melanoma Cell Lines ................................ 79 
3.2.2 Characterisation of Melanoma Patient Derived Cell Strains .............................. 82 
3.2.2.1 Establishing Patient Derived Cell Strains ........................................................ 83 
3.2.2.2 Cell Morphology .............................................................................................. 86 
3.2.2.3 Patient Derived Cell Strains Form Invadopodia .............................................. 88 
3.2.2.4 The Invasion of Patient Derived Cells in the 3D Spheroid Invasion Assay ...... 91 
3.3 Discussion .......................................................................................................... 94 
4 Chapter 4 – Role of PAK1 and PAK4 in Melanoma Invasion ............................... 99 
4.1 Introduction ....................................................................................................... 99 
4.2 Results ............................................................................................................. 101 
4.2.1 PAK Isoform Expression in Melanoma Cell Lines .............................................. 101 
4.2.1.1 Group I PAKs - PAK1 and PAK2 are Overexpressed in Melanoma Cell Lines 102 
4.2.1.2 Group II PAKs  - PAK4 is Overexpressed in Melanoma Cell Lines ................. 105 
4.2.2 PAK1 and PAK4 are Overexpressed in Invasive Patient Derived Cell Strains .... 107 
4.2.3 siRNA Oligonucleotides can Transiently Reduce PAK1 and PAK4 Expression               
                  in A-375M2 and WM-115 Melanoma Cell Lines ............................................... 109 
4.2.4 PAK1 and PAK4 Depletion Reduces Invadopodia Formation and Degradation 113 
4.2.5 PAK1 and PAK4 Depletion Reduces 3D Melanoma Invasion ............................ 117 
4.2.6 Construction of GFPPAK1r Rescue Vector ........................................................ 120 
4.2.7 GFPPAK1r Rescues Invadopodia Formation and Degradation in WM-115           
                  Cells with Reduced PAK4 Expression ................................................................ 122 
4.2.8 GFPPAK4r Rescues Invadopodia Formation and Degradation in WM-115         
                  Cells with Reduced PAK4 Expression ................................................................ 124 
4.2.9 Reduction of PAK1 and PAK4 Expression in an In Vivo Zebrafish Yolk          
                  Invasion Assay ................................................................................................... 125 
4.2.9.1 Stable Reduction of PAK1 and PAK4 Expression in A-375M2 cells ............... 125 
4.2.9.2 PAK1 and PAK4 Depletion Reduces Invasion of A-375M2 cells In Vivo ........ 126 
4.3 Discussion ........................................................................................................ 131 
5 Chapter 5 – PAK1 and PAK4 have Converging and Unique Pathways in   
                              Melanoma Cell Invasion............................................................... 136 
5.1 Introduction ..................................................................................................... 136 
5.2 Results ............................................................................................................. 138 
5.2.1 GFPPAK4 Can Rescue Invadopodia Degradation in WM-115 Cells with      
                  Reduced PAK1 Expression................................................................................. 138 
6 
 
5.2.2 Overexpression of PAK4 Does Not Increase Invadopodia Formation                     
                  or Degradation .................................................................................................. 141 
5.2.3 Depletion of PAK4 Expression Does Not Reduce the Percentage of Cells                  
                  with Actin Puncta on Gelatin ............................................................................ 143 
5.2.4 Cell Shape is Unaffected by the Depletion of PAK1 and PAK4 Expression               
                  in WM-115 and A-375M2 Cells ......................................................................... 144 
5.2.5 Reduced PAK4 Expression Increases Prominent Actin Fibres in WM-115            
                  and A-375M2 Cells ............................................................................................ 146 
5.2.6 GFPPAK4r siRNA Resistant Vector Rescued the Prominent Actin Fibre       
                  Phenotype in PAK4 Diminished WM-115 Cells ................................................. 148 
5.2.7 A Reduction in PAK4 Protein Expression Leads to an Increase in                         
                  RhoA Activation ................................................................................................ 150 
5.2.8 PAK4 Does Not Signal Through GEF-H1 in WM-115 Cells ................................. 152 
5.2.9 PDZ-RhoGEF Dominant Negative Mutant Can Rescue the PAK4             
                  Knockdown Prominent Actin Fibre Phenotype ................................................ 154 
5.2.10 PDZ-RhoGEF∆DH Dominant Negative Mutant Can Rescue the               
                  Invadopodia Formation and Degradation in PAK4 Diminished Cells ................ 156 
5.2.11 Overexpression of PDZ-RhoGEF Mimics PAK4 Knockdown in Wildtype             
                  WM-115 Cells .................................................................................................... 158 
5.2.12 PDZ-RhoGEF and PAK4 Localise to Invadopodia ............................................... 160 
5.3 Discussion ........................................................................................................ 162 
6 Chapter 6 - Concluding Remarks ..................................................................... 168 
6.1 Future Work ..................................................................................................... 175 






List of Figures 
 
Figure 1-1: Diagrammatic representation of the human skin. ................................................... 14 
Figure 1-2: Melanoma radial and vertical growth phase. ........................................................... 16 
Figure 1-3: Diagram of the metastatic cascade. ......................................................................... 21 
Figure 1-4: Mechanisms of single cell and collective migration. ................................................ 23 
Figure 1-5: Control of Rho GTPase activity. ................................................................................ 27 
Figure 1-6: Rho GTPases in mesenchymal cell migration. .......................................................... 29 
Figure 1-7: Invadopodia as visualised in a 2D assay. .................................................................. 33 
Figure 1-8: Diagrammatic representation of a nascent and mature invadopodia. .................... 35 
Figure 1-9: Domain Structure of PAKs. ....................................................................................... 39 
Figure 1-10: Activation of group I and group II PAKs. ................................................................. 41 
Figure 3-1: Cell shape analysis of melanoma cell lines and normal melanocytes. ..................... 71 
Figure 3-2: Quantification of the percentage of cells with prominent actin fibres. ................... 72 
Figure 3-3: Co-localisation of cortactin with F-actin and TRITC gelatin degradation. ................ 73 
Figure 3-4: Representative invadopodia assay images of melanoma cell lines and melanocyte 
controls. .................................................................................................................... 75 
Figure 3-5: Invadopodia assay of melanoma cell lines and melanocyte controls. ..................... 76 
Figure 3-6: Adhesion assay on glass and collagen I. ................................................................... 78 
Figure 3-7: MTT assay of the melanoma cell lines. ..................................................................... 80 
Figure 3-8: 3D spheroid invasion assay of melanoma cell lines.................................................. 81 
Figure 3-9: HMWMAA staining of patient derived tissue populations. ...................................... 84 
Figure 3-10: Fluorescence activated cell sorting (FACS) confirming the purity of melanoma cell 
in patient derived cell strains. ................................................................................... 85 
Figure 3-11: Cell shape analysis of patient derived cell strains. ................................................. 87 
Figure 3-12: Representative images of the patient derived cell strain invadopodia assay at 24 
hrs. ............................................................................................................................ 89 
Figure 3-13: 3 hrs and 24 hrs Invadopodia assay of patient derived cell strain and neonatal 
melanocyte (1) control. ............................................................................................. 90 
Figure 3-14: 3D spheroid invasion assay of patient derived cell strains compared to neonatal 
melanocytes (1)......................................................................................................... 92 
Figure 4-1: PAK Protein expression in neonatal and adult melanocytes. ................................. 102 
Figure 4-2: Group I PAK protein expression in melanoma cell lines. ........................................ 104 
Figure 4-3: Group II PAK protein expression in melanoma cell lines. ....................................... 106 
Figure 4-4: PAK1 and PAK4 protein expression in patient derived cell strains. ........................ 108 
Figure 4-5: Transient reduction of PAK1 and PAK4 expression in the WM-115 cell line. ......... 111 
Figure 4-6: Transient reduction of PAK1 and PAK4 expression in the A-375M2 cell line. ........ 112 
Figure 4-7: Representative invadopodia assay images of WM-115 cells in which PAK1 and PAK4 
proteins are knocked down (individually and simultaneously). ............................. 114 
Figure 4-8: Representative invadopodia assay images of A-375M2 in which PAK1 and PAK4 
proteins are depleted (individually and simultaneously). ...................................... 115 
Figure 4-9: Invadopodia assay with WM-115 and A-375M2 cells in which PAK1 and PAK4 
expression was depleted (individually and simultaneously). ................................. 116 
8 
 
Figure 4-10: Representative images at day 0 and day 3 of the 3D spheroid invasion assay in 
WM-115 and A-375M2 cells in which PAK1 and PAK4 have been knocked down 
(individually and simultaneously). .......................................................................... 118 
Figure 4-11: 3D spheroid invasion assay of WM-115 and A-375M2 cell lines in which PAK1 and 
PAK4 have been knocked down (individually and simultaneously). ....................... 119 
Figure 4-12: Construction of the GFPPAK1r rescue vector. ...................................................... 121 
Figure 4-13: Confirmation of siRNA resistant proteins in siRNA depleted WM-115 cells. ....... 122 
Figure 4-14: Invadopodia assay of PAK1 depleted WM-115 cells expressing GFPPAK1r. ........ 123 
Figure 4-15: Invadopodia assay of PAK4 depleted WM-115 cells expressing GFPPAK4r. ........ 124 
Figure 4-16: Stable Reduction of PAK1 and PAK4 in the A-375M2 cell line. ............................ 126 
Figure 4-17: Cell invasion in a zebrafish embryo 4 dpi with A-375M2 control shRNA. ............ 127 
Figure 4-18: Representative phase contrast and fluorescent images of the In vivo zebrafish yolk 
invasion assay. ........................................................................................................ 129 
Figure 4-19: In vivo zebrafish yolk invasion assay using PAK1 and PAK4 stably depleted A-
375M2 cells. ............................................................................................................ 130 
Figure 5-1: Invadopodia assay of WM-115 cells with diminished PAK1 protein expressing 
GFPPAK4. ................................................................................................................. 139 
Figure 5-2: Invadopodia assay of WM-115 cells with diminished PAK4 protein expressing 
GFPPAK1. ................................................................................................................. 140 
Figure 5-3: Invadopodia assay of WM-115 cells expressing GFPPAK4. .................................... 142 
Figure 5-4: The percentage of WM-115 and A-375M2 cells with actin puncta on gelatin when 
PAK1 and PAK4 expression was depleted (individually and simultaneously). ........ 143 
Figure 5-5: Cell shape analysis of PAK1, PAK4 and PAK1&PAK4 depleted WM-115 and A-375M2 
cells. ........................................................................................................................ 145 
Figure 5-6: Percentage of WM-115 and A-375M2 cells with prominent actin fibres in PAK1 and 
PAK4 knockdown (individually and simultaneously) on glass and gelatin.............. 147 
Figure 5-7: Percentage of cells with prominent actin fibres in PAK4 knockdown A-375M2 cells 
transfected with GFPPAK4r siRNA resistant rescue construct. .............................. 149 
Figure 5-8: Percentage of cells with prominent actin fibres in PAK1 and PAK4 knockdown (both 
individually and simultaneously) in A-375M2 RhoA cells. ...................................... 151 
Figure 5-9: FRET analysis of RhoA activation in A-375M2 RhoA cells in which PAK1 and PAK4 
expression was diminished. .................................................................................... 152 
Figure 5-10: The expression of p-GEF-H1 (Ser885) in WM-115 cells with reduced expression of 
PAK1 and PAK4 (individually or simultaneously). ................................................... 153 
Figure 5-11: Percentage of cells with prominent actin fibres in PAK4 reduced WM-115 cells 
expressing myc-PDZ-RhoGEF∆DH on gelatin. ......................................................... 155 
Figure 5-12: Invadopodia assay of PAK4 knockdown WM-115 cells expressing myc-PDZ-
RhoGEF∆DH. ............................................................................................................ 157 
Figure 5-13: Invadopodia assay of WM-115 cells expressing myc-PDZ-RhoGEF. ..................... 159 
Figure 5-14: Co-localisation of GFPPAK4 and myc-PDZ-RhoGEF (wildtype and ∆DH mutant) with 
F-actin and TRITC gelatin degradation. ................................................................... 161 
Figure 6-1: Possible functions for PAK1 and PAK4 in the invadopodial lifecycle. ..................... 171 




List of Tables 
 
Table 1-1: American Joint committee on Cancer (AJCC) TNM Staging System .......................... 19 
Table 2-1: General Reagents. ...................................................................................................... 53 
Table 2-2: Cell lines. .................................................................................................................... 54 
Table 2-3: Primary Antibodies. ................................................................................................... 54 
Table 2-4: Secondary Antibodies. ............................................................................................... 55 
Table 2-5: Plasmid Constructs. .................................................................................................... 55 
Table 2-6: Solutions and buffers (working concentrations)........................................................ 56 
Table 2-7: siRNA oligonucleotides and shRNA constructs used in this study. ............................ 63 
Table 2-8: The sequence of the primers used in this study. ....................................................... 65 
Table 3-1: Collation of the melanoma cell line and melanocyte invasive phenotypes in the 2D 
and 3D invasion assay. ................................................................................................. 82 
Table 3-2: Clinical data for all successfully established patient cell strains. ............................... 86 
Table 3-3: Collation of the patient derived cell strains and neonatal melanocytes (1) invasive 
phenotypes in the 2D and 3D invasion assay. ............................................................. 93 
Table 4-1: Collation of the trends of invasiveness and the PAK expression of melanoma cell 
lines............................................................................................................................ 107 
Table 4-2: Collation of the patient derived cell strains and neonatal melanocytes (1) invasive 








AID Autoinhibitory domain 
BPE Bovine pituitary extract 
BSA Bovine serum albumin 
C. elegans Caenorhabditis elegans 
c-Src Cellular Src 
CIP4 Cdc42-interacting protein 4 
CO2 Carbondioxide 
DH domain Dbl homology domain 
DHR1/2 DOCK Homology Region 1/2 
DMEM F-12 Ham Dulbecco's modified eagle's medium: nutrient F-12 ham 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTPs Deoxyribonucleotide triphosphates 
Dpf Days post-fertilisation 
Dpi Days post injection 
DQ Dequenched 
E. coli Escherichia coli 
ECL Enhance chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
F-actin Filamentous actin 
FACS Fluorescence activated cell sorting 
FRET Fluorescence resonance energy transfer 
FLIM Fluorescence lifetime imaging microscope 
FBS foetal bovine serum 
Fwd Forward 
G-actin Globular actin 
GAPs GTPase-activating proteins 
GBD GTPase binding domain 
GDIs Guanine nucleotide-dissociation inhibitors 
GEFs Guanine nucleotide exchange factors 
GID GEF interacting domain  
H2O Water 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGF Hepatocyte growth factor  
HMWMAA High molecular weight melanoma associated antigen 
Hpf Hours post-fertilisation 
Hr(s) Hour(s) 
IQGAP1 IQ motif containing GTPase activating protein 1 
kDa Kilodaltons 
LB Luria-Bertani 
LIMK Lim Kinase 
MAP Mitogen activated protein 
MEM minimum essential medium 




miRNA Micro ribonucleic acid 
MLC Myosin light chain 
MLCK Myosin light chain kinase  
MMP Matrix metalloprotease 
MTOC Microtubule organising centre 
MTT Methylthiazolyldiphenyl-tetrazolium bromide 
NaCl Sodium chloride 
Nck1 Non-catalytic region of tyrosine kinase adaptor protein 1 
NCS Newborn calf serum 
N-WASP N-wiskott-aldrich syndrome protein 
OPCs Oligodendrocyte progenitor cells 
PAK p21 activated kinase 
PBS+/+ Phosphate buffer saline plus calcium and magnesium 
PBS-/- Phosphate buffer saline minus calcium and magnesium 
PDGF Platelet derived growth factor 
PFA Paraformaldehyde 
PGE2 prostaglandin E2 
PH domain Pleckstrin domain 
PMA phorbol 12-myristate 13-acetate 
PTU N-phenylthiourea 
REF52 Rat embryonic fibroblast 
Rev Reverse 
RGP Radial growth phase 
Rpm Revolutions per minute 
RNAi Ribonucleic acid interference 
ROCK Rho-associated protein kinase 
SCC Squamous cell carcinoma 
SEM Standard error of the mean 
siRNA Short interfering ribonucleic acid 
shRNA Short hairpin ribonucleic acid 
TAE Tris Acetate-EDTA 
TBST Tris-buffered saline with Tween-20 
TCSPC Time-correlated single-photon counting 
TE Tris/EDTA 
UV Ultraviolet 
VGP Vertical growth phase 






1 Chapter 1 - Introduction 
  
1.1 The Skin 
 
The skin is the largest human organ and has many functions such as providing a physical barrier 
against pathogens, thermoregulation, sensation and vitamin production. This organ is made up 
of 2 layers, the dermis and epidermis, both of which serve vital functions. The epidermis is a 
dynamic structure, typically 0.05-0.1mm thick (Rook, 2010). It contains 95% keratinocytes and 
consists of multiple sub-layers, commonly referred to as stratum (Rook, 2004). Continual 
proliferation at the base of the epidermis (the stratum basale), moves keratinocytes outwards, 
until they are lost to the external environment at the outer most sub-layer, the stratum corneum 
(Figure 1-1) (Rook, 2010). Above the stratum basale, keratinocytes initiate the production of 
keratin, thus forming the layer known as the stratum spinosum. Following this, the keratinocytes 
produce keratohyalin granules in the stratum granulosum, and then lose their nuclei and 
organelles to become dead corneocytes in the stratum corneum (Rook, 2010). This process 
collectively called cornification, provides the strength and near impermeability of the skin.    
The remaining 5% of the epidermis consists of melanocytes, Langerhans’ cells and Merkel cells. 
Melanocytes and Merkel cells are both situated at the base of the stratum basale. Melanocytes, 
which account for 10% of the cell population of the stratum basale, produce melanin which is 
transported to the surrounding keratinocytes providing protection against ultraviolet (UV) light. 
Merkel cells contain mechanoreceptors which sense light tactile sensations (Maricich et al., 
2009). Conversely, Langerhans’ cells can be found throughout the epidermis and function as 
antigen-presenting cells (Katz et al., 1985). 
The dermis, which is located below the epidermis, consists of fibroblasts, adipocytes and 
macrophages. The main functions of this layer are to supply gaseous and nutrient exchange to 
the epidermis, as well as to provide a supportive matrix to prevent any damage from 
environmental forces. This support, which amounts to 18-30% of the dermis volume, is primarily 
provided by collagen type I and III, secreted by the dermal fibroblasts (Rook, 2004). Lastly, a 
subcutaneous fat layer is situated below the dermis and this provides insulation. Underneath 






Figure 1-1: Diagrammatic representation of the human skin.  
(A) The skin is made up of the epidermis and dermis, followed by a layer of subcutaneous fat. (B) The 














1.2 Cutaneous Melanoma 
 
Melanoma arises from the neoplastic growth of melanocytes, and originates de novo or, in 50% 
of cases, from existing naevi (moles) (Bishop et al., 2007). Despite an average age of diagnosis 
of 50, 20% of patients are diagnosed in adolescence (Bishop et al., 2007), with a steady increase 
in the incidence rate from the age of 20 onwards (Cancer Research UK, 2014). Melanoma 
accounts for <2% of all skin cancers and has a total lifetime risk of 1 in 34 for men and 1 in 53 
for women (American Cancer Society, 2014). However, it is estimated that ~79% of skin cancer 
deaths in 2011, in the UK, were attributable to melanoma (Cancer Research UK, 2014). 
Melanomas diagnosed in young individuals are most commonly found on areas that receive high 
intensity sun exposure, such as the trunk in men and legs in women (Whiteman et al., 2011). 
However, when diagnosed at an older age, melanoma is more commonly found on areas that 
receive consistent sun exposure, such as the head and neck (Whiteman et al., 2011). The main 
contributing factors for increased risk of melanoma are: large number of naevi (being the highest 
factor), having a family history of melanoma, fair skin that is susceptible to sun burning and 
freckling, and intense sun exposure during childhood (Whiteman et al., 2011).  
Initial transformation of melanocytes result in increased growth at the stratum basale in a 
horizontal manner, known as the radial growth phase (Figure 1-2) (Whiteman et al., 2011). 
Following radial growth, the tumour cells develop invasive potential and can grow into the 
remaining upper epidermis layers (invasive radial growth phase). Finally, cells can enter the 
vertical growth phase, resulting in the breach of the epidermal-dermal junction and invasion 
into the dermis layer. The vertical growth phase brings the tumour mass within close proximity 
to the blood and lymphatic vasculature, greatly increasing the risk of metastasis. During this 
stage, tumour infiltrating lymphocytes often elicit an immune response. In some cases, this 
immune response can eliminate the primary tumour. However, in other cases the immune 




Figure 1-2: Melanoma radial and vertical growth phase. 
Melanoma arises from the growth of melanocytes in the stratum basale layer of the epidermis. Melanoma 
grows within the stratum basale in a horizontal manner, known as the radial growth phase. Cells become 
invasive and grow into the epidermis (invasive radial growth phase) Following this, the cells invade 
through the epidermal/dermal basement membrane and grow vertically into the dermis. This is known as 
the vertical growth phase. 
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1.2.1 Diagnosis of Melanoma 
 
As cutaneous melanomas can be seen on the exterior surface of the body, a high proportion are 
first identified by the patient using the well publicised ‘ABCDE’ monitoring guide. This guide 
recommends that medical advice be sought if a skin pigmentation has the following 
characteristics: Asymmetry; Border irregularity; Colour variation; Diameter larger than 5mm; 
and Evolution from the original characteristic (Neila and Soyer, 2011).  
The first stage of diagnosis involves a biopsy. Unlike other cancers, the entire mass and a 2mm 
normal skin margin is surgically excised (Marsden et al., 2010). Positive primary biopsies result 
in further excision of a larger margin of up to 3cm normal skin (Marsden et al., 2010). 
Additionally, a sentinel node biopsy is performed via the injection of a radioisotope and blue dye 
solution directly into the excision site to identify the closest drainage lymph nodes (sentinel 
node). The dyed and radiation positive nodes are surgically removed and analysed for the 
presence of metastasis. If the sentinel nodes show evidence of the melanoma, the entire 
surrounding lymph nodes are removed. Diagnosed melanomas are assigned a Breslow thickness 
(described below) and a Staging in order to assess the relevant treatment.  
 
1.2.2 Breslow Thickness 
 
 A direct link between melanoma thickness and prognosis was first described in 1970 by 
Alexander Breslow (Breslow, 1970). This was quickly adopted and the Breslow thickness is still 
in use today as a reliable classification of melanoma. This classification measures the thickness 
(in millimetres) of the tumour from the stratum granulosum to the deepest invaded tumour 
cells. The Breslow thickness is grouped into the following categories: <1mm; 1.01-2mm; 2.1-
4mm; and >4mm. The survival rates greatly diminish in each group from a 5-year survival rate 
of 95-100% for <1mm to 37-50% for >4mm Breslow thickness (Melanoma Research Foundation 
2011). The poor prognosis of tumours with a Breslow thickness of >4mm is due to a 50% higher 
risk of metastasis, compared to other thicknesses (Marsden et al., 2010). This grading system is 
also used to indicate the clinical excision margins, ranging from 1cm for a thickness of <1mm to 




1.2.3 Staging - American Joint Committee on Cancer (AJCC) TNM Staging 
System 
 
The AJCC TNM staging system was first published in 2001 and has continued to be updated in 
subsequent years, providing relevant staging for cutaneous melanoma (Balch et al., 2001; Balch 
et al., 2009). Within this system the independent prognostic factors such as the Breslow 
thickness, presence of ulceration and mitotic rate, as well as the site and number of metastases 




Stage Primary Tumour (T) Lymph Nodes (N) Metastasis (M) 
IA < 1mm, no ulceration, mitoses < 1 
mm-2 
  
IB < 1mm, with ulceration or mitoses 
≥ 1 mm-2 
 
1.01 - 2mm, no ulceration 
  
IIA 1.01 - 2mm, with ulceration 
 
2.01 - 4mm, no ulceration 
  
IIB 2.01 - 4mm, with ulceration 
 
> 4mm, no ulceration 
  
IIC > 4mm, with ulceration   





IIIB Any Breslow thickness, with 
ulceration 
 
Any Breslow thickness, no 
ulceration 
 









No nodes, but in-
transit or satellite 
metastasis/es 
 
IIIC Any Breslow thickness, with 
ulceration 
 





Any Breslow thickness, with 
ulceration 
1-3 palpable 
metastatic nodes  
 
≥ 4 metastatic nodes 




No nodes, but in-
transit or satellite 
metastasis/es 
 
IV, M1a   Skin, subcutaneous 
or distant nodal 
disease 
IV, M1b   Lung metastasis 
IV, M1c   All other sites or any 











The survival rate for patients suffering from early stage (no metastasis) melanoma is extremely 
high, with a five year survival of 98%. However, around 16% of patients presenting with 
melanoma will go on to develop metastatic disease (American Cancer Society, 2014). Once 
melanoma metastasises the available therapies provide little effective treatment with the five 
year survival rate decreasing to 62% for regional metastasis (the surrounding tissue) and 16% 
when distant metastasis has occurred (American Cancer Society, 2014).  This emphasises the 
need for further research into new therapeutic targets for metastatic melanoma.  
Metastatic melanoma has a very low median survival time of 6-9 months, with the worst survival 
rate of 3-4 months predicted for bone, liver and brain metastases (Becker et al., 2000). 
Metastasis to distant lymph nodes, lungs or the skin have an increased median survival of 12-15 
months, as these sites show a better response to treatments with chemotherapy medications 
(Becker et al., 2000). 
The current treatments, post-excision, for metastatic melanoma are chemotherapy: 
Dacarbazine, Vemurafenib and Ipilimumab. Radiotherapy is also commonly used for bone and 
brain metastases. Even with these treatments the patient survival rates for metastatic 
melanoma is less than a year. In fact, due to the lack of effective treatments for metastatic 
disease some patients with late stage IV disease often receive only palliative treatment. 
Further investigations are therefore required to increase our understanding of metastatic 
melanoma such that the transition from localised to metastatic disease can be prevented. 
 
1.3 The Metastatic Cascade 
 
Metastasis, the growth of tumour cells at a distant site to that of the primary tumour, is the 
most life threatening aspect of human cancers, accounting for >90% of mortalities (Sahai, 2005; 
Valastyan and Weinberg, 2011). The successful metastatic growth of tumour cells is a rare 
occurrence, with <0.01% of the total cells which enter blood vessels resulting in the formation 
of a secondary tumour in animal models (Chiang and Massague, 2008). This is unsurprising as 
metastasis is a multistep process in which the metastatic tumour cells must survive and adapt 
to a wide variety of different environments. This process includes invasion through the 
basement membrane and surrounding tissue, entrance into blood vessels (intravasation) or 
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lymph vessels, exiting of the blood vessels (extravasation) into distant tissue and growth at this 
site (Figure 1-3) (Nguyen et al., 2009). In addition, these steps rely on a multitude of pathways 
in which the manipulation of cell motility, cytoskeletal remodelling and cellular adhesion play 
prominent roles (Yilmaz and Christofori, 2009). Understanding these processes is crucial for the 
treatment and/or prevention of metastatic disease.   
 
 
Figure 1-3: Diagram of the metastatic cascade. 
Tumour cells grow at the primary site. Some cells acquire an invasive metastatic phenotype that enable 
the invasion through the basement membrane and into the surrounding normal tissue. These cells can 
intravasate into blood vessels or into lymphatic system where they disseminate throughout the body. At 







1.3.1 Mechanisms of Cell Invasion 
 
In normal cells, migration is achieved through co-ordinated control of cytoskeleton dynamics, 
cell-cell status and cell-matrix adhesion turnover. To migrate, cells become polarised, producing 
a clear front characterised by protrusions such as filopodia (thin finger-like protrusions) or 
lamellipodia (broad protrusions), and a contractile rear (uropod). These protrusions are 
extended and anchored to the extracellular matrix (ECM) by cell adhesions that create a traction 
force for forward movement (Friedl and Alexander, 2011). In contrast, at the rear, the cell 
adhesions are dissolved and the membrane retracted to promote forward movement (Friedl and 
Alexander, 2011; Ridley, 2011).   
During the initial stage of metastasis, cells break away from the primary mass and interact with 
the surrounding tissue. In order to invade through underlying tissue, cells migrate by adapting 
their cell shape, cell-cell adhesions and adhesions to the ECM. To reach the blood or lymph 
vessels, tumour cells must migrate and invade through the underlying ECM. Invasive protrusions 
called invadopodia (which are discussed in more detail in section 1.5) are used to degrade the 
ECM to aid the invasion of tumour cells through the basement membrane and the surrounding 
tissue. Other cell types in the tumour microenvironment can also control the invasive potential 
of tumour cells. For example, cells located in the surrounding stroma, such as fibroblasts and 
infiltrating immune cells, can secrete factors that enhance the metastatic phenotype of the 
invading cells (Goswami et al., 2005; Joyce, 2005). In addition, these cells can directly modulate 
the ECM structure by the secretion of proteases to aid the invasion of tumour cells (Sahai, 2005) 
and guide tumour cells to the surrounding blood vessels where they also assist in intravasation 
(Wyckoff et al., 2007). 
Tumour cells are thought to migrate through the ECM via two methods, as individual cells (single 
cell migration) or as a collective group (collective migration) (Figure 1-4) (Friedl and Wolf, 2003; 
Sanz-Moreno and Marshall, 2010). These methods of migration are not mutually exclusive and 
can occur simultaneously in tumours (Friedl and Wolf, 2003).  
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 Figure 1-4: Mechanisms of single cell and collective migration.  
Cells can invade either individually (single cell migration) or collectively (collective cell migration), each of 
which occurs via different mechanisms. Single cell migration can be separated into mesenchymal, with an 
elongated cell shape that uses protease degradation, and amoeboid cell movement, with a highly 
contractile cell shape that invades independent of protease degradation. In collective cell migration a 
group of cells invade in either a small cluster, file (line of cells) or a sheet, all utilising cell-cell adhesions 








Single cell migration utilises two interchangeable mechanisms, mesenchymal and amoeboid 
(Figure 1-4) (Sanz-Moreno and Marshall, 2010). Cells using mesenchymal migration have an 
elongated polarised cellular structure similar to that seen by migrating non-tumourigenic cells. 
Unlike normal cells, tumour cells that adopt the mesenchymal mechanism of migration rely on 
protease degradation of the ECM (via invadopodia protrusions) to enable invasion. In addition, 
this mode of migration is often triggered by receptor tyrosine kinases, including c-MET (by 
hepatocyte growth factor (HGF)).  
In contrast, the amoeboid mechanism of migration is protease independent and relies on a 
highly contractile, rounded cell shape that allows cells to squeeze through strands of ECM. This 
high contractile force is often accompanied by membrane blebbing due to hydrostatic pressure 
that disconnects cortical actin from the plasma membrane (Lammermann and Sixt, 2009). In 
addition, amoeboidal cells often have weak cell-matrix adhesions, with small adhesions rather 
than the large stable focal adhesions used by non-tumourigenic cells.   
While both forms of migration facilitate invasion, the amoeboidal mechanism is thought to be 
associated with an increased invasive potential compared to mesenchymal migration (Gadea et 
al., 2008; Calvo et al., 2011). These forms of migration are not fixed, and metastatic cells, 
especially metastatic melanoma, have high plasticity, switching between these to allow for the 
most appropriate mode of migration (Sahai and Marshall, 2003; Sanz-Moreno et al., 2008). This 
plasticity is also seen in vivo, with cells from tumour samples exhibiting both amoeboidal and 
mesenchymal morphologies (Rosai and Ackerman, 2004).  
Collective migration involves the movement of multiple cells which invade as a collective group. 
The overall structure of the collective mass can vary depending on the number of cells, the 
structure of the tissue that is being invaded and also the cell type, resulting in the formation of 
cell clusters, files or sheets (often found in melanoma) (Figure 1-4) (Geiger and Peeper, 2009; 
Friedl and Alexander, 2011). Within these groups, cell-cell and cell-matrix adhesion components 
such as cadherins and integrins, respectively, are present and aid migration (Sahai, 2005). 
Cadherins, which are the major transmembrane component of adherens junctions, bind 
adjacent cells to form cell-cell adhesions, while integrins are transmembrane proteins that bind 
the ECM and connect the external matrix with the cytoskeleton to form cell-matrix adhesions. 
The collective migration of melanoma clusters through 3D collagen I matrices are highly 
dependent on β1 integrin (Hegerfeldt et al., 2002). In this form of migration, ‘leader’ cells are 
often found at the front of the group, and these cells exhibit similar characteristics to 
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mesenchymal migration, generating forward traction and using pericellular protease 
degradation to form a track in which the following cells can migrate (Friedl and Alexander, 2011).  
 
1.3.2 Intravasation, Extravasation and Colonisation at Secondary Sites 
 
In order to form a secondary tumour at a distant site cancer cells must pass from the tissue, 
through the basement membrane and into blood vessels (intravasation) or into the lymph ducts. 
Tumour cells can directly orient their migratory direction towards that of blood vessels (Sahai, 
2007). This directional migration may be induced by tumour associated macrophages, that can 
be found clustered around blood vessels, and may provide an epidermal growth factor (EGF) 
chemotactic gradient that attracts tumour cells (Wyckoff et al., 2007).  
When at the blood vessels, tumour cells can transmigrate either between endothelial cells 
(paracellular) or through endothelial cells (transcellular) (Reymond et al., 2013). The cell shape 
and mechanism of migration can influence this step of metastasis, as amoeboid cells are more 
efficient at transmigration than their mesenchymal counterparts (Sahai et al., 2007). Cells can 
also exit the primary tissue through intravasation into the lymphatic system where they can 
form metastatic growths in the lymph nodes or drain into the cardiovascular system.  
Once inside blood vessels, tumour cells must evade intracellular anchorage dependent cell 
death (anoikis), as well as death from shear stress and from the immune system (Valastyan and 
Weinberg, 2011). To reach the secondary tissue, cells have to adhere to the blood vessel wall, 
or become lodged in small capillaries, to become stationary. Once this occurs, cells transmigrate 
across the endothelial wall (extravasate) and initiate colonisation and cell growth (Reymond et 
al., 2013). 
 
1.4 The Rho GTPase Family 
 
Actin cytoskeletal dynamics is an essential part of cell motility and it is regulated largely by Rho 
family GTPases. The Rho GTPase family are proteins of the Ras related superfamily of small 
GTPases and contain 20 members. These proteins interact with a range of different effectors 
including protein kinases, actin nucleators and phospholipases to exert their functions (Heasman 
and Ridley, 2008). The three most characterised Rho GTPases are Cdc42, Rac1 and RhoA, and 
these will be discussed in more detail herein.  
25 
 
The control of Rho GTPase activity is governed by guanine nucleotide exchange factors (GEFs), 
GTPase-activating proteins (GAPs) and guanine nucleotide-dissociation inhibitors (GDIs). Rho 
GTPases cycle between an inactive, GDP bound state, and an active, GTP bound state (Jaffe and 
Hall, 2005). GEFs catalyse the dissociation of GDP and formation of GTP bound, active Rho 
GTPases (Rossman et al., 2005). Most GEFs, which are part of the Dbl family, contain two 
representative domains; the Dbl Homology (DH) domain that functions in the catalysis of Rho 
GTPases; and the Pleckstrin Homology (PH) domain, which cooperates with the DH domain to 
aid its catalytic activity and binds phospholipids to localise the GEF to the plasma membrane 
(Rossman et al., 2005). Other GEFs, such as the DOCK family of GEFs, have the DOCK Homology 
Region 1 (DHR1) which targets the protein to the membrane through phospholipid binding, and 
the catalytic domain DOCK Homology Region 2 (DHR2) which is responsible for the GEF activity 
(Goicoechea et al., 2014). 
Conversely, GAPs increase the rate of GTP hydrolysis to promote the formation of inactive, GDP 
bound Rho GTPases. These proteins are characterised by the presence of a Rho GAP domain 
which binds the GTP binding site of Rho GTPase when GTP is bound. 
GDIs function differently to GEFs and GAPs by binding the Rho GTPases and sequestering the 
protein in the cytosol in the GDP bound state, thus inhibiting the activation (Rossman et al., 
2005). In addition, it is believed that GDIs also prevent the release of GDP and thus the binding 





 Figure 1-5: Control of Rho GTPase activity. 
Rho GTPases, which are tethered to the plasma membrane, cycle between an inactivated GDP bound 
protein and a GTP bound activated protein. Rho GTPases are activated using GEFs and inactivated by 




1.4.1 Rho GTPases are Major Regulators of Cell Motility 
 
The Rho family GTPases, which include Cdc42, Rac1 and RhoA, are able to control actin 
polymerisation dynamics and organisation to protrude the plasma membrane and thus elicit cell 
movement (Jaffe and Hall, 2005).  
Actin exists as either free globular actin (G-actin) monomers or as filamentous actin (F-actin) 
bound to other actin monomers in a polymeric fashion. Actin polymerisation consists of the 
addition of G-actin at sites of nucleation on actin filaments referred to as barbed ends, the result 
being filament elongation. The addition of the monomeric actin to F-actin is controlled by the 
Arp2/3 complex (which is activated by Rac1 and Cdc42) or formins such as Diaphanous-related 
formin (mDia) (which is activated by RhoA) (Jaffe and Hall, 2005; Le Clainche and Carlier, 2008). 
The polymerisation of F-actin occurs via a ‘treadmilling’ method involving the polarised addition 
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of G-actin at barbed ends along with the depolymerisation of F-actin to G-actin at the pointed 
end creating movement of the filament in the direction of polymerisation (Le Clainche and 
Carlier, 2008). The depolymerisation at the pointed end requires the actin severing protein 
cofilin. Cdc42, Rac1 and RhoA can all control cofilin activity. ROCK activation via RhoA can 
activate LIM kinase (LIMK), while Cdc42 and Rac1 can activate LIMK via PAK activation. Activated 
LIMK phosphorylates and inhibits the activation of cofilin. 
ROCK activation via RhoA also directly phosphorylates and activates myosin light chain (MLC) 
and inhibits MLC inactivation by the phosphorylation and inhibition of myosin phosphatase (an 
inactivator of MLC) to enhance myosin induced actin contractility (O'Connor and Chen, 2013).   
The control of the actin cytoskeletal dynamics, including actin polymerisation and actomyosin 
contraction are essential for cell movement. During migration, cells form protrusions 
(lamellipodia and filopodia) at the leading edge (Figure 1-6). Rac1 functions to produce broad 
protrusions called lamellopodia (containing branched actin filaments), and to form focal 
adhesions, at the leading edge of the cell (Nobes and Hall, 1995; Nobes and Hall, 1999). The 
formation of these focal adhesions provides a connection between the ECM and the 
cytoskeleton which enables cells to generate a traction force, which is translated into forward 
movement. Rac1 activation at the rear has also been implicated in tail retraction in motile 
neutrophils (Gardiner et al., 2002). 
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 Figure 1-6: Rho GTPases in mesenchymal cell migration. 
In mesenchymal cell migration, Rac1 forms lamellopodia protrusions which cause directional movement. 
Rac1 forms filopodia finger-like protrusions and promote the assembly of focal adhesion at the leading 
edge. RhoA promotes actomysin contraction at the rear of the cell and disassembly of focal adhesions.  
 
Cdc42 promotes the formation of finger-like protrusions called filopodia which are associated 
with linear, unbranched actin polymerisation (Nobes and Hall, 1995). Cdc42 drives the polarity 
and directional movement of cells. Cdc42 also functions to position the golgi body and 
microtubule organising centre (MTOC) at the leading edge side of the nucleus to aid delivery of 
vesicles to the leading edge protrusions (Etienne-Manneville and Hall, 2003). Though Rac1, 
Cdc42 and RhoA all localise in lamellipodia protrusions (Machacek et al., 2009), the functions 
elicited are dependent on their activation, which can involve a significant amount of cross talk 
between the proteins. Cdc42 can directly control Rac1 activation through PIX and Tiam1, which 
are both Rac GEFs (Li et al., 2003; Cau and Hall, 2005; Pegtel et al., 2007). Rac1, in turn, can 
inhibit the activation of RhoA through PAK induced inhibition of RhoA GEFs, including GEF-H1. 
In fact Rac1 and RhoA are mutually inhibitory proteins, with each protein being able to inhibit 
the activity of the other (Sanz-Moreno et al., 2008; Machacek et al., 2009).  
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RhoA functions in actomyosin contractility, via ROCK, and the disassembly of integrin based focal 
adhesions, both of which occur at the rear of a motile cell (Chrzanowska-Wodnicka and Burridge, 
1996; Alblas et al., 2001). The retraction and reduction of adhesions at the rear (along with 
protrusions at the leading edge), allows for the cell to move in a forward motion and provides 
membrane availability for the extension of the leading protrusion. RhoA activity is not confined 
to the rear of the cell, with RhoA activation having been seen in the first 2µm of cell protrusions, 
indicating a possible function in this process (Machacek et al., 2009).  
 
1.4.2 Rho GTPases are Central to Cancer Cell Invasion 
 
Given their role in driving cell migration it is perhaps not surprising that Cdc42, Rac1 and RhoA 
all contribute to the mechanisms by with tumour cells migrate, whether it be via single or 
collective migration. Indeed, the mesenchymal and amoeboid mechanisms of single cell 
migration are finely controlled through the reorganisation of the cytoskeleton by Rac1, Cdc42 
and RhoA.  
The activation of Rac1 promotes mesenchymal migration, which can be induced by activators 
including DOCK3, or through adaptor proteins such as NEDD9 (Sanz-Moreno et al., 2008). This 
protein also functions to simultaneously inhibit the formation of an amoeboid shape by reducing 
actomyosin contractility (Sanz-Moreno et al., 2008). Similarly, the depletion of Rac1 can reduce 
cell invasion (Wheeler et al., 2006), further implicating these proteins in cancer cell invasion. 
However, recent findings have suggested that Rac1 is required for the disassembly of 
invadopodia protrusions (Moshfegh et al., 2014), indicating that the role played by this protein 
in cancer invasion is complex. 
Cdc42 plays a role in both mesenchymal migration to polarise the cell and also in amoeboidal 
migration through PAK2 to increase MLC phosphorylation and actomyosin contractility (Gadea 
et al., 2008). Cdc42 is also a major inducer of the invasive protrusion, invadopodia, which is 
thought to be used by tumour cells to invade through the ECM (Murphy and Courtneidge, 2011). 
In fact, the depletion of Cdc42 has been shown to reduce the metastasis of breast cancer cells 
in vivo (Reymond et al., 2012).  
In contrast, the amoeboid mechanism of migration, is highly dependent on RhoA (Sahai and 
Marshall, 2003; Orgaz and Sanz-Moreno, 2013). The activation of this protein is responsible for 
the highly contractile shape that is representative of this form of migration. This occurs via the 
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activation of ROCK, which in turn, activates myosin light chain 2 (MLC2) to enhance myosin 
induced actin contraction (O'Connor and Chen, 2013). The signalling pathways that induce 
amoeboid motility also result in the inhibition of mesenchymal migration. This is achieved by 
the ROCK induced activation of ARHGAP22, which in turn inhibits the activation of Rac1 (Sanz-
Moreno et al., 2008).  
The studies investigating the function of RhoA in cell invasion have produced contradictory 
results. Some studies indicate that a reduction in RhoA expression and activity results in an 
increase in invasion of breast and prostate cancer cell lines in vitro (Simpson et al., 2004; Vega 
et al., 2011). Others have found that a knockdown of this protein in breast cancer cell lines 
reduces in vitro cell invasion and lung metastases in an in vivo murine tail injection assay (Sahai 
and Marshall, 2003; Valastyan et al., 2009; Sanz-Moreno and Marshall, 2010). In addition, RhoA 
is overexpressed in a range of different tumour types such as colon, breast and lung cancer (Fritz 
et al., 1999; Kamai et al., 2001; Sahai and Marshall, 2002). Given the key role that RhoA plays in 
cytoskeletal dynamics and actomyosin contractility it is unsurprising that the function of this 
protein in cell invasion is quite complex, and may vary depending on the cell type and/or 
spatiotemporal distribution of the protein.  Additional studies are therefore required to further 




During the initial stages of invasion, cells must degrade (when amoeboid migration is not used) 
and invade through the basement membrane and the ECM to reach blood vessels or the 
lymphatic system (Nguyen et al., 2009). In order to achieve this, it is thought that tumour cells 
form an actin rich, protease secreting invasive protrusion in the direction of movement, referred 
to as invadopodia (Stylli et al., 2008; Buccione et al., 2009; Ridley, 2011). These invadopodia 
degrade the ECM, promoting cellular invasion. Invadopodia are also used by tumour cells during 
intravasation, another important step in the metastatic process (Gligorijevic et al., 2012).  
Invadopodia are thought to be related to podosomes, a degradative protrusion that is formed 
by highly migratory, non-transformed cells of the haematopoietic lineage such as macrophages 
and dendritic cells (Buccione et al., 2004; Yilmaz and Christofori, 2009) and which aids the 
migration of these cells, in and through tissue (Murphy and Courtneidge, 2011). Podosomes can 
be induced in endothelial and smooth muscle cells by growth factors such as platelet derived 
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growth factor (PDGF) and EGF (Murphy and Courtneidge, 2011). Invadopodia differ from 
podosomes in that they produce a more stable, longer protrusion of over 2µm (podosome 
protrusions are typically 0.5-2µm) that can last for hours, compared to the 2-10 minute lifespan 
that is typical of podosomes (Li et al., 2010a; Murphy and Courtneidge, 2011; Mak, 2014).  
Invadopodia and podosomes show similarities with the adhesive structure, focal adhesions and 
share a large proportion of their proteins such as paxillin and integrins (Hoshino et al., 2013). 
Interestingly, recent findings have indicated that focal adhesions also have degradative capacity, 
further strengthening the similarities between invadopodia/podosomes and focal adhesions 
(Wang and McNiven, 2012). However, studies have suggested a reciprocal relationship with 
focal adhesion kinase (FAK) phosphorylation of Src promoting the turnover of focal adhesions 
and inhibition of invadopodia formation (through sequestering Src to focal adhesions) (Chan et 
al., 2009). While the inhibition of FAK induced Src phosphorylation promotes focal adhesion 
disassembly and the formation of invadopodia (Vitale et al., 2008; Liu et al., 2010b). Similar 
results have been found for podosomes and focal adhesions with Yu and colleagues suggesting 
that they both arise from the same precursor with the resulting structure being determined by 
the force exerted by the matrix to stimulate stress fibre incorporation (focal adhesion) or actin 
polymerisation (podosomes) (Yu et al., 2013),  
Invadopodia structures were first described in fibroblasts transformed using the Rous sarcoma 
virus (which contains the oncogene v-Src) (Chen, 1989). However, it was known for many years 
before this that v-Src induced and localised to ventral protrusions in fibroblasts (Chen et al., 
1985) that had degradative capacity (Chen et al., 1984), when plated on fibronectin. These 
structures have since been identified in a wide variety of cell lines including melanoma (Aoyama 
and Chen, 1990; Chen et al., 1994; Mueller et al., 1999; Baldassarre et al., 2003), breast cancer 
(Chen et al., 1994; Lorenz et al., 2004; Artym et al., 2006), prostate cancer (Desai et al., 2008), 
colon cancer (Schoumacher et al., 2010), head and neck squamous cell carcinoma (SCC) (Clark 
et al., 2007) and glioma (Chuang et al., 2004).  
Invadopodia form an actin comet structure, which consists of a stationary actin cluster at the 
head, followed by a highly motile tail that exhibits spiral movement (Baldassarre et al., 2006; 
Takkunen et al., 2010). Protein expression in these actin comets are spatially distributed with N-
WASP (neural Wiskott-Aldrich syndrome protein) localising at the base of the comet 
(Baldassarre et al., 2006). It is thought that this actin comet provides the force needed to 
elongate the invadopodia. 
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Invadopodia are visualised in a 2D environment by plating cells on a matrix, where the 
protrusion forms on the ventral surface of the cell, often in the centre, underneath the nucleus 
(Lorenz et al., 2004; Baldassarre et al., 2006; Ayala et al., 2008; Poincloux et al., 2009). To identify 
the regions of degradation, the matrix, which can be native ECM proteins (such as fibronectin) 
or gelatin (a denatured collagen substitute), is fluorescently labelled. When these matrices are 
degraded, a region lacking fluorescence is produced and those regions which correspond with 
actin puncta are distinguished by cell staining for F-actin (Figure 1-7). These regions of actin 




Figure 1-7: Invadopodia as visualised in a 2D assay. 
(A) Invadopodia are visualised in 2D assays by plating cells on a fluorescently labelled matrix (e.g. TRITC-
Gelatin) and staining for F-actin. Actin puncta that correspond with matrix degradation are classed as 
invadopodia. (B) Example images of an invadopodia assay (actin, TRITC-gelatin and merged images) 




Though invadopodia are easily visualised in an in vitro 2D setting, their identification in a 3D 
matrix and in an in vivo context has been challenging. In a 3D matrix, the use of dequenched 
(DQ) collagen, which fluoresces in areas of matrix degradation, has allowed for the identification 
of protrusions that have a degradative capacity, and that are believed to be invadopodia (Wolf 
et al., 2007; Yu et al., 2012; Beaty et al., 2013; Moshfegh et al., 2014). The introduction of the 
circular invasion assay (Kam et al., 2008), which has been utilised by Yu and Machesky, has the 
added benefit of allowing for the high resolution imaging of cells in DQ collagen in which 
invadopodia-like structures are evident (Yu and Machesky, 2012).  
In vivo, the difficulties of capturing images of invadopodia and identifying matrix degradation 
become even more prominent. However, invadopodia-like protrusions that were positive for 
cortactin (an invadopodial protein) and that showed signs of local degradation (proteolytic 
activity) were successfully visualised in invading tumours cells (Gligorijevic et al., 2012) and in 
cells undergoing intravasation (Yamaguchi et al., 2005b). In a recent study in Caenorhabditis 
elegans (C. elegans) anchor cells utilising invadopodial-like protrusions were imaged invading 
through the basement membrane. Thus for the first time invasive protrusions were visualised in 
their native environment (Hagedorn et al., 2014).  In addition, primary tumour cells from glioma 
patients have shown the ability to form invadopodia in culture, pointing to the potential 
relevance of this protrusion in vivo (Stylli et al., 2008). However, this study only utilised cells 
from two patients and only used one cancer type. To confirm that cells from patients do in fact 
form invadopodia, it would be useful to conduct additional studies with a higher number of 
patients and also utilise cells from a different cancer type. 
Despite, the difficulties associated with the in vivo visualisation of invadopodia in tumours, a 
correlation has been shown between the invasive potential of cell lines in vivo and in vitro and 
the ability of these cells to form invadopodia, along with the degradative capacity of these 
invadopodia in a 2D matrix (Coopman et al., 1998; Bowden et al., 1999). This highlights the 
importance and relevance of investigating these structures in the context of cancer metastasis.    
 
1.5.1 Invadopodia Formation 
 
Invadopodia formation involves the recruitment of multiple proteins, followed by actin 
polymerisation and elongation of the plasma membrane (Figure 1-8). While integrin and growth 
factor signalling proteins such as β1 integrin (Beaty et al., 2013) and EGF (Bromann et al., 2004; 
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Oser et al., 2009), respectively, can initiate the signalling cascade involved in invadopodia 
formation (Poincloux et al., 2009), the Rho GTPase Cdc42 and cellular Src (c-Src) are the primary 
initiators linked to invadopodia formation. Indeed, the inhibition of either of these latter 
proteins prevents the formation of invadopodia. The importance of Cdc42 is further highlighted 
by the fact that when bound at the membrane to Cdc42-interacting protein 4 (CIP4), this protein 
aids in the plasma membrane curvature needed for invadopodia formation (Pichot et al., 2010). 
 
 
Figure 1-8: Diagrammatic representation of a nascent and mature invadopodia.  
Diagram showing proteins in nascent and mature invadopodia. Nascent invadopodia protrude into the 
ECM. After this, the protrusion stabilises and becomes a degradative mature invadopodia. Additional 




Substrates of Cdc42 (including N-WASP and formins) and c-Src (including cortactin) contribute 
to the formation of invadopodia in several ways. Cortactin accumulates at invadopodia where it 
is bound in an inhibitory complex with cofilin (Bowden et al., 1999). Cofilin binds and severs actin 
filaments, allowing the binding of proteins such as formins, for linear actin polymerisation 
(Lizarraga et al., 2009), and the Arp2/3 complex, for branched actin filament polymerisation 
(Buccione et al., 2004). During the formation of invadopodia, it is thought that cortactin 
becomes phosphorylated, which results in the release of cofilin, allowing the actin filaments to 
be severed, thus creating free barbed ends for actin polymerisation (Oser et al., 2009). 
Activation of the N-WASP protein occurs either through Cdc42 or via phosphorylated cortactin 
which promotes the interaction and activation of N-WASP by Nck1 (non-catalytic region of 
tyrosine kinase adaptor protein 1) (Tehrani et al., 2007). N-WASP then activates the Arp2/3 
complex to promote actin polymerisation.  
After the formation of invadopodia, cortactin is de-phosphorylated and exerts an inhibitory 
function on cofilin, leading to invadopodia stabilisation (Yamaguchi et al., 2005a; Oser et al., 
2009). Some debate exists over the function of cofilin in invadopodia, with another study 
suggesting that the activity of cofilin also plays a role in the turnover of invadopodia. Indeed, 
active cofilin was essential for the formation of discrete invadopodia-like protrusions in vivo and 
the promotion of actin recycling (to provide a pool of free actin for new invasive protrusion 
formation) in C. elegans (Hagedorn et al., 2014). However, whether this activation is via cortactin 
or another protein is unknown. As cortactin is a prominent player in invadopodia function, 
localising to invadopodia through the entire life cycle (Artym et al., 2006), this protein is used by 
many, along with F-actin, as a marker of invadopodia in vitro (Lorenz et al., 2004; Baldassarre et 
al., 2006; Ayala et al., 2008; Poincloux et al., 2009).  
Other members of the Rho GTPases such as Rac1 and RhoA may be involved in invadopodia 
formation. However, studies investigating the roles played by these proteins provide conflicting 
results. Initial studies have implicated Rac1 in the formation of invadopodia with active mutants 
enhancing a diffuse-type degradation from invadopodia (Nakahara et al., 2003), and the 
depletion of Rac1 in glioma cell lines reducing the formation of invadopodia (Chuang et al., 
2004). However, a recent study, using a Rac1 FRET biosensor, has found low activity during 
invadopodia formation with increased activity evident during the disassembly of the protrusion 
suggesting the importance of Rac1 for invadopodia dissolution (Moshfegh et al., 2014). Similar 
contradictory data have also been found regarding the role of RhoA in invadopodia. Bravo-
Cordero and colleagues, detected no localised variation in RhoA activity at invadopodia 
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structures (Bravo-Cordero et al., 2011). A decrease in RhoA expression in this study reduced 
invadopodia formation and degradation suggesting RhoA activity may be important for 
invadopodia function. In contrast, other studies using active and dominant negative RhoA 
mutants have suggested that this protein has no effect on invadopodia degradation (Nakahara 
et al., 2003). Therefore, to further understand the role that RhoA plays in invadopodia function, 
additional investigation is required. 
 
1.5.2 Invadopodia Maturation 
 
The maturation of invadopodia produces a stable, prolonged protrusion with degradative 
capacity. During this maturation, the de-phosphorylation of cortactin occurs, leading to the 
reformation of the cofilin complex, and preventing actin polymerisation (Oser et al., 2009). 
Mature invadopodia contain vimentin filaments and microtubules that are thought to play a role 
in invadopodia elongation and the transport of matrix degrading enzymes to the plasma 
membrane respectively (Schoumacher et al., 2010). The actin bundling protein, fascin, is 
important in the stabilisation of invadopodia (Machesky and Li, 2010), with fascin depleted cells 
exhibiting more transient and smaller invadopodia (Li et al., 2010a).  
The degradative stage of invadopodia maturation involves the transport and exocytosis of 
extracellular matrix degrading enzymes. The most prominent matrix degrading enzymes present 
at invadopodia are the MMPs, primarily membrane type 1 MMP (MT1-MMP), MMP-2 and MMP-
9 (Nakahara et al., 1997; Poincloux et al., 2009). MT1-MMP is a membrane bound enzyme that 
can degrade a range of matrices, including fibronectin, gelatin, vitronectin, as well as collagen I, 
II and III (Overall and Dean, 2006). MMP-2 and MMP-9 are both enzymes that are secreted into 
the extracellular matrix as inactive pro-MMPs where they are activated by membrane bound 
receptors such as MT1-MMP (Poincloux et al., 2009). MMP-2 and MMP-9 can degrade collagen 
type IV, one of the most abundant basement membrane components (Poincloux et al., 2009). It 
is believed that the accumulation of actin and cortactin stimulates MT1-MMP localisation to 
invadopodia, as well as MMP-2 and MMP-9 secretion at this protrusion (Artym et al., 2006; Clark 
et al., 2007; Clark and Weaver, 2008). 
Integrins play an important role in invadopodia degradation by activating MMPs, including 
MMP-2 (integrin αvβ3) and seprase (integrin α3β1) (Mueller et al., 1999; Gimona et al., 2008). 
Indeed, the activation of β1 integrin can increase invadopodia induced degradation (Nakahara 
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et al., 1998), while reduction in levels of this protein inhibits the formation of invadopodia 
(Destaing et al., 2010). 
MMPs are thought to be delivered to invadopodia by transportation from the golgi body, in 
vesicles, down microtubules to the invadopodia (Schnaeker et al., 2004). Electron microscopy 
found that invadopodia protrusions form proximal to the golgi body, suggesting an important 
role for this complex in this structure (Baldassarre et al., 2003). The exocyst complex has been 
shown to be important in MMP localisation to invadopodia (Sakurai-Yageta et al., 2008). RhoA 
activity promotes the interaction of the exocyst complex, with IQ motif containing GTPase 
activating protein 1 (IQGAP1) to aid the tethering of vesicles (containing MMPs) to the 
invadopodia plasma membrane for matrix degradation (Sakurai-Yageta et al., 2008). 
Fusion of the vesicle and plasma membranes result in the release of MMPs. This leads to 
degradation of the extracellular matrix, thus facilitating cellular invasion. Inhibition of the RhoA 
effectors, ROCK and myosin II, has been shown to inhibit this invadopodia degradation 
(Alexander et al., 2008).  
Subsequent removal of MMPs from invadopodia occurs via endocytosis, followed by recycling 
back to the plasma membrane. The endocytosis and thus removal of MT1-MMP at invadopodia 
is prevented by the formation of a FAK/c-Src complex which inhibits endophilin A2 (a membrane 
curvature protein essential for endocytic vesicle formation) (Wu et al., 2005).  
Non-MMP proteins such as dynamin 2 (a protein localised to the invadopodial cytoplasm) are 
also important for invadopodia degradation. The expression of dominant negative dynamin 2 
mutants were found to decrease both the number of degrading cells as well as the size of the 
degradation area (Baldassarre et al., 2003).  
 
1.6 p21-Activated Kinases 
 
There are many known effectors of the Rho GTPases, the most well characterised being the p-
21 activated kinase (PAK) family of serine/threonine kinases (King et al., 2014). PAKs are involved 
in several cellular processes including gene transcription, proliferation, changes in cell 
morphology, cell motility and cancer cell invasion (King et al., 2014). These kinases are highly 
conserved across a wide range of organisms including, yeast, flies and humans (Bokoch, 2003). 
Human PAKs consist of 6 isoforms, which are separated into two groups according to their 
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sequence and structural homology: group I, containing PAKs 1-3; and group II, containing PAKs 
4-6 (Figure 1-9).  
Deletion of the PAK gene in mice has varying effects on viability and phenotype depending on 
which PAK isoform has been depleted. PAK1, PAK5 and PAK6 show no obvious developmental 
requirement as knockout mice are viable (Li and Minden, 2003; Arias-Romero and Chernoff, 
2008; Nekrasova et al., 2008). However, PAK2 and PAK4 knockout mice are embryonically lethal, 
showing the necessity for these 2 isoforms during embryonic development (Qu et al., 2003; 
Arias-Romero and Chernoff, 2008). Uniquely, PAK3 knockout mice are viable but show defects 




Figure 1-9: Domain Structure of PAKs.  
PAK family kinases consist of 6 isoforms, divided into two groups according to their sequence homology. 
Protein sizes: PAK1, 68kDa; PAK2, 62KDa; PAK3, 65KDa; PAK4, 68KDa; PAK5, 80KDa: and PAK6, 75KDa 





1.6.1 PAK Domain Structure and Regulation of Activity 
 
All the PAK isoforms contain a highly conserved N-terminal GTPase binding domain (GBD) and a 
C-terminal kinase domain (Dummler et al., 2009). However, the central intervening sequences 
differ greatly across and within the two groups. Group I PAKs and PAK5 (a group II PAK) contain 
an autoinhibitory domain (AID) in the GBD that blocks protein activation (Lei et al., 2000).  
Group I PAKs have a low basal kinase activity which is increased by the binding of Cdc42 and 
Rac1 to the GBD (Figure 1-10). In the inactive state, group I PAKs form a homodimer in a trans-
inhibitory conformation, with the AID of one protein binding to the kinase domain of the other 
to block protein activation (Lei et al., 2000; Parrini et al., 2002). Although PAK2 and PAK3 
dimerisation has not previously been investigated it is assumed (due to the sequence homology 
within the binding sites), that these proteins also form homodimers (Lei et al., 2000).  
The binding of active Cdc42 and Rac1 to the GBD dissociates the AID from the homodimer, 
allowing autophosphorylation to occur at Thr423 (in PAK1), Thr402 (PAK2) or Thr421 (PAK3), 
resulting in kinase activation (Zenke et al., 1999; Arias-Romero and Chernoff, 2008). Uniquely, 
the PAK3 gene has splice exons located in the GBD/AID region, resulting in four splice variants. 
Three of these have constitutive kinase activity (Kreis et al., 2008), with the splice variant PAK3a, 
preferentially binding PAK1 to form a heterodimer rather than a homodimer (Combeau et al., 
2012). 
In contrast, regulation of group II PAK activity is more complex and to date is not fully 
understood. PAK5 is the only group II PAKs to contain an AID, similar to that used to regulate 
group I PAK activity (Ching et al., 2003). Conflicting studies exist regarding the mechanism of 
PAK4 regulation.  A 1998 report suggests that PAK4 has a high basal kinase activity that is not 
affected by the binding of the activated small GTPases, Cdc42 and Rac1 (Abo et al., 1998). 
However, more recent studies suggest that the regulation of PAK4 activity occurs via one of two 
alternative mechanisms. One such mechanism involves a putative AID, located in the N-terminal 
domain (amino acid 20-68) that maintains PAK4 in an inactive confirmation until binding of 
activated Cdc42 occurs (Baskaran et al., 2012). In the second PAK4 regulatory process an N-
terminal autoinhibitory pseudosubstrate motif binds the kinase domain (Ha et al., 2012). This 
pathway has in fact been  validated via nuclear magnetic resonance (NMR), which identified an 
AID, incorporating the autoinhibitory pseudosubstrate motif, that occupies the entire kinase 
cleft to achieve autoinhibition (Wang et al., 2013).  
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 Figure 1-10: Activation of group I and group II PAKs. 
Group I PAKs forms an inhibitory homodimer where the AID of one protein binds in trans to the kinase of 
another. The binding of Rac1 or Cdc42 to the GBD dissociates this dimer and allows for PAK 
autophosphorylation and thus activation. There are currently two possibilities for activation of group II 
PAKs. PAK4 may have an inhibitory conformation with a putative AID domain that blocks the kinase 
domain. The binding of Cdc42 to the GBD results in a conformational change that releases the kinase 
domain from the inhibitory domain resulting in activation of the protein. Alternatively, PAK4 may use a 
pseudosubstrate, located in the GBD to block the substrate binding site in the kinase domain thus 
inhibiting protein function. The binding of Cdc42 changes the conformation, releasing the 






These reports indicate that PAK4 activity is controlled by conformational changes mediated by 
the AID and not by the autophosphorylation of PAK4 at Ser474 (used previously as an indicator of 
PAK4 activity), which is in fact likely to be constitutively phosphorylated at this site. In addition, 
as this region is highly conserved in all group II PAKs it is highly probable that this method of 
regulation is also adopted by PAK5 and PAK6 (Ha et al., 2012; Wang et al., 2013).  
The regulation of PAK kinase activity occurs not only through the interaction of Cdc42 and Rac1 
GTPases, but also through a range of different proteins and pathways. For example, activation 
of phosphoinositide 3-kinase (PI3K), results in the PI3K induced phosphorylation of PAK1, 
leading to increased cell motility (Adam et al., 1998). PAK1 can also be activated by growth 
factors, with stimulation of platelet derived growth factor (PDGF) resulting in 3-
phosphoinositide-dependent kinase-1 (PDK1) phosphorylation of PAK1 at the Thr423 
autophosphorylation site (King et al., 2000). Furthermore, PDGF induced cell activation results 
in the binding of the SH3 domain adapter protein Nck to the  N-terminal proline rich site of PAK1 
(Figure 1) (Bokoch et al., 1996). Nck translocates PAK1 to the plasma membrane where it is 
activated by receptor tyrosine kinases. This leads to the downstream activation of the MAP 
kinase cascade similarly seen with Cdc42 and Rac1 induced PAK1 activation (Galisteo et al., 1996; 
Lu et al., 1997).  PAK1 can also be translocated to focal complexes by the binding of PIX guanine 
nucleotide exchange factor to a centrally located proline rich site in group I PAKs (PIX binding 
site; Figure 1). This translocation enhances the activation by Cdc42 and Rac1 at focal complexes 
(Manser et al., 1998).  
Further studies into the regulation of group II PAKs have demonstrated the presence of an 
integrin binding domain on PAK4 which binds to the β5 subunit of the αvβ5 integrin.  This 
integrin is involved in the motility and movement of cells on the extracellular matrix protein, 
vitronectin. The PAK4-αvβ5 integrin interaction leads to the translocation of PAK4 to 
lamellipodia and promotes cell motility and migration (Zhang et al., 2002). All 6 PAK isoforms 
have high homology at the corresponding location of the PAK4 integrin binding domain, making 
it very likely that similar integrin interactions do occur across the PAK family members.  
Given the key role played by the PAK family of kinases in several cellular pathways one would 
expect their activity to be tightly controlled by inhibitors or negative regulators. The latter have 
in fact been identified for group I PAKs.  
One form of negative regulation involves the phosphorylation and inhibition of PAK1 activation 
by Protein Kinase A. This PAK inhibition can inhibit the activation of anchorage independent 
42 
 
growth signalling through the MAP kinase cascade (Howe and Juliano, 2000). Additionally 
proteins such as PAK interacting proteins (PIP) and Nischarin can bind PAK1, forming a complex 
which blocks phosphorylation and downstream signalling (Xia et al., 2001; Alahari et al., 2004). 
The partners of PIX1 (POPX1) and PIX2 (POPX2) employ a different mechanism of inhibition 
which involves the dephosphorylation and thus inactivation of PAK1 (Koh et al., 2002).  In yet 
another PAK1 inhibitory pathway, Rac1 activated PAK1 has been shown to phosphorylate Merlin 
at Ser518, with the resulting activated Merlin protein subsequently competitively binding to 
PAK1, preventing Rac1 induced activation (Kissil et al., 2003). This negative feedback mechanism 
allows tight regulation of Merlin-PAK1 signalling, which in turn leads to tight regulation of cell 
growth. While most of the regulators and inhibitors have been discovered through the use of 
PAK1, inhibitory pathways also exist for other group I PAKs (Zhan et al., 2003) and play a vital 
role in controlling the activity of these kinases and the key downstream pathways in which they 
signal.  
 
1.6.2 PAK Expression in Cancer  
 
Given the involvement of PAKs in cell cycle control, proliferation, cell movement and apoptosis, 
it is not surprising that this family of kinases also plays a role in cancer growth and progression. 
The overexpression of group I PAKs is evident in a wide variety of cancers, with the PAK1 isoform 
being the most commonly overexpressed. Increased levels of this protein have been observed 
in human cancer tissue from breast (Holm et al., 2006; Ong et al., 2011), liver (Ching et al., 2007), 
lung (Ong et al., 2011), colorectal (Li et al., 2010b) and also in a subset of melanoma (Ong et al., 
2013).  PAK2 overexpression is found in breast (Li et al., 2011) and lung cancer tissue (Kikuchi et 
al., 2012), while increased levels of PAK3 has to date only been found in thymic neuroendocrine 
tumours (Liu et al., 2010a).  
In group II PAKs, PAK4 is the most commonly overexpressed in tumour tissues including breast 
(Liu et al., 2008), gastric (Ahn et al., 2011) and ovarian cancer (Siu et al., 2010a). In addition PAK4 
is the only isoform to date where overexpression of the wildtype protein (in NIH3T3 cells) 
induces tumour formation when injected in athymic mice. For all other PAKs, only phospho PAK1 
is tumourigenic with an activated mutant being required for tumour formation. In fact PAK4 
tumour formation took longer to occur when wildtype protein was expressed versus an 
activated mutant (wildtype = 44 days; Activated = 16 days) (Liu et al., 2008). Overexpression of 
PAK5 and PAK6 occurs less often than PAK4, but has been found in colorectal (PAK5) (Gong et 
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al., 2009), prostate (PAK6) (Kaur et al., 2008) and breast cancer cell lines (PAK6) (Kaur et al., 
2008), as well as in hepatocellular carcinoma tissue (PAK6) (Chen et al., 2014). 
An alteration of the phosphorylation state of various PAKs isoforms has also been found in 
human cancers. An increase in PAK1 phosphorylation (pPAK1) is found in tumour tissues 
including colorectal cancer (Li et al., 2010b; Liu et al., 2013), with an increase of pPAK1, pPAK2 
and pPAK4 being evident in ovarian cancers (Siu et al., 2010a; Siu et al., 2010b). Interestingly, a 
constitutively active PAK1 mutant can induce mammary gland tumours in mice (driven by the β-
lactoglobulin promoter) indicating that PAK1 kinase activity has the ability to induce tumour 
development (Wang et al., 2006).  
In addition to protein overexpression and increased protein kinase activity, genomic 
amplification is also observed for some PAK isoforms, in particular PAK1 and PAK4 in bladder 
(Ito et al., 2007) and ovarian cancer (Davis et al., 2013), respectively.  
Taken together these data suggest a key role particularly for PAK1 and PAK4 in tumour formation 
and development.  
In cutaneous melanoma specifically, increased PAK1 protein expression is observed in primary 
melanoma tissue that lack a common BRAF mutation, when compared to primary melanoma 
tissue with this mutation (Ong et al., 2013). However, little is known about the expression of 
PAK1 protein in metastatic melanoma (irrespective of BRAF mutation status). At the 
transcriptional level, PAK4 mRNA is overexpressed in melanoma cell lines, while no increase in 
PAK6 mRNA is seen (Callow et al., 2002). In addition, no increase in PAK2 or PAK3 gene 
expression was observed in primary melanoma tissues (Ong et al., 2013). However, it is unclear 
whether the gene expression or mRNA transcription of these PAK isoforms corresponds to an 
increase, or lack thereof, of protein expression in melanoma cells.  
 
1.6.3 PAK1 and PAK4 in Invasion 
 
As PAKs are the downstream effectors of the Rho GTPases Cdc42 and Rac1, and therefore play 
a key role in cell motility, it is not surprising that these kinases can influence tumour cell invasion. 
As the most commonly overexpressed isoforms in cancer, PAK1 and PAK4 in particular play a 
key role in tumour invasion in some cancers (Callow et al., 2002; King et al., 2014).  
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For PAK1, this role in cell migration involves the regulation of lamellipodial protrusions, cell 
directionality (Sells et al., 1999; Sells et al., 2000), as well as focal adhesion assembly and 
dissolution (Manser et al., 1997; Nayal et al., 2006). In a study utilising an ovarian cancer cell 
line, the depletion of PAK1 expression reduced migration and invasion, while the overexpression 
of PAK1 enhanced migration and cell invasion (Siu et al., 2010b). Similarly, cellular invasion was 
blocked in a breast cancer cell line with a kinase dead PAK1 mutant. This indicates a dependency 
on kinase activity in PAK1 induced invasion (Adam et al., 2000). The level of PAK1 expression 
correlates directly with cell invasion and therefore disease progression. In a range of uveal 
melanoma cell lines, PAK1 overexpression correlated with invasive potential (determined in 
vitro), with the depletion of PAK1 expression resulting in a corresponding reduction in cellular 
invasion (Pavey et al., 2006). Furthermore, the inhibition of PAK1 and PAK2 expression 
simultaneously in primary melanoma cell lines (lacking a BRAF mutation) reduced cell migration, 
indicating that one (or both) of these isoforms can promote melanoma cell motility (Ong et al., 
2013). However, to elucidate which PAK isoform is contributing to the melanoma cell migration, 
investigations using isoform specific PAK inhibitors are required. 
In addition, through various signalling pathways PAK1 plays a role in the inhibition of E-cadherin 
expression, a key protein in cell-cell adhesion. Data obtained using cells with dominant negative 
and depleted PAK1 demonstrated that this protein is required for Rac1 induced disassembly of 
E-cadherin junctions (Lozano et al., 2008). Additionally, PAK1 has been found to phosphorylate 
Snail resulting in its translocation to the nucleus and subsequent inhibition of E-cadherin 
expression (Elloul et al., 2010). This diminished expression promotes cell-cell dissociation and 
the epithelial-mesenchymal transition in ovarian cancer cell lines, thus promoting cell migration 
and tumour invasion. In non-small cell lung cancer cells PAK1 phosphorylates CRK-II to reduce 
E-cadherin and p120-catenin expression, both components of cell-cell junction, thus increasing 
cell invasion (Rettig et al., 2012), while reduced PAK1 expression prevents the dissociation of 
cell-cell junctions in prostate cancer cells (Bright et al., 2009).  
Like PAK1, PAK4 can be involved in tumour cell invasion, with the level of PAK4 expression being 
indicative of disease prognosis in some cancers. PAK4 expression is found at a higher level in 
metastatic compared to primary gastric tumours (Guo et al., 2014), and overexpression of PAK4 
in this cancer type is associated with a lower overall survival compared to patients that lack PAK4 
overexpression (Ahn et al., 2011). Similarly, PAK4 expression was further increased in more 
advanced serous and clear cell ovarian cancer tissue samples and was associated with lower 
overall patient survival (Siu et al., 2010a). This is due to the greater invasive capacity of tumour 
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cells with increased levels of PAK4 as has been demonstrated in multiple studies. Expression of 
constitutively active PAK4 mutants in pancreatic ductal cell lines, (Kimmelman et al., 2008), and 
overexpression of wildtype PAK4 in choriocarcinoma cell lines, both resulted in enhanced cell 
invasion (Zhang et al., 2011). Conversely the depletion of PAK4 expression reduced cell 
migration and invasion in glioma (Kesanakurti et al., 2012), SCC (Zanivan et al., 2013), 
choriocarcinoma (Zhang et al., 2011) and breast cancer cells (Wong et al., 2013). 
PAK4 aids cell migration and invasion through the promotion of focal adhesion turnover. 
Reduced PAK4 expression increases the number of focal adhesions present (Wells et al., 2010), 
therefore increasing cellular adhesion and reducing invasion.  This PAK4 induced adhesion 
turnover is thought to be facilitated through the phosphorylation of paxillin (Ser272) (a key focal 
adhesion associated protein) and through the phosphorylation of β5 integrin which reduces cell-
matrix attachment and promotes cell migration (Li et al., 2010c). 
Therefore, both PAK1 and PAK4 have been linked to invasion in a range of human cancers. 
However, very few studies focus on the role these kinases may play in melanoma progression, 
which could prove vitally important given the significant difference in survival rates between 
primary and metastatic melanoma. 
 
1.6.4 Expression and Localisation of PAK1 and PAK4 
 
The distribution and cellular localisation of PAK1 and PAK4 vary in normal tissue. PAK1 are highly 
expressed in various tissues including the brain (common feature for group I PAKs), muscle, 
heart and liver (Arias-Romero and Chernoff, 2008). While PAK1 is concentrated in the cytosol, 
certain stimuli can also cause localisation to different regions of the cell, including at filopodia 
and lamellipodia protrusions, (Sells et al., 2000; Nayal et al., 2006), cortical actin 
(Dharmawardhane et al., 1997), focal adhesions (Manser et al., 1997; Delorme-Walker et al., 
2011), cell-cell adhesions (Zegers et al., 2003) and the nucleus (Li et al., 2002; Rayala and Kumar, 
2007). 
PAK4,  is thought to be expressed ubiquitously with higher protein levels in certain tissues such 
as colon, testis and prostate (Callow et al., 2002). PAK4 is also localised to the cytosol and 
targeted to different subcellular locations when stimulated, including filopodia protrusions (Abo 




1.6.5 PAK1 and PAK4 Substrates 
 
The group I and group II PAKs, to which PAK1 and PAK4 belong, respectively, differ in several 
ways including protein sequence. All PAK isoforms contain a conserved N-terminal p21 binding 
domain (PBD) and a C-terminal kinase domain (Dummler et al., 2009). However, there is less 
than 40% and 54% homology between the PBD and the kinase domain sequences respectively, 
of group I and II PAKs (Jaffer and Chernoff, 2002). These differences in sequence suggest that 
PAK1 and PAK4 could have differing substrates in cells which could drive divergent functions 
(Jaffer and Chernoff, 2002). In fact a positional scanning peptide library study by Rennefahrt and 
colleagues showed differing optimal phosphorylation sequences between PAK1 and PAK4, 
suggesting differential substrate specificities (Rennefahrt et al., 2007).  
These two proteins are rarely directly compared, however some studies suggest that PAK1 and 
PAK4 share the majority of their substrates, with little evidence to date suggesting that these 
isoforms are involved in different pathways (Arias-Romero and Chernoff, 2008). However, 
differences do exist, with wildtype PAK4 having a tumourigenic capacity, while PAK1 can only 
bring about this transformation with constitutively active mutants (Wang et al., 2006; Liu et al., 
2008). The signalling pathways that may be contributing to this difference in phenotype are 
unknown. 
A unique feature of the PAK4 protein, that is not present in PAK1, is the GEF interacting domain 
(GID) (Figure 1-9) (Callow et al., 2005). Through this domain, PAK4 phosphorylates GEF-H1 at 
Ser885, which inhibits the GEF function. Due to the lack of GEF-H1, RhoA remains inactive leading 
to the dissolution of stress fibres (Callow et al., 2005). Indeed, PAK4 can inhibit the formation of 
prominent actin fibres via the phosphorylation of GEF-H1, inhibiting the activation of RhoA in 
prostate cancer cells (Wells et al., 2010). However, the results found with PAK1 are less 
consistent, with some studies demonstrating that phosphorylation of GEF-H1 at Ser885 by PAK1 
inhibits the GEF activity towards Rho (Zenke et al., 2004; Tian et al., 2014), while others report 
no activation of RhoA when PAK1 expression is depleted (Coniglio et al., 2008).  
PAK1 and PAK4 have differential binding to another GEF, PDZ-RhoGEF - whilst PAK1 does not 
bind, PAK4 both binds and inhibits protein function (Barac et al., 2004; Rosenfeldt et al., 2006). 
However, while exciting, this data is preliminary and has not been linked to distinct PAK1 or 
PAK4 cellular processes. 
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One study indicates a separation in PAK1 and PAK4 signalling in the phosphorylation of MLC. In 
NIH3T3 fibroblasts, constitutively active PAK4 mutants are unable to phosphorylate MLC while 
PAK1 activated mutants increase the MLC phosphorylation (Qu et al., 2001). However, the 
functional implications of this remains to be investigated. 
There may be other distinct substrates for PAK1 and PAK4, however, the substrates or signalling 
pathways of these two isoforms are rarely directly compared in the same cell type. Given the 
key role that both proteins play in tumour formation and invasion, a direct comparison of the 
substrates and signalling pathways of these PAKs could prove invaluable in furthering our 
understanding of cancer progression. This could be achieved through phospho proteomic arrays 
(using cells with depleted PAK1 and PAK4 protein expression) that may detect differential 
phosphorylated substrates. 
 
1.6.6 PAK1 and PAK4 in Invadopodia 
 
Given the potential role of PAK1 and PAK4, in tumour invasion and the fact that invadopodia are 
also implicated in this process, it is not surprising that several studies demonstrate a potential 
involvement of PAKs in invadopodia function. PAK1 has been shown to localise to invadopodia 
protrusions (as demonstrated in MTLn3 rat mammary adenocarcinoma cells) (Moshfegh et al., 
2014), and can also phosphorylate cortactin at Ser113, thus activating this protein which is vital 
for invadopodia formation (Ayala et al., 2008). However, studies in which PAK1 activity is 
reduced have produced conflicting results, with one study demonstrating that PAK1 activity is 
required to sustain invadopodia formation and activity during the invasion of the A375MM cell 
line (Ayala et al., 2008), while a more recent study indicates that PAK1 is involved in invadopodia 
dissolution, in MTLn3 and MDA-MB-231 cells (Moshfegh et al., 2014). Therefore, to fully 
understand the role that PAK1 plays in invadopodia function, additional studies are required. 
Much less is known about the involvement of PAK4 in invadopodia formation with studies 
indicating that this protein may be involved in podosome (protrusions that often share the same 
signalling pathways with invadopodia (Murphy and Courtneidge, 2011)) formation/activity. 
PAK4 has been shown to localise to podosomes in bone-marrow-derived mouse dendritic cells 
(Wells and Jones, 2010) and primary human macrophages (Gringel et al., 2006). In addition 
studies in macrophages involving the depletion and enhancement of PAK4 activity suggest that 
this kinase enhances podosome size and number (Gringel et al., 2006). These studies implicate 
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PAK4 in podosome formation, and highlight the need for studies to investigate a possible role 
for PAK4 (and other PAK isoforms) in invadopodia formation.  
PAK1 and PAK4 have been implicated in matrix degradation pathways, with both proteins 
influencing MMP expression and secretion in a variety of cell lines. Recent studies involving PAK1 
suggest that this protein has different effects on different MMPs. PAK1 was shown to induce the 
secretion of MMP-1 and MMP-3 in breast cancer cells and downregulate the expression and 
secretion of MMP-9 in collagen I, and MMP-2 in collagen IV (Rider et al., 2013).  The effect of 
PAK4 on MMPs is more straightforward with overexpression enhancing MMP-2 expression (Siu 
et al., 2010a), and knockdown down regulating MT1-MMP expression in CCA choriocarcinoma 
cells (Zhang et al., 2011). Therefore, PAK1 and PAK4 may also impact invadopodia induced 







The aims of this project are to address the following questions: 
1. What is the invasive capacity of a panel of melanoma cell lines and patient derived cell 
strains?  
2. Are the PAK isoforms expressed in melanoma cells, and if so, does this expression 
correlate with the invasive characterisation? 
3. Do PAKs play a role in melanoma invasion? 






2 Chapter 2 - Materials and Methods 
 
2.1 Materials 
2.1.1 General Materials 
Reagent Company 
152mm glass capillary, with a central filament World Precision Instruments, USA 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (Hepes)  
GIBCO®, Invitrogen, UK 
 
4’, 6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich, UK 
96-well, U-bottomed, suspension culture plate Greiner, UK 
96 well, V-bottomed, plate Sigma-Aldrich, UK 
Acetic acid Sigma-Aldrich, UK 
Acrylamide (30%) Severn Biotech Ltd, UK 
Agarose Sigma, UK 
Ammonium persulfate (APS) Sigma-Aldrich, UK 
Ampicillin Sigma-Aldrich, UK 
Aprotinin Sigma-Aldrich, UK 
Bovine serum albumin (BSA) VWR International, UK 
Bromophenol blue Bio-Rad, UK 
Calcium phosphate transfection kit Sigma-Aldrich, UK 
Control siRNA oligonucleotide (non-silencing) Qiagen Ltd, UK 
Crimson Taq polymerase New England Biolabs, UK 
Cell dissociation solution  Sigma-Aldrich, UK 
DAPI Invitrogen, UK 
Deoxyribonucleotide triphosphate (dNTPs) mix New England Biolabs, UK 
DH5αTM Competent Escherichia coli (E. coli) Cells Invitrogen, UK 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, UK 
Dithiothreitol (DTT) Sigma-Aldrich, UK 
DMEM (Dulbecco’s Modified Eagle’s Medium)  Sigma-Aldrich, UK  
DMEM (1x) Powder, High Glucose PAA, UK 
DMEM (High Glucose) PAA, UK 
DMEM F-12 (Dulbecco's modified eagle's 
medium: nutrient F-12 ham)  
Lonza, UK  
Dulbecco's Phosphate buffered saline (PBS) 
without Calcium & Magnesium 
PAA, UK 
Enhanced chemiluminescence (ECL) Plus western 
blotting detection system 
Amersham Biosciences, UK 
Ethidium bromide Thermo Fisher Scientific, UK 
Ethyl 3-aminobenzoate methanesulfonate 
(MS222) 
Sigma-Aldrich, UK 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, UK 
Fibronectin Sigma-Aldrich, UK 
FluorSaveTM Reagent Calbiochem, UK 
Flexitube siRNA HsPAK4 (PAK4 Oligo 2) Qiagen, UK 
Foetal bovine serum (FBS) GIBCO®, Invitrogen, UK 
Falcon™ 5ml polystyrene round-bottom tubes BD Biosciences, UK 
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Gateway® LR and BP ClonaseTM enzyme kit 
(including proteinase K) 
Invitrogen, UK 
Gelatin- Type A from porcine skin  Sigma-Aldrich, UK  
Gentamicin Sigma-Aldrich, UK 
Glutaraldehyde solution, Grade I, 25%  Sigma-Aldrich,UK  
Glycerol Sigma-Aldrich, UK 
Glycine Sigma-Aldrich, UK 
HiPerfect transfection reagent Qiagen Ltd, UK 
Human Adult Epidermal Melanocytes TCS CellWorks, UK 
Illustra GFX PCR DNA and gel band purification 
kit 
GE Healthcare, UK 
Kanamycin Invitrogen, UK 
L-glutamine Lonza, UK 
Leupeptin Sigma-Aldrich, UK 
Lipofectamine 2000 Invitrogen, UK 
Lithium chloride (LiCl) Fisons Scientific Apparatus, UK 
Low Melting Point Agarose Invitrogen, UK 
Luria-Bertani agar (LB-agar) Sigma-Aldrich, UK 
Luria-Bertani broth (LB-broth) Invitrogen, UK 
Magnesium chloride (MgCl2) Sigma-Aldrich, UK 
Melanocyte Growth Medium Package including 
epidermal melanocyte growth supplement 
TCS CellWorks, UK 
Methylene blue Thermo Fisher Scientific, UK 
Methylcellulose Sigma-Aldrich, UK 
Minimum essential medium Eagle (MEM) media Sigma-Aldrich, UK 




Newborn calf serum (NCS) Sigma-Aldrich, UK 
Non-fat milk powder Marvel, UK 




One Shot® TOP10 Chemically Competent E. coli 
Cells 
Invitrogen, UK 
OptiMEM GIBCO®, Invitrogen, UK 
Roswell Park Memorial Institute (RPMI)-1640 
medium 
Sigma-Aldrich, UK 
PAK1 siRNA  Oligo 1 Dharmacon, Thermo Fisher, UK 
PAK1 siRNA  Oligo 3 Dharmacon, Thermo Fisher, UK 
PAK4 silencer pre-designed siRNA (PAK4 Oligo 1) Ambion, Invitrogen, UK 
Paraformaldehyde (PFA) Sigma-Aldrich, UK 
pDONORTM 207 Invitrogen, UK 
Penicillin/Streptomycin Sigma-Aldrich, UK 
Phalloidin CruzFluor™ 647 Conjugate Santa Cruz 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, UK 
Phusion® HF New England Biolabs, UK 
Phosphate buffered saline (PBS) tablets Oxoid Limited, UK 
Pierce® ECL western blotting substrate Thermo Scientific, USA 
Protein G SepharoseTM 4 Fast Flow beads Amersham Biosciences, UK 
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Precision Plus Protein Marker Bio-Rad, UK 
ProLong® Gold antifade reagents Life Technologies, UK 
Protran Nitrocellulose hybridization transfer 
membrane 
Perkin Elmer, USA 
PureCol Collagen Type I Solution 3mg/ml Nutacon, NL 
PurelinkTM Hi Pure Plasmid mini-prep kit Invitrogen, UK 
Puromycin Sigma-Aldrich, UK 
Q5™ High-fidelity DNA polymerase New England Biolabs, UK 
QIAGEN Plasmid maxi-prep kit Qiagen Ltd, UK 
QIAGEN Plasmid midi-prep kit Qiagen Ltd, UK 
Quick-Load® 100bp DNA ladder New England Biolabs, UK 
Quick-Load® 1kbp DNA ladder New England Biolabs, UK 
Rhodamine B Isothiocyanate  Sigma-Aldrich,UK  
Roswell Park Memorial Institute (RPMI)-1640 
medium 
GIBCO®, Invitrogen, UK 
Slide-A-Lyzer® dialysis cassette Thermo Fisher Scientific, UK 
Sodium borohydride  Sigma-Aldrich,UK  
Sodium chloride (NaCl) Sigma-Aldrich, UK 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, UK 
Sodium fluoride (NaF) Alfa Aesar, UK 
Sodium hydroxide (NaOH) Sigma-Aldrich, UK 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich, UK 
Sodium pyrophosphate BDH Chemicals, UK 
Sucrose Sigma-Aldrich, UK 




Tris-base Sigma-Aldrich, UK 
Triton X-100 VWR International, UK 
Trypsin/EDTA GIBCO®, Invitrogen, UK 
Tween 20 VWR International, UK 
X ray film Scientific Laboratory Supplies 
X-tremeGENE HP transfection reagent Roche, UK 
Borosilicate glass capillary, 1.0mm outer diameter 
x 0.78mm inner diameter  
Harvard Apparatus, USA 
Zebra Channel Device MMB Foundry, USA 










2.1.2 Cell lines 
Cell line Source 
A-375M2 Dr. Erik Sahai, London Research Institute 
A-375M2 RhoA Dr. Penny Morton, King’s College London 
Adult Melanocytes TCS CellWorks, UK 
HaCaT Dr. Victoria Sanz-Moreno, King’s College London 
Neonatal Melanocytes (1) Dr. Katie Lacy, King’s College London 
Neonatal Melanocytes (2) TCS CellWorks, UK 
NIH3T3 Dr. Maddy Parsons, King’s College London 
SK-MEL-2 Dr. Katie Lacy, King’s College London 
SK-MEL-28 Dr. Katie Lacy, King’s College London 
WM-115 Dr. Katie Lacy, King’s College London 
Table 2-2: Cell lines. 
 
2.1.3 Antibodies 
Antibody Species Dilution Application Company 
Anti-β-Actin Mouse 1:10,000 Western Blotting Sigma-Aldrich (#A5441) 
Anti-c-Myc Mouse 1: 500 Western Blotting Santa Cruz (#sc-40) 
Anti-Cortactin Mouse 1:50 Immunofluorescence Upstate (#05-180) 
Anti-GAPDH Mouse 1: 20,000 Western Blotting Millipore (#MAB374) 




Human 1:600 FACs  
 
Gift from Dr. Sophia 
Karagiannis, King’s 
College London 1:50 Immunofluorescence 
Anti-p-GEF-H1 
(Ser885) 
Rabbit 1:500 Western Blotting Abcam (#ab94348) 
































































Human 1:166 FACS Stratech, UK (#044887-
USB) 




Antibody Species Dilution Application Company 
Alexa Fluor® 488 anti-
human IgG 
Goat 1:200 FACs Dr. Sophia 
Karagiannis, King’s 
College London 1:100 Immunofluorescence 
Alexa Fluor® 488 anti-
mouse IgG 
Goat 1:200 Immunofluorescence Invitrogen 
(#A11001) 
Alexa Fluor® 488 anti-
rabbit IgG 













conjugated anti goat 







Goat 1: 1000 - 
1: 2000 
Western Blotting Dako (#P0448) 




GFP Alone Clontech, UK 
GFPPAK4 Produced by lab of Dr. Claire Wells 
GFPPAK1 Produced by lab of Dr. Claire Wells 
GFPPAK1r Made by author 
GFPPAK4r Produced by lab of Dr. Claire Wells 
mTFP Alone  Gift from Maddy Parsons, King’s College 
London, UK 
pDONR™207 Invitrogen, UK 
pEGFP-C1 Destination vector Clontech, UK 
myc-PDZ-RhoGEF Gift from John Masters, University College 
London (UCL), UK  
myc-PDZ-RhoGEF∆DH Gift from John Masters, UCL, UK  
RhoA Biosensor Gift from Maddy Parsons, King’s College 
London, UK 













Blocking solution 5% w/v milk powder or 5% w/v bovine serum albumin in 
TBS-Tween 
Collagen I matrix 1.617mg/ml Purecol collagen type I, 3mM NaOH, 10% 
FBS in DMEM 
DNA loading buffer 5% w/v glycerol, 0.04% bromophenol blue (w/v) in H2O 
Cell lysis buffer 0.5% NP-40, 30mM sodium pyrophosphate (Na4O7P2), 
50mM Tris-HCl pH7.6, 150mM NaCl, 0.1mM EDTA, 
50mM sodium fluoride (NaF), 1mM sodium 
orthovanadate (Na3VO4), 1mM phenylmethylsulfonyl 
fluoride (PMSF), 10µg/ml leupeptin, 1µg/ml aprotinin 
and 1mM dithiothreitol (DTT) in H2O 
PBS-Tween PBS + 0.1% Tween-20 
SDS-PAGE running buffer 192mM glycine, 19mM Tris Base + 0.1% w/v SDS in H2O 
SDS-PAGE sample buffer  100mM Tris pH 6.8, 10% w/v SDS, 30% v/v glycerol, 
0.2% w/v bromophenol blue in H2O 
SDS-PAGE transfer buffer 192mM glycine, 19mM Tris base + 20% methanol v/v in 
H2O 
Stripping buffer 25mM glycine pH2 + 1% SDS in H2O 
TAE buffer 40mM Tris-HCl, 10mM EDTA in H2O 
TBST  50mM NaCI, 0.1% v/v Tween, 25mM Tris pH7.6 in H2O 
E3 media 5mM NaCl, 0.17mM KCl, 0.44mM CaCl2, 0.68mM MgSO4 
in H2O 
FACS Buffer PBS-/- + 5% FBS 
Table 2-6: Solutions and buffers (working concentrations). 
 
2.2 Methods 
2.2.1 Cell Line Culture 
 
The melanoma cell lines A-375M2, SK-MEL-2 and SK-MEL-28 were grown in Dulbecco's modified 
eagle's medium: nutrient F-12 ham (DMEM F-12) (containing 2.5mM L-glutamine), and the WM-
115 cell line was grown in minimum essential medium (MEM) (containing 2.5mM L-glutamine). 
The HaCaT keratinocyte cell line was grown in Dulbecco’s modified eagle’s medium (DMEM) 
(containing 2.5mM L-glutamine). All the growth media above were supplemented with 10% 
foetal bovine serum (FBS), 100U/ml penicillin and 100μg/ml streptomycin sulphate. The NIH3T3 
fibroblast cell line was grown in DMEM (high glucose (4.5g/L))) supplemented with 10% newborn 
calf serum (NCS), 2.5mM L-glutamine, 100U/ml penicillin and 100μg/ml streptomycin sulphate. 
Human melanocytes were cultured in epidermal melanocyte basal growth medium to which was 
added epidermal melanocyte growth supplement (5µg/ml bovine insulin, 0.18µg/ml 
hydrocortisone, 3µg/ml heparin, 10ng/ml phorbol 12-myristate 13-acetate (PMA), 5µg/ml 
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bovine transferrin, 3ng/ml basic fibroblast growth factor, 0.5% (v/v) FBS, 0.2% (v/v) bovine 
pituitary extract (BPE)) and antibiotic supplement (25µg/ml gentamicin and 50ng/ml 
amphotericin B). Cells were maintained in a humidified incubator at 37°C, with 5% CO2. Cells 
were sub-cultured using 0.5% trypsin/ 0.2% ethylenediaminetetraacetic acid (EDTA) when the 
culture flasks were ~80% confluent.  
 
2.2.2 Thawing and Freezing Cells 
 
To thaw cells, cryovials (from liquid nitrogen) were rapidly warmed in a 37°C water bath and 
transferred into 10ml (T-75 flask) or 5ml (T-25 flask) of cell specific media in a tissue culture flask. 
The media was changed the following day and cells were cultured using the method described 
in 2.2.1.  
When freezing, cells were trypsinised and transferred into cryovials in a 90% FBS and 10% DMSO 
solution. Cryovials were placed in a cryo freezing container at -80°C, overnight, to ensure slow 
freezing, then stored long term in liquid nitrogen tanks.  
 
2.2.3 Preparation of Ethanol Washed Coverslips 
 
13mm round glass coverslips were rocked in 70% ethanol for 30 mins at room temperature, 
after which the process was repeated for a further 30 mins in 96% ethanol. Following this, 
coverslips were air dried in a sterile tissue culture hood. The ethanol washed coverslips were 
stored in a sealed 10cm2 plate for later use.  
 
2.2.4 Immunofluorescent Staining 
 
Cells were seeded onto the ethanol washed coverslips (Section 2.2.3) at a density of 2x104/ml. 
The following day, cells were fixed with 4% (w/v) paraformaldehyde (PFA) for 20 mins at room 
temperature, or overnight at 4°C. Cells were permeabilised for 5 mins using 0.2% (v/v) triton X-
100. Following this, cells were washed three times with phosphate buffer saline plus calcium 
and magnesium (PBS+/+). Non-specific binding was blocked by incubating for 30 mins at room 
temperature with 3% bovine serum albumin (BSA):PBS+/+. After blocking, coverslips were 
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incubated for 2 hrs at room temperature with the primary antibody diluted in 3% BSA:PBS+/+. 
The unbound antibody was removed by washing three times with PBS+/+ and cells were 
incubated for 1 hr at room temperature with the appropriate fluorophore conjugated secondary 
antibody and fluorophore conjugated phalloidin (to stain for F-actin) in 3% BSA:PBS+/+. When 
staining only for F-actin, cells were incubated with phalloidin for 1 hr at room temperature 
directly after permeabilisation with triton X-100. When required, nuclei were stained by adding 
100µM DAPI:PBS+/+ to the cells for 5 mins at room temperature prior to mounting. The coverslips 
were then washed three times with PBS+/+ fixed to microscope slides using Fluorsave™ reagent. 
The fluorescence was visualised using an Olympus Ix71 microscope with Image-Pro Plus 7.0 
software. Confocal images were taken using a Nikon Eclipse Ti confocal microscope or Nikon 
A1R Si Spectral confocal microscope with NIS Element 64bit software. Image analysis was 
performed using ImageJ software.  
 
2.2.5 Establishment and Isolation of Patient Derived Cell Strains 
 
The human melanoma tumour tissues were obtained with written informed consent and all 
work was approved by the Guy's Research Ethics Committee, Guy's and St. Thomas' NHS Trust 
(reference number 08/H0804/139, approval date 15/10/2008).  
Patient tissue was collected (submerged in PBS-/-) the day of surgery from St. John's Institute of 
Dermatology. The adhesive surfaces of a 6 well plate were scratched using a scalpel and coated 
with 10ng/ml fibronectin:PBS-/-. The patient tissue was diced and placed into the 6 well plate. 
Using the padded inner compartment from a 1ml syringe, the patient tissue was firmly pressed 
and spread across the scratched surfaces. The tissue was left to dry and attach for 5 mins at 
room temperature before RPMI 1640 media was added to each well. Once proliferative 
populations were visible, cells were trypsinised and transferred to a new fibronectin coated 6 
well plate and allowed to grow. When the cells were next sub-cultured 2x104 cells were removed 
and stained for high molecular weight melanoma associated antigen (HMWMAA) to assess the 
purity of melanoma cells in the cell population. Thereafter, fluorescence activated cell sorting 
(FACS) by flow cytometry was used to isolate the melanoma cells (FACSAria™ II Cell Sorter) or 
confirm a pure melanoma population (using a BD FACSCanto™ II system). All the experiments 
using the patient derived cell strains were performed within 6 months of the initial seeding to 




2.2.6 Fluorescence Activated Cell Sorting (FACS) 
 
>5x104 cells (in FACS buffer) were added to each well of a 96 well V-bottom plate and centrifuged 
at 1000rpm for 5 mins at 4°C. The supernatant was removed by inverting the plate and the cell 
pellet was dislodged by briefly vortexing. Cells were incubated in 50µl anti-HMWMAA primary 
antibody/anti-IgG isotype control antibody (1.5µg/ml in FACS buffer) for 1 hr at 4°C. Cells were 
washed by centrifugating at 1000rpm for 5 mins at 4°C, inverting the plate, vortexing and adding 
100µl FACS buffer. A further two washes were performed before 50µl secondary antibody (in 
FACs buffer) was added for 90 mins at 4°C, in the dark. To remove the unbound secondary 
antibody the cells were washed three times with FACS buffer. Cells were transferred in 4ml FACS 
buffer containing 0.5% PFA to a Falcon™ 5ml polystyrene round-bottom tube. Samples were 
subject to FACS by flow cytometry within 24hrs.    
 
2.2.7 MTT Assay 
 
4x103 cells were plated in a 96 well plate and left to grow for 4 days. Media was removed and 
replaced with 50µl 5mg/ml methylthiazolyldiphenyl-tetrazolium bromide (MTT) solution:PBS-/- 
and incubated at 37°C, in 5% CO2, for 4 hrs (in the dark). The MTT solution was then removed 
and 50µl DMSO was added. The cells were mixed thoroughly and the absorbance at 570nm was 
measured using an Alpha-Fusion plate reader.  
 
2.2.8 Adhesion Assay 
 
The adhesion assay was performed either on ethanol washed glass coverslips (Section 2.2.3) 
lacking any additional coating or coated with collagen I. The collagen I coated coverslips were 
prepared by adding 200µl 50μg/ml collagen I in 20 mM acetic acid and incubating for 1 hr at 
room temperature. The unbound collagen was removed by washing the coverslips three times 
with PBS-/-.  
Cells were seeded on the coverslips at a concentration of 1x105. All melanocytes were seeded 
at a density of 5x104 when plated on collagen I, due to reduced cell quantity. After 1 hr and 8 
hrs, cells were washed twice with PBS+/+, fixed with 4% PFA and stained for F-actin using the 
immunofluorescent staining protocol (Section 2.2.4). Images were taken at five evenly spaced 
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sites on the coverslip using an Olympus Ix71 microscope with Image-Pro Plus 7.0 software (x10 
objective). The total number of cells in each site were counted using ImageJ software. Cell 
adherence was calculated as a percentage of cells that were adhered at 1 hr compared to the 
cells at 8 hrs.   
 
2.2.9 Cell Morphology Analysis 
 
Cell morphology was analysed using ImageJ software. Within ImageJ, the actin images were 
inverted and the threshold adjusted to fully highlight one cell. Using the Wand Tool, the 
highlighted cell was selected and the cell area, perimeter and elongation was measured. This 
process was repeated for 90 cells over three experiments. The cell elongation was calculated as 
a relative value of the longest axis to the shortest axis of a cell, subtracted from 1 (Ahmed et al., 
2008). Cells classed as having prominent actin fibres were those with at least two prominent 
actin fibres that crossed over the nucleus. 
 
2.2.10 Invadopodia Assay 
 
Rhodamine conjugated gelatin was prepared by incubating 2mg/ml Type A Gelatin (from porcine 
skin) in H2O at pH 9.3 (with 61mM sodium chloride (NaCl) and 50mM sodium borohydride 
(NaBH4)) for 1 hr at 37oC. 36ng/ml Rhodamine B isothiocyanate was added and the mixture was 
rocked for 4 hrs at room temperature in the dark. Large precipitations were removed by filtering 
the rhodamine gelatin through a 0.45µm filter. The filtrate was injected into a Slide-A-Lyzer® 
dialysis cassette and dialysed for 4 days in PBS+/+ at 4°C in the dark. The PBS+/+ was replaced three 
times each day. The rhodamine gelatin was removed from the cassette and centrifuged at 
4000rpm for 2 mins at room temperature to remove any additional precipitations. 20mg/ml 
sucrose was added and the rhodamine gelatin was stored at 4°C until use. 
Ethanol washed coverslips (Section 2.2.3) were coated with 300µl rhodamine conjugated gelatin 
(pre-warmed to 37°C) and incubated at room temperature for 10 mins. The coverslips were then 
inverted onto 120µl 0.5% gluteraldehyde:PBS minus calcium and magnesium (PBS-/-) and 
incubated for 15 mins at room temperature. The coverslips were washed three times using  
PBS-/- and incubated at room temperature for 3 mins with 132mM sodium borohydride:PBS-/-. 
Coverslips were again washed three times with PBS-/- and sterilised using 70% ethanol for 5 mins 
at room temperature. After this, the ethanol was removed and the coverslips were air-dried for 
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10 mins. DMEM media was added to the coverslips, which were then incubated for 1 hr at 37°C. 
Cells were detached from 6 well plates using cell dissociation buffer for 10 mins at 37°C. The 
DMEM media was removed from the gelatin coated coverslips and 2x104 cells were seeded and 
incubated at 37°C for 3 hrs in 5% CO2 (unless otherwise stated). Cells were fixed using 4% PFA 
and stained for the desired protein and F-actin using the immunofluorescent staining protocol 
(Section 2.2.4).  
 
2.2.11 Gelatin Degradation Analysis 
 
The gelatin degradation area was measured for invadopodia producing cells using the gelatin 
degradation plug-in with ImageJ software (kind gift from Laura Machesky, Beatson Institute for 
Cancer Research, Glasgow). Each actin cell image and corresponding gelatin image was cropped 
to contain only one cell and converted to an 8-bit format using Adobe Photoshop. The actin and 
gelatin images were compiled into two separate image stacks (all actin images in one and gelatin 
in another). The stacks were opened using the ImageJ gelatin degradation plug-in to measure 
the degradation area per cell (in pixels). The values were multiplied by the pixel area to convert 
values to real degradation area (µm2). 
 
2.2.12 Fluorescence Intensity Co-Localisation Analysis 
 
The co-localisation of proteins and gelatin degradation was calculated by measuring the 
fluorescence intensity using ImageJ software. Confocal single Z-plane fluorescent images were 
opened in ImageJ, saved as a stack and a single line was drawn across the invadopodia to be 
analysed. The intensity was measured along this line using the Plot Profile tool and exported to 
Microsoft Excel. A plot profile was generated for each channel in the stacked image to show the 
co-localisation of fluorescence intensity.   
 
2.2.13 3D Spheroid Invasion Assay 
 
Spheroids were formed by adding 2.5x102-5x102 cells in 100µl of cell specific media, containing 
5% FBS and 0.32% methylcellulose, into a 96-well U-bottomed suspension culture plate. Cells 
were incubated at 37°C in 5% CO2, for 3 days to enable a spheroid mass to form. On the 3rd day, 
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collagen I matrix (from bovine hide) was prepared on ice and 400µl was added to a 24 well plate 
and allowed to polymerise for 2 hrs at 37°C in 5% CO2. Following this, another 400µl of collagen 
I matrix was added onto the polymerised collagen I layer and the spheroid was transferred 
directly into this layer. The collagen/spheroid layer was allowed to polymerise for 2 hrs at 37°C 
in 5% CO2. Images were taken at day 0 and day 3 or 4 using an Olympus Ix71 microscope with 




WM-115 and A-375M2 cells were plated into a 6 well plate with the cell specific media (without 
antibiotic) at least 24hrs prior to transfection. For WM-115 cells, 2µg DNA and 2µl XtremeGENE 
HP transfection reagent were incubated in 100µl optiMEM for 30 mins at room temperature. To 
transfect A-375M2 cells, 3µg DNA and 3µl Lipofectamine 2000 transfection reagent were 
incubated in 100µl optiMEM for 30 mins at room temperature. Following this, the DNA and 
transfection reagent mix was added, drop wise, to the cells and incubated at 37°C for 48 hrs in 
5% CO2 prior to any further experiments or fixation.  
 
2.2.15 RNA Interference (RNAi) 
 
When transiently knocking down a protein, 2x104 cells were seeded into a 6 well plate. The 
following day, 3µl short interfering RNA (siRNA) oligonucleotides and 12µl HiPerfect transfection 
reagent were added to 97µl optiMEM and incubated at room temperature for 30 mins. When 
two oligonucleotides were used to achieve a double knockdown, 3µl of each oligonucleotide 
was added to the transfection mix (total of 6µl). This mixture was then added, dropwise to the 
cells. Experiments were performed 4-7 days after transfection. The siRNA oligonucleotides used 
in this study (including the target sequence) are shown in Table 2-7.   
To create stable knockdowns of PAK1 or PAK4 A-375M2 cell lines, one T-25 flask (at 70% 
confluency, in media without antibiotic) was transfected with 4µg short hairpin RNA (shRNA) 
DNA construct and 4µl Lipofectamine reagent using the transfection protocol (Section 2.2.14). 
The shRNA constructs used in this study (including the target sequence) are shown in Table 2-7. 
Puromycin selection antibiotic, at a concentration of 1µg/ml, was added to the media 3 days 
post-transfection. Cells were cultured in 1µg/ml puromycin from here onwards to maintain the 
protein knockdown.   
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 siRNA/shRNA Target Sequence (5’-3’) Company 
Control siRNA AATTCTCCGAACGTGTCACGT  Qiagen Ltd, UK (1022076) 
PAK1 Oligo 1 AGAAATACCAGCACTATGA Dharmacon, Thermo Fisher 
Scientific, UK (D-003521-07) 
PAK1 Oligo 3 CATCAAATATCACTAAGTC Dharmacon, Thermo Fisher 
Scientific, UK (D-003521-03) 
PAK4 Oligo 1 GGTGAACATGTATGAGTGT Ambion, UK (AM16708) 
PAK4 Oligo 2 CGAGAATGTGGTGGAGATGTA Qiagen Ltd, UK (SI02660315) 
Control shRNA 
(pGIPz) 
CTTACTCTCGCCCAAGCGAGAG Open Biosystems, Thermo 
Fisher Scientific, UK (RHS4346) 
PAK1 shRNA  1 
(pGIPz) 
GCCTAGACATTCAAGACAA Open Biosystems, Thermo 
Fisher Scientific, UK 
(V2LHS_152618) 
PAK1 shRNA 2 
(pGIPz) 
TATTGTCACTCTTGATGTC Open Biosystems, Thermo 
Fisher Scientific, UK 
(V2LMM_68590) 
PAK4 shRNA 1 
(pGIPz) 
TCTTGATGAAGTTGTCCAG Open Biosystems, Thermo 
Fisher Scientific, UK 
(V2LHS_197812) 
PAK4 shRNA 3 
(pGIPz) 
CTTCGGACATTCATGATCG Open Biosystems, Thermo 
Fisher Scientific, UK 
(V3LHS_646396) 
Table 2-7: siRNA oligonucleotides and shRNA constructs used in this study.  
 
2.2.16 Cell Lysates 
 
Cells were seeded into 6 well plates and when at 90% confluency were lysed using cell lysis 
buffer. Cell debris was removed by centrifugation at 13,000rpm for 10 mins at 4°C. The 
supernatant was placed in 1.5ml eppendorf tubes and gel sample buffer was added. Samples 
were boiled for 3 mins and stored at -20°C until use. 
 
2.2.17 Western Blotting 
 
Lysate samples were thawed, boiled for 3 mins and solubilised proteins were then separated by 
electrophoresis at 125V for 1-2 hrs on a 6.5 - 10% (w/v) polyacrylamide-SDS gel, submerged in 
SDS-PAGE running buffer. 5µl precision plus protein marker was used as a size indicator. Proteins 
were transferred onto protran nitrocellulose hybridization transfer membranes using SDS-PAGE 
transfer buffer at 100V for 1-1.5 hrs. Blots were placed in Tris-buffered saline with Tween-20 
(TBST), containing 5% (w/v) non-fat milk powder or 5% BSA (w/v) for 1 hr at room temperature 
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to block non-specific binding. The membranes were incubated overnight at 4°C in primary 
antibody in TBST with 1% (w/v) non-fat milk powder or BSA. To remove unbound primary 
antibody, the membranes were washed three times for 10 mins each, in TBST. When probing 
the membranes with the polyclonal rabbit anti-PAK5 antibody the wash time was increased to 
15 mins per wash. Following this, membranes were incubated for 1 hr at room temperature with 
the respective secondary antibody conjugated with horseradish peroxidase at double the 
dilution of primary antibody in TBST with 1% (w/v) non-fat milk powder or BSA. Proteins were 
detected using Pierce® enhance chemiluminescence (ECL) western blotting substrate and 
analysed using ImageJ software. The western blots shown in figures are exposure copies and 
may not be film that was used for analysis. 
To remove the antibodies to allow for another protein to be detected (used for phosphorylated 
and total protein levels), the blot was rocked twice, each for 15 mins in fresh stripping buffer. 
The unbound antibody was washed for 5 mins with PBS-Tween. The membrane was blocked 
with TBST containing 5% (w/v) non-fat milk powder or 5% BSA (w/v) for 1 hr at room 
temperature and the western blot protocol was repeated.  
 
2.2.18 Fluorescence Resonance Energy Transfer (FRET) 
 
2x104 A-375M2 cells, stably transfected with a RhoA biosensor, were seeded onto ethanol 
washed glass coverslips (Section 2.2.3). The following day, cells were fixed, permeabilised and 
washed, using the immunofluorescent staining protocol (Section 2.2.4). To quench the 
autofluorescence, often caused by the PFA, the cells were incubated in 1mg/ml sodium 
borohydride:PBS+/+ for 15 mins at room temperature. Coverslips were then washed three times 
with PBS+/+ and mounted onto glass slides using ProLong® Gold antifade reagent. FRET was 
measured using a multiphoton, time-correlated single-photon counting (TCSPC) fluorescence 
lifetime imaging microscope (FLIM). FRET efficiency was analysed using TRI2 software (Barber et 
al., 2009). 
 
2.2.19 Polymerase Chain Reaction  
 
When PCRs were performed for diagnostic techniques the PCR sample contained 10ng of 
template DNA, 100ng of each primer, 1 unit crimson Taq DNA polymerase and 2.5µl crimson Taq 
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reaction buffer, in a final volume of 25μl. The primers used in this study are shown in Table 2-8. 
The PCR program was as follows: 94°C for 2 mins; thereafter 30 cycles consisting of: 94°C for 30 
secs (denaturing phase); 55°C for 30 secs (annealing phase); and 72°C for 1 min per kilobase pair 
(kbp) of DNA to be amplified (elongation phase). Lastly, an additional incubation at 72°C for 5 
mins was performed to ensure all PCR fragments were fully elongated.  
When PCR fragments were required for further molecular cloning techniques, the Taq 
polymerase-containing mixes were substituted for 2.5 units of the proof reading enzyme 
Phusion® HF or Q5™ high-fidelity DNA polymerase and a 800μM dNTP mix in the corresponding 
buffer. Negative controls contained no template DNA. Positive controls contained a plasmid with 
the correct primer binding sites to produce the desired PCR product. 
 
Primer Use Sequence (5’-3’) 


















Table 2-8: The sequence of the primers used in this study.  
 
PCR samples were visualised by gel electrophoresis. The Quick-Load® 100bp DNA ladder or 
Quick-Load® 1Kb DNA ladder was included in all gels. Electrophoresis gels consisted of 1% 
agarose and ethidium bromide (1:100,000 dilution) in Tris-acetate-EDTA TAE buffer. 1% low 
melting point agarose containing gels were used when band excision was required for use in 
further cloning experiments. Gels were submerged in TAE buffer and run at 60-90 Volts for 45 
mins. DNA fragments were visualised with a Gel Doc-It™ TS Imaging System. Excised bands were 
visualised using a UVP dual intensity transilluminator and removed with a sterile scalpel. PCR 
fragments were purified from electrophoresis gels by using the Illustra GFX™ PCR DNA and gel 





2.2.20 Site Directed Mutagenesis 
 
To produce the PAK1 Oligo 1 siRNA resistant mutant, two PCR reactions were performed to 
produce one fragment from the 5’ PAK1 (flanked by the attB1 site) to the mutated sequence 
and one fragment from the mutated sequence to the 3’ (flanked by the attB2 site) PAK1 
sequence. The resulting two PCR products were mixed and used as template DNA in a further 
PCR reaction to produce the full length PAK1 gene containing the desired mutations. The 
Gateway® Technology system (Invitrogen, UK) was used to clone the PAK1 mutated fragment 
into a GFP tagged vector using two recombination reactions, the BP and LR reaction.  
Firstly, an entry clone was created in the BP reaction by incubating 120ng PAK1 fragment 
(flanked by attB sites), 150ng pDONR™207 vector and 4µl BP clonase in TE buffer to a total 
volume of 20µl, for 1 hr at room temperature. 2µl proteinase K was added to stop the reaction 
and incubated for 10 mins at 37°C.  
DNA was then transformed in Escherichia coli (E. Coli). 5μl of the reaction mix was added to 25μl 
chemically competent E. coli cells (DH5α strain) and incubated on ice for 30 mins. Following this, 
cells were heat shocked at 42°C for 20 secs and again placed on ice for a further 2 mins. Cells 
were added to 500μl Luria-Bertani (LB) broth and placed in a shaking incubator for 1 hr at 37°C. 
After this, 250μl of incubated cells were spread on LB agar plates containing the appropriate 
antibiotic (100µg/ml ampicillin or 50µg/ml kanamycin) and incubated overnight at 37°C. 
Colonies were screened by adding a proportion of the colony into 10µl H2O, incubating for 10 
mins at 95°C and then inserting into a PCR reaction. The positive colonies were amplified and 
purified using a Mini or Midi prep or kit. The vectors were sequenced to screen for any mutations 
that may have been produced during PCR amplification. Purified DNA was diluted to 100ng/µl 
in a total volume of 15µl. Primers were diluted to 2pmol/µl, with a total volume of 15µl. DNA 
was sequenced by Eurofins MWG (London, UK).  
Secondly, 100ng of the resulting entry clone was incubated, in the LR reaction, with 150ng 
pEGFP-C1 destination vector and 4µl LR clonase in TE buffer, in a total volume of 20µl. The LR 
reaction mixture was incubated for 1 hr at room temperature, the 2µl proteinase K was added 
and incubated for 10 mins at 37°C. The reaction mix was transformed in E. Coli and the resulted 





2.2.21 Zebrafish Embryo Maintenance  
 
All work that was conducted using zebrafish were performed under the UK Home Office project 
licence PPL 70/7912 and approved by the King’s College Ethical Review committee.  
Adult zebrafish were maintained in H2O produced by a reverse osmosis system at 28°C and 
exposed to a light:dark cycle of 14:10 hrs. Embryos were obtained by placing one male and 
female in a gated breeding tank (containing a grated inner tank and a lower collection tank) the 
evening before embryos were required. The following morning the gate was removed from the 
breeding tank, enabling the adults to spawn. Embryos were collected 2 hours after the gate 
removal.  
To collect the embryos, the zebrafish were removed from the breeding tank and the lower 
collection tank H2O was poured through an inverted sieve, where the embryos were caught. The 
embryos were transferred from the sieve to a 10cm petri dishes containing E3 media with 
0.0002% methylene blue. Faeces and debris was removed from the media and the embryos were 
stored at 28°C. 6-8 hours post-fertilisation (hpf), unfertilised cells were removed to prevent the 
apoptosis of fertilised embryos. 1 day post-fertilisation (dpf) the chorion (the capsule enclosing 
the embryo) was removed from each embryo, to prevent curling of the embryo during 
development. After the completion of experiments or after 6 dpf (whichever was sooner) 
embryos were killed, via exposure for 1 hr to an anaesthetic overdose of 15mM Ethyl 3-
aminobenzoate methanesulfonate (MS222).   
 
2.2.22 Zebrafish Yolk Invasion Assay 
 
Injection needles were prepared using a P-87 flaming/brown micropipette puller. Each 
borosilicate glass capillary (1.0mm outer diameter x 0.78mm inner diameter) was pulled at both 
ends away from a central heating element until the glass had extended to create two fine 
needles.  
A-375M2 stably transfected cells were detached from a T-75 flask using dissociation buffer and 
2.1x107 cells/ml were added to PBS-/-, in at total volume of 50µl, and placed on ice. 2 dpf embryos 
were submerged in 3.5mM MS222, 50 units/ml penicillin and 50µg/ml streptomycin and placed 
in a V-shaped grooved 2% agarose (in H2O) mould. The cells were loaded into a borosilicate glass 
capillary needle and approximately 500 A-375M2 cells were injected into the embryo yolk sac 
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using a Nikon SMZ-U zoom 1:10 Picospritzer II microinjection station. Injected embryos were 
placed in E3 media (containing 50 units/ml penicillin and 50µg/ml streptomycin) and incubated 
at 28°C for 1 hr to recover, then transferred to 35°C for the remainder of the experiment. 4 hrs 
post-injection, embryos that lacked a clear tumour mass within the yolk sac or that had cells 
outside of the yolk sac were removed and humanely killed using 15mM MS222. The percentage 
of embryos with A-375M2 cell tail invasion was calculated 4 days post-injection. The embryos 
were then humanely killed by the addition of 15mM MS222 for 1 hr. 
 
2.2.23 Imaging of Zebrafish Embryos 
 
To obtain representative fluorescent and brightfield images, the embryos were firstly 
anaesthetised with 3.5mM MS222. Embryos were placed, on their side, in a V-shaped grooved 
2% agarose (in H2O) mould, submerged in reverse osmosis H2O (containing 3.5mM MS222 and 
200mM PTU) and imaged using a Nikon SMZ1500 dissecting microscope. Alternatively, for the 
tiled images, embryos were placed in a zebra channel device (containing 3.5mM MS222 and 
200mM PTU) and imaged using an Olympus Ix71 microscope with Image-Pro Plus 7.0 software. 
After imaging, the H2O was replaced with fresh H2O (lacking MS222) and the embryos were 
carefully removed from the mould and returned to the incubator.  
 
2.2.24 Statistical Analysis 
 
An unpaired, two-tailed t-Test was used to measure all statistical significance, except for the 
FACS efficiency significance, where a Kolmogorov–Smirnov test was used. Data was considered 









The survival rate for patients suffering from early stage melanoma is extremely good (5 year 
survival of 98%). However, around 16% of melanoma patients are diagnosed with metastatic 
disease (American Cancer Society, 2011; American Cancer Society, 2014). Once melanoma 
metastasises, the available therapies provide little effective treatment with a 5-year survival rate 
of 62% for regional metastasis (the surrounding tissue) and 16% when distant metastasis has 
occurred (Whiteman et al., 2011; American Cancer Society, 2014).  This highlights the need to 
improve knowledge regarding the mechanisms by which melanoma metastasises with a view to 
identifying new therapeutic targets and prognostic tools.  
Tumour metastasis involves multiple steps - breaking through the basement membrane, 
invasion through the surrounding tissue, intravasation into blood or lymph vessels, 
extravasation into surrounding tissue and ultimately cell growth at distant sites (Chambers et 
al., 2002). During the initial stages of metastasis, cancer cells are thought to use actin rich 
protrusions called invadopodia to degrade the basement membrane and surrounding 
extracellular matrix (Stylli et al., 2008; Buccione et al., 2009; Ridley, 2011) and inhibition of 
proteins associated with invadopodia function can inhibit tumour cell invasion both in vitro and 
in vivo (Yamaguchi et al., 2005a; Gligorijevic et al., 2012; Paz et al., 2013). Indeed, the formation 
of invadopodia is often used as a marker of invasive potential (Yamaguchi, 2012). However, the 
regulation and co-ordination of these proteins in invadopodia protrusions are not fully 
understood, and in particular, the function of serine/threonine kinases remains unknown.  
This chapter characterises the morphology and invasive properties (using both 2D and 3D 
assays) of a variety of melanoma cell lines and patient derived cell strains, and compares these 
properties to melanocyte wildtype controls. These studies are designed to inform and 






In order to investigate the role of PAKs in melanoma invasion (Chapter 4 and 5), the level of 
invasiveness of the cell lines used in this study needs to be established. The use of a single cell 
line to investigate the pathways involved in cancer cell invasiveness is not ideal, as the data 
obtained could be specific to the cell line in question and not be representative of the more 
general cancer signalling pathways. This chapter, therefore aims to rank the relative cell 
invasiveness of the chosen melanoma cell lines compared to melanocyte controls. As such, a 
range of assays were employed, including cell morphology, 2D invadopodia and the 3D spheroid 
assay. Therefore in this study a number of different cell lines were utilised to conduct these 
invasive studies. 
 
3.2.1 Characterisation of Melanoma Cell Lines 
 
Four melanoma cell lines were selected for this study: two from primary origins (SK-MEL-28 and 
WM-115); and two from metastatic origins (A-375M2 and SK-MEL-2). Melanocytes from both 
neonatal (from two sources, named (1) and (2)) and adult origins were used as wildtype controls. 
  
3.2.1.1 Cell Morphology  
 
Cell shape has previously been used as an indicator of cell invasiveness (Friedl and Wolf, 2003). 
Cell morphology may therefore be an indicator of invasive potential and thus this characteristic 
was studied in the melanoma cell lines. 
To determine their shape, cells were seeded on glass coverslips, incubated overnight, then fixed 
and stained for F-actin. The cell area, cell perimeter and cell elongation were calculated for each 
cell line and melanocyte control using ImageJ software (Figure 3-1). All the cell lines had 
significantly different cell areas, when compared to neonatal melanocytes (1), with the 
exception of the SK-MEL-2 cells (Figure 3-1). Cell area also varied between the various cell lines. 




Figure 3-1: Cell shape analysis of melanoma cell lines and normal melanocytes.  
Cells were seeded on glass coverslips and stained for F-actin. The cell area (A), cell perimeter (B) and cell 
elongation (C) were calculated for 90 cells over 3 independent experiments. Cell elongation was 
represented as a scale from 0 to 1 where 0 = circular and 1 = straight. Significance was calculated to 
neonatal melanocyte (1). Data are mean values ± S.E.M.; * = P < 0.05.  
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The A-375M2, WM-115 and SK-MEL-2 cell lines exhibited a reduced cell perimeter and cell 
elongation compared to the melanocyte controls (Figure 3-1B and C). This indicates that these 
cell lines are more circular with potentially less ruffles or protrusions at the cell membrane. In 
contrast the SK-MEL-28 cell line exhibited an increased cell perimeter and elongation compared 
to the melanocyte controls. However, this increased perimeter is likely accounted for by the 
large cell area of these cells.  
During the cell shape analysis (which was performed on F-actin stained cells) a difference in the 
number of cells with prominent actin fibres was noted. Therefore, the nature of actin fibre 
formation in these cells was examined. The presence of prominent actin fibres has been linked 
to cell rigidity and a reduction in invasion (Friedl and Wolf, 2003).  
Normal melanocytes from all three populations had prominent actin fibres (Figure 3-2). 
However of the melanoma cell lines only WM-115 cells showed a significant reduction in 
prominent actin fibres compared to the melanocyte control. This suggests that the WM-115 cell 




Figure 3-2: Quantification of the percentage of cells with prominent actin fibres.  
Cells were seeded on either glass coverslips and stained for F-actin. Significance was calculated to 
neonatal melanocyte (1). Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * 




3.2.1.2 Invadopodia Assay as a Measure of Cell Invasiveness 
 
A 2D invadopodia assay was utilised as part of our cell characterisations. Actin rich protrusions 
were identified by F-actin staining and were confirmed to be invadopodia structures by their 
degradative capacity and ability to co-localise with the invadopodia localising protein cortactin 
(Figure 3-3). Confocal images were taken and fluorescence intensity plots through an 
invadopodia structure were measured, both of which showed co-localisation of cortactin and F-




Figure 3-3: Co-localisation of cortactin with F-actin and TRITC gelatin degradation. 
A-375M2, WM-115 and SK-MEL-2 cells were seeded on TRITC gelatin coated coverslips for 3 hrs and then 
fixed and stained for F-actin and cortactin. (A) Representative confocal images showing co-localisation of 
F-actin, cortactin and gelatin degradation. Scale bar = 10µm. (B) A representative fluorescence intensity 
plot for each cell line showing co-localisation of cortactin, F-actin and gelatin degradation. Fluorescence 





The number of cells with invadopodia protrusions was measured, as well as the area of gelatin 
degradation per cell (when appropriate), for each melanoma and melanocyte cell line (Figure 
3-4 and Figure 3-5). As expected, none of the melanocyte controls were able to make 
invadopodia (Figure 3-5A). Of the melanoma cell lines, a significant number of cells belonging to 
the A-375M2, SK-MEL-2 and WM-115 cell lines produced invadopodia. Interestingly, the WM-
115 primary cell line not only formed invadopodia, but had a significantly higher percentage of 
cells with these structures, compared to the other invadopodia forming cell lines. This was also 
true for the area of degradation, where the invadopodia producing WM-115 cells had a higher 
degradative capacity than both the A-375M2 and SK-MEL-2 cells (Figure 3-5B). Less than 1% of 
cells produced invadopodia in the primary melanoma cell line SK-MEL-28, and this was not 
statistically significant when compared to the neonatal or adult melanocytes. This data shows 
that the A-375M2, WM-115 and SK-MEL-2 cell lines produce invadopodia and can be classed as 




Figure 3-4: Representative invadopodia assay images of melanoma cell lines and melanocyte controls. 
Cells were seeded on rhodamine conjugated gelatin for 3 hrs and stained for F-actin. Only actin rich dots 
that corresponded with gelatin degraded dots were counted as invadopodia. The degradation was 
measured using ImageJ software. Scale bars = 20µm. 
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 Figure 3-5: Invadopodia assay of melanoma cell lines and melanocyte controls.  
(A) The percentage of cells with invadopodia. Significance was calculated to neonatal melanocytes (1) and 
between all melanoma cell lines. Data are mean values ± S.E.M. of 150 cells, over 3 independent 
experiments; * = P < 0.05. (B) The area of degradation from invadopodia per cell. Significance was 
calculated between all cell lines. Data are mean values ± S.E.M. of 90 invadopodia producing cells, over 3 
independent experiments; * = P < 0.05, ns = not significant.  
 
 
3.2.1.3 Characterisation of Cellular Adhesion 
 
Cellular adhesions play a functional role in invadopodia structures as well as cell motility (Friedl 
and Wolf, 2003; Beaty et al., 2013), and as such, the intrinsic adhesive properties of the various 
cell lines were investigated to identify any differences between primary and metastatic 
melanoma. In addition, the adhesion to collagen I was investigated due to the in vivo relevance 
(the dermal extracellular matrix surrounding melanoma cells in vivo being comprised mostly of 
collagen I) (Rook, 2010) and to validate the use of this matrix in the 3D spheroid invasion assay 
(section 3.2.1.4). Melanoma cell lines were plated on glass or collagen I coated coverslips and 
allowed to adhere for 1 or 8 hrs. Adherence was calculated as the number of cells adhered at 1 
hr compared to 8 hrs (taken at 100%) (Figure 3-6).  
76 
 
Interestingly, on glass coverslips all the cell lines and the melanocyte controls had similar 
adherence values, except for A-375M2 and SK-MEL-2 cells, which were reduced (Figure 3-6). 
However, on a collagen I matrix all cell lines (including melanocyte controls) adhered equally 






 Figure 3-6: Adhesion assay on glass and collagen I.  
Cells were plated at 1x105, fixed and stained for F-actin 1 hr and 8 hrs after seeding. Melanocytes were 
plated at 5x104 per well when plated on collagen I. (A) Representative F-actin images of cells at 1 hr post-
seeding on glass or collagen I. Scale bar = 100µm. (B) The percentage of cells attached at 1 hr compared 
to 8 hrs after seeding. Significance was calculated to neonatal melanocyte (1) and between plastic and 






3.2.1.4 3D Spheroid Invasion Assay using Melanoma Cell Lines 
 
Cells can exhibit phenotypic differences in 2D environments, when compared to 3D (Sahai, 
2007). Thus, to complement 2D experiments many scientists also employ 3D assays to 
investigate invasion in environments that would more closely resemble that seen in vivo (Zaman 
et al., 2006; Yamazaki et al., 2009). One such 3D assay that has been used reliably in the past is 
the spheroid invasion assay (Wolf et al., 2007; Sabeh et al., 2009; Wiercinska et al., 2011). In this 
assay, spheroid tumour masses are created and encapsulated by a 3D matrix, such as collagen I, 
to represent the primary tumour mass and the surrounding tissue. Over time, the tumour cell 
invasion away from the spheroid mass can be measured.   
The dermis extracellular matrix (often the site where melanoma invasion occurs) is comprised 
predominantly of collagen I (Rook, 2010). Data from the previously described adhesion assay 
(Figure 3-6) revealed that all the tested melanoma and melanocyte cell lines adhered to a 
collagen I matrix. Therefore, the 3D spheroid invasion assay was chosen as a suitible model to 
quantify cellular invasion in a 3D environment. 
Cells were firstly submerged in methylcellulose media for 3 days to allow for the formation of 
the spheroid mass. They were then transferred into a collagen I matrix, where the level of 
invasion was quantified after 4 days.  
During assay optimisation, the diameter of the A-375M2, SK-MEL-2 and SK-MEL-28 spheroids 
dramatically increased when in the collagen I matrix for 4 days, while the diameter of the WM-
115 cell line derived spheroid and the melanocyte derived spheroids did not change. These 
differences in spheroid diameter could indicate differences in cell proliferation rates. Therefore, 
an MTT assay was performed, over the length of 4 days, to estimate the difference in 
proliferation between the A-375M2, SK-MEL-2, SK-MEL-28 and WM-115 cells (Figure 3-7). The 
MTT assay confirmed that the A-375M2, SK-MEL-2 and SK-MEL-28 cell lines had significantly 
higher proliferation when compared to the WM-115 cells (Figure 3-7). It was deduced from the 
MTT assay that the WM-115 cells had a 40% reduction in proliferation rate. Thus the seeding 




 Figure 3-7: MTT assay of the melanoma cell lines.  
Cells were grown over 4 days to simulate the time that the spheroid would spend in the collagen I matrix 
in the 3D spheroid invasion assay. Cells were incubated in MTT solution and solubilised in DMSO. The 
absorbance was measured using a plate reader and normalised relative to A-375M2 cells. Significance was 
calculated between all cell lines. Data are mean values ± S.E.M., over 3 independent experiments; * = P < 
0.05. 
 
Subsequent cell invasion was measured in two ways: the number of cells that exhibited clear 
spatial separation from the spheroid mass (see red arrows in Figure 3-8) and the number of cells 
that had migrated further than 100µm from the spheroid edge.  
Using the 3D spheroid invasion assay it was demonstrated that all the melanoma cell lines had 
a higher number of invading cells when compared to neonatal melanocytes (1) (Figure 3-8A and 
B).  
Interestingly, when the number of cells that invaded further than 100µm was calculated (Figure 
3-8C), only the A-375M2 and WM-115 cell lines were found to be significantly different 
compared to the neonatal melanocytes (1). Thus, in this assay the WM-115 cell line is the most 
invasive melanoma cell line, followed by A-375M2, SK-MEL-2 and then SK-MEL-28. These results 
phenocopy those seen in the 2D invadopodia assay (Figure 3-5), suggesting that there is  a good 






Figure 3-8: 3D spheroid invasion assay of melanoma cell lines.  
Spheroid were produced in methylcellulose for 3 days, then submerged in a collagen I matrix. The cell 
invasion was measured at day 4 commencing when the spheroids were placed in the collagen I matrix. (A) 
Representative phase contrast images of the spheroids at day 0 and 4. Examples of invading cells are 
indicated by red arrows. Scale bar = 100µm (B) The number of cell that had invaded away from the 
spheroid mass. Significance was calculated to neonatal melanocytes (1). Data are mean values ± S.E.M., 
of 9 spheroids over 3 independent experiments; * = P < 0.05.  (B) The number of cells that invaded further 
than 100µm from the spheroid mass. Significance was calculated to neonatal melanocytes (1). Data are 
mean values ± S.E.M., of 9 spheroids over 3 independent experiments; * = P < 0.05. 
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 Cell Line Invadopodia 
Assay 
3D Spheroid Invasion Assay (Number of 
invading cells) 
Total >100µm from the 
Spheroid 
WM-115 +++ +++ +++ 
A-375M2 ++ ++ ++ 
SK-MEL-2 + + ns 
SK-MEL-28 ns + ns 
Neonatal 
Melanocytes (1) ¥ ¥ ¥ 
Neonatal 
Melanocytes (2) ns ns ns 
Adult 
Melanocytes ns ns ns 
Table 3-1: Collation of the melanoma cell line and melanocyte invasive phenotypes in the 2D and 3D 
invasion assay.  
The trend in invasion is depicted by the number of + symbols (+ = low invasion, +++ = highest invasion). 
The number of + symbols indicates the trend in invasiveness and may not necessarily indicate significant 
differences in invasion to other cell lines with the + symbol. ¥ indicates the control cells to which 
significance was calculated: ns= not significant (P > 0.05).   
 
3.2.2 Characterisation of Melanoma Patient Derived Cell Strains 
 
Most commercially available cell lines have been established many years ago and cultured 
through several passage numbers. As such these cell lines may have acquired differing 
phenotypes to that present in the patient. In addition, it is not known whether melanoma cells, 
recently derived from patient tissue, can form invadopodia and/or invade collagen I matrices. 
Therefore, to complement the cell line findings, cell strains from melanoma patient primary and 
metastatic lesions were established and utilised in various experiments in parallel with the 
commercially available cell lines.   
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Surgical biopsies of primary and metastatic melanoma tissue are used for histological testing, 
but, when possible, small samples can also be used for scientific research. The excised 
melanoma tissue samples contain a range of cell types along with the melanoma cells, including 
fibroblasts and keratinocytes. Thus, melanoma cell isolation is required. 
In this study six patient derived cell strains were established from both primary (M133, M460 
and M586) and metastatic (M581, M575 and M35) patient tissue with associated clinical data.    
 
3.2.2.1 Establishing Patient Derived Cell Strains 
 
Tissue from patients with primary and metastatic melanoma were grown on fibronectin coated 
plates and a small number were removed and stained for high molecular weight melanoma 
associated antigen (HMWMAA) in order to estimate the percentage of melanoma cells present. 
The A-375M2 cell line was used as a positive control. In addition, the NIH3T3 fibroblast cell line 
and HaCaT keratinocyte cell line were used as a negative control for HMWMAA staining (Figure 
3-9). Those samples in which the initial immunofluorescent stain suggested over 90% of 
HMWMAA positive cells were further analysed via FACS to obtain a more accurate cell count 
(Figure 3-10). All other patient strains were FACS sorted to isolate the HMWMAA positive cells. 
The successfully established patient derived cell strains, with associated patient clinical data, are 











 Figure 3-9: HMWMAA staining of patient derived tissue populations.  
The cells grown from patient tissue were stained for HMWMAA and F-actin to identify and estimate the 
population of melanoma cells. A-375M2 (positive), NIH3T3 (negative) and HaCaT (negative) were stained 






Figure 3-10: Fluorescence activated cell sorting (FACS) confirming the purity of melanoma cell in patient 
derived cell strains.  
(A) FACS fluorescence intensity histograms (fluorescence intensity plotted against the number of events) 
of the patient derived cell strains, the positive control (A-375M2) and two negative control (NIH3T3 and 
HaCaT) cell lines. (B) The percentage of HMWMAA positive cells in the cell population. Data are mean 













M133 Primary IIC 11/2009 
(cells then 
frozen) 
IIC Died 02/2010 
(carcinomatosis 
bronchus) 
M586 Primary IIC 01/2013 IIC Alive 
M460 Primary IIIA 03/2012 IV Died 10/2013 
(metastatic melanoma) 
M581 Metastatic IIIB 01/2013 IIIB Alive 
M575 Metastatic IIIB 12/2012 IV Died 12/2013 
(pneumonia and 
metastatic melanoma) 
M35 Metastatic IIIC 04/2012 IV Died 12/2012 
(metastatic melanoma) 
Table 3-2: Clinical data for all successfully established patient cell strains.  
 
3.2.2.2 Cell Morphology   
 
To complement the previously described melanoma cell line characterisation (Section 3.2.1.1), 
the cell shape of patient derived cell strains was recorded. Cell elongation was of special interest 
as our melanoma cell line findings suggested a decreased elongation in melanoma cells 
compared to melanocyte controls (Figure 3-1C). The cells were seeded on glass coverslips, 
incubated overnight and stained for F-actin (Figure 3-11). The cell area and perimeter of the 
different patient derived cell strains was diverse, with no representative cell area identified 
(Figure 3-11A and B). Indeed, no consistent difference in cell shape was seen between cells that 
were from primary or metastatic sites. 
In contrast, there was a decrease in elongation across all patient derived cell strains when 
compared to neonatal melanocytes (1) (Figure 3-11C). However, there was no difference 
between those strains derived from patients with primary or metastatic melanoma. These 
findings are in line with the data obtained from the melanoma cell lines and suggest that a less 
elongated/more circular cell shape is adopted by melanoma cells when compared to wildtype 




Figure 3-11: Cell shape analysis of patient derived cell strains.  
The cell area (A), cell perimeter (B) and cell elongation (C) were calculated for 90 cells, over 3 independent 
experiments. Cell elongation was represented as a scale from 0 to 1 where 0 = circular and 1 = straight. 





3.2.2.3 Patient Derived Cell Strains Form Invadopodia 
 
Studies in section 3.2.1.2 and 3.2.1.4 demonstrated that a combination of the invadopodia assay 
and 3D spheroid invasion assay gave a good indication of invasive potential across a variety of 
melanoma cell lines. Thus, the invasiveness of the patient derived cell strains were tested in the 
invadopodia assay.  
Cells were initially plated on rhodamine conjugated gelatin coverslips and incubated for 3 hrs 
before fixing and staining for F-actin in line with the previous studies (Figure 3-5). However, in 
contrast to the melanoma cell lines, only the M35 patient derived cell strain produced 
invadopodia after a 3 hr incubation (Figure 3-13). Interestingly, the M35 strain (derived from a 
patient with advanced disease) produced a higher percentage of cells with invadopodia (89%) 
than any of the melanoma cell lines (74% for WM-115) (Figure 3-5). 
Previous studies have analysed invadopodia activity up to 24 hrs post seeding (Artym et al., 
2006; Caldieri et al., 2009; Stylli et al., 2009), thus a longer incubation time of 24 hrs was also 
used. Even, after 24hrs the M133, M581 and M575 cell lines were unable to produce a significant 
number of invadopodia compared to neonatal melanocytes (1) (Figure 3-12 and Figure 3-13). A 
small number of M581 cells were able to form invadopodia, however, not at significant levels 
compared to the control melanocytes.  
In contrast, the M586, M460 and M35 cell strains all produced significant percentages of cells 
with invadopodia when incubated on the gelatin for 24 hrs. Moreover, the M35 cell strain had 
the highest degradation level per cell (Figure 3-13B), which is particularly noteworthy given it 
has the smallest cell area of all invasive cell strains (Figure 3-11), thus suggesting a high degree 




 Figure 3-12: Representative images of the patient derived cell strain invadopodia assay at 24 
hrs. 
Cells were seeded on rhodamine conjugated gelatin for 24hrs and stained for F-actin. Only actin 
rich dots that corresponded with gelatin degraded dots were counted as invadopodia. The 




 Figure 3-13: 3 hrs and 24 hrs Invadopodia assay of patient derived cell strain and neonatal 
melanocyte (1) control.  
(A) The percentage of cells with invadopodia when cells were plated on gelatin for 3 hrs and 24 hrs. 
Significance was calculated to neonatal melanocytes (1). Data are mean values ± S.E.M. of 150 cells, 
over 3 independent experiments; * = P < 0.05. (B) The area of degradation per cell when cells were 
plated on gelatin for 3 hrs and 24 hrs. No degradation was quantified for M586 and M460 at 3 hrs 
due to the lack of cell number. Significance was calculated between all cell lines at the same time 
point. Data are mean values ± S.E.M. of 90 invadopodia producing cells, over 3 independent 











3.2.2.4 The Invasion of Patient Derived Cells in the 3D Spheroid Invasion Assay 
 
Following the invadopodia study, the cell strains were subsequently tested in the 3D spheroid 
assay. The 3D spheroid assay had produced robust, differential invasive phenotypes of the 
melanoma cell lines compared to melanocyte controls (Section 3.2.1.4), which correlated with 
the results obtained from the melanoma cell line 2D invadopodia assay (Section 3.2.1.2). The 
behaviour of the patient derived cell strains was tested in the 3D spheroid assay to ascertain if 
the result also correlated with invadopodia formation.  
As all melanoma cell lines and melanocytes from adult and neonatal melanocytes were able to 
adhere to collagen I (Section 3.2.1.3) and the major component of the dermis is collagen I, it was 
assumed that the patient derived cell strains would also adhere to collagen I.  
Unlike the 3D spheroid invasion assay performed with the melanoma cells lines, which 
submerged the spheroid in collagen I matrix over 4 days, the patient derived cell strains were 
only in the collagen I matrix for 3 days. This timeframe was altered as there were cells outside 
the field of view on day 4, which would not have been quantified and thus may have skewed the 
invasion data. All the patient derived cell strains were able to form spheroid masses in the 
methylcellulose, except for M35, therefore, this strain was not included in the 3D spheroid 
invasion assay.  
Significant numbers of cells invaded away from the spheroid mass for all tested patient derived 
cell strains, compared to neonatal melanocytes (1) (Figure 3-14A and B). The M575 cell strain 
had the highest number of invading cells and the highest number of cells that invaded further 
than 100µm from the spheroid, followed by M460, M586, M581 and lastly M133 (Figure 3-14B). 






Figure 3-14: 3D spheroid invasion assay of patient derived cell strains compared to neonatal 
melanocytes (1).  
Spheroid were produced in methylcellulose over 3 days, then submerged in collagen I matrix. The cell 
invasion was measured day 3 from when the spheroids were placed in the collagen I matrix. A) 
Representative phase contrast images of the spheroids at day 0 and 3 in the collagen I matrix. Examples 
of invading cells are indicated by red arrows. Scale bar = 100µm (B) The number of cells that invaded away 
from the spheroid mass. Significance was calculated to neonatal melanocytes (1). Data are mean values ± 
S.E.M., of 9 spheroids over 3 independent experiments; * = P < 0.05.  (B) The number of cells that invaded 
further than 100µm from the spheroid mass. Significance was calculated to neonatal melanocytes (1). 












Number of Cells 
Further than 100µm 
from the Spheroid 
M35 Yes +++ Ω Ω 
M460 Yes ++ ++ + 
M586 No + ++ + 
M575 Yes ns +++ ++ 
M581 No ns ++ + 





¥ ¥ ¥ 
Table 3-3: Collation of the patient derived cell strains and neonatal melanocytes (1) invasive 
phenotypes in the 2D and 3D invasion assay.  
The trend in invasion is depicted by the number of + symbols (+ = low invasion, +++ = highest invasion). 
The number of + symbols indicates the trend in invasiveness and may not necessarily indicate significant 
differences in invasion to other cell lines with the + symbol. ¥ indicates the control cells to which 
significance was calculated: ns= not significant (P > 0.05). Ω symbol indicates the assay was not performed 
on these cells. Strains were considered to have disease progression if there was an increase in the stage 








For a cell to metastasise many complex processes must occur, including invading through the 
basement membrane and the surrounding tissue, intravasation into blood vessels or lymph 
nodes, extravasation and growth at distant sites (Sahai, 2005). This process undoubtedly relies 
on various contributing cell characteristics which all play a role in the overall invasiveness of a 
cell (Friedl and Wolf, 2003). This chapter focuses on optimising the use of a 2D and 3D measure 
of invasion to characterise the melanoma cell lines and cell strains.  
The cell area and perimeter varied greatly in the melanoma cell lines and patient derived cell 
strains, with most cells differing significantly from the melanocyte controls. These findings 
indicate that there is no cell area that can be considered representative of melanoma cells when 
they become tumourous. Furthermore, there were no consistent differences in cell area and 
perimeter between invasive and non-invasive melanoma cell lines/strains.  
The SK-MEL-28 cells were shown to be significantly larger than the melanocytes and the other 
melanoma cell lines. This is a well known feature of SK-MEL-28 cells (Hoashi et al., 2005; Watabe 
et al., 2008) and is mostly likely a representative feature of this cell type and therefore not linked 
to invasiveness.  
There was a trend across the cell lines and patient derived cell strains which showed reduced 
cell elongation, compared to neonatal melanocytes (1). These results indicate that melanoma 
cells may have a more rounded morphology in 2D. However, there were no consistent 
differences between invasive and non-invasive melanoma cell lines/strains, therefore, this 
phenotype is unlikely to indicate cell invasiveness.  
However, the 2D invadopodia assay and the 3D spheroid invasion assay provided more reliable 
results. Cumulatively, the assays performed in this chapter have shown the WM-115, SK-MEL-2 
and A-375M2 cell lines to have an invasive phenotype compared to melanocyte controls. 
Conversely, SK-MEL-28 cells showed little or no invasive phenotype, compared to melanocyte 
controls. Of the patient derived cell strains the M35, M460, M586, M581 and M575 showed an 
invasive phenotype in one or more of the invasion assays. The M133 was the only patient 
derived cell strain that lacked an invasive phenotype in all the assays performed.  
The WM-115 cell line, a primary cell line, showed significant levels of invasiveness in 2D and 3D 
invasion assays, higher than that seen for the metastatic cell lines, A-375M2 and SK-MEL-2. This 
result was perhaps unexpected due to the primary tumour origins of the WM-115 cell line. 
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However, the excised tumour was in the vertical growth phase (VGP), which is characterised by 
vertical invasion through the basement membrane and dermal tissue, the first steps of 
melanoma invasion (Herlyn et al., 1985; Hsu et al., 2000; Silini et al., 2010). Indeed, in a skin 
reconstruction assay WM-115 cells were able to breach the basement membrane and invade 
the dermis (Meier et al., 2000). The lesion from which the WM-115 cell line originated produced 
metastatic disease in the patient after 16 months post-excision (Silini et al., 2010). Furthermore, 
studies have shown that WM-115 cells can form lung metastases in mice with a success rate of 
80% (Herlyn et al., 1985; Silini et al., 2010), therefore, representing a melanoma in the state of 
early invasion at the primary site. Additionally, this study shows for the first time that the WM-
115 cell line can produce invadopodia protrusions and can invade through a 3D collagen invasion 
assay. This confirms that these cells can exhibit a robust, highly invasive phenotype in multiple 
in vitro assays. Therefore, this study would define the WM-115 cell line as an invasive primary 
cell line.  
The A-375M2 and SK-MEL-2 cell lines also demonstrated invasive phenotypes in this study, 
which is confirmed in the literature. The A-375M2 cell line, is a highly metastatic sub-population 
(isolated from lung metastases) of the parental A-375 cell line and has been shown to form lung 
metastases in mice (Kozlowski et al., 1984). In addition, the A-375M2 cell line exhibits an invasive 
phenotype in a range of in vitro assays including the invadopodia assay (Baldassarre et al., 2006; 
Ayala et al., 2008; Md Hashim et al., 2013), collagen I invasion assay (Gadea et al., 2008; Sanz-
Moreno et al., 2008; Calvo et al., 2011) and the inverted invasion assay (collagen/Matrigel 
matrix) (Li et al., 2010a). The SK-MEL-2 cell line was isolated from a skin metastasis and, like A-
375M2 cells, has shown the ability to form lung metastases in mice (Fogh and Trempe, 1975; 
Claffey et al., 1996). SK-MEL-2 cells, have shown invasion in in vitro invasion assays including 
Matrigel transwell invasion assays (Gouon et al., 1996; Knutson et al., 1996) and dermal 
equivalent invasion assays (collagen I matrix containing dermal fibroblasts) (Bizik et al., 1999). 
Therefore, the invasive phenotype of A-375M2 and SK-MEL-2 cell lines shown in this study, is 
very much in line with previous findings.  
The SK-MEL-28 cell line was the only melanoma cell line in this study to show no or very low 
invasive potential. Originally, this cell line was isolated from a primary melanoma lesion (Fogh 
and Trempe, 1975) and is in fact currently used by many as a non-invasive, early stage, 
representative for melanoma (Watabe et al., 2008). SK-MEL-28 cells have shown non-invasive 
phenotypes in multiple invasion assays, including the invadopodia assay (Aoyama and Chen, 
1990; Monsky et al., 1994) and the Boyden chamber invasion assay (collagen I or Matrigel 
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matrix) (Wach et al., 1996). In contrast, there are also reports that the SK-MEL-28 cell line can 
exhibit invasive characteristics in a Matrigel invasion assay (Liu et al., 2012), dermal equivalent 
(collagen I matrix containing dermal fibroblasts) and organ-cultured dermal (human neonatal 
foreskin dermis co-polymerised with dermal equivalents) invasion assays  (Bizik et al., 1999). 
Therefore, depending on the invasion assay used SK-MEL-28 cells may or may not display an 
invasive phenotype. These findings were also found in this current study, as SK-MEL-28 cells 
were unable to produce invadopodia protrusions to degrade the gelatin matrix but were able to 
invade into the collagen I matrix in the 3D spheroid invasion assay  (albeit at a distance that was 
not significant when compared to the melanocyte controls). Therefore, in this study the SK-MEL-
28 showed a non-invasive phenotype and was classed thusly.  
The six patient derived cell strains were established from primary (M133, M586 and M460) and 
metastatic (M581, M575 and M35) tissue. However, as with the melanoma cell lines, the 
invasive capacity was not restricted to those cells produced from metastatic tissue. Indeed, two 
patient derived cell strains, from primary tissue (M586 and M460) showed a robust invasive 
phenotype in both the 2D and 3D invasion assays. Therefore, the patient stage and disease 
outcome may provide a better indication of the potential cell invasiveness.  
The M35 patient derived cell strain was shown to have an invasive phenotype as it had the 
highest percentage of invadopodia producing cells (at both 3 hrs and 24 hrs) of all the strains. 
Interestingly, M35 was the only strain to have a significant number of cells that produced 
invadopodia at 3hrs. Furthermore, the percentage of cells with invadopodia at this time point 
was higher than that seen in the WM-115 melanoma cell line. Unfortunately, no data was 
obtained for the M35 cells in the 3D spheroid assay as this strain was unable to form spheroids 
in the methylcellulose. To produce these spheroid masses, cells must be able to form at least a 
basal level of cell-cell adherence. Over the years, the correlation between invasion/metastasis 
and reduction in cell adhesion has been well documented (Hirohashi, 1998; Cavallaro and 
Christofori, 2001). Therefore, M35 cells may not sufficiently adhere to each other to form a 
spheroid mass due to their high invasive potential. Indeed, the patient clinical data suggests that 
the M35 cells are extremely invasive, as the disease caused patient death 8 months after the 
lesion was removed. Consequently, only the invadopodia assay was used to assess the M35 cell 
invasiveness and the extremely high invasive capacity demonstrated by this assay was firmly in 
line with the clinical data.  
All other patient derived cell strains, other than strain M575, showed a correlation between the 
phenotype shown in the 2D invadopodia assay and 3D spheroid invasion assay. The M575 strain 
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was unable to produce invadopodia, but had a highly invasive phenotype in the 3D spheroid 
invasion assay. Some modes of cell movement can be devoid of matrix degradation (Friedl and 
Wolf, 2003) and therefore, one explanation for this difference in the invasive phenotype 
between the two assays may be that the M575 cells invade the collagen I matrix in a protease 
independent manner. To address this question, the 3D spheroid invasion assay could be 
performed in the presence of a matrix metalloprotease (MMP) inhibitor to investigate the effect, 
if any, on the invasive capacity of the M575 cell strain. One suitable inhibitor that could be used 
is GM6001, a broad-spectrum MMP inhibitor that has been previously used to investigate 
protease independent invasion in a 3D spheroid invasion assay (Sabeh et al., 2009).  
The M133 patient derived cell strain was classified alongside the SK-MEL-28 cell line as 
demonstrating little to no invasive potential. M133 was in fact the only non-invasive patient 
derived cell strain in this study, as these cells were unable to form invadopodia and invade 
further than 100µm from the spheroid (as shown by the invadopodia and 3D spheroid invasion 
assays respectively). Similar to that which was seen with the non-invasive SK-MEL-28 cell line, 
the number of M133 patient derived cells invading into the collagen I matrix (in the 3D spheroid 
invasion assay) was significant, compared to neonatal melanocytes (1). Therefore, non-invasive 
melanoma cells may still possess a basal level of invasiveness compared to melanocytes (albeit 
dramatically lower than that of invasive melanoma cells).  
The use of the patient derived cell strains has provided data that has both complemented and 
validated the results obtained from the melanoma cell lines in the 2D and 3D invasion assays. 
These cell strains provide a valuable tool and their use is highly recommended for any future 
melanoma studies. Within this study, cell strains were cultured for no more than 6 months, and 
this limit is recommended for any further work utilising these patient strains. The tumourigenic 
nature of these cells predisposes them to acquiring mutations that may affect the cell 
phenotype, which may then not be representative of that present in the patient.             
Based on the results obtained with the melanoma cell lines and the patient derived cell strains, 
it can be concluded that while cell morphology is not a representative indicator of invasiveness, 
the 2D invadopodia assay and 3D spheroid assay correlate well and can be used to quantitatively 
measure invasive potential. Moreover, it has now been demonstrated that patient derived cells 
can both produce invadopodia and invade through a 3D collagen matrix, further validating these 
in vitro assays. The correlation between these two invasion assays was not evident for all cell 




The invadopodia assay and the 3D spheroid invasion assay enabled a level of invasiveness to be 
assigned to the melanoma cell lines and patient derived cell strains. This will be used in 
subsequent chapters to assess the potential role of PAK family members in melanoma cell 








During invasion and metastasis, cells utilise cytoskeletal remodelling pathways, including the 
Rho GTPase family, to regulate cell movement (Vega and Ridley, 2008; Yilmaz and Christofori, 
2009). Two of the most extensively studied Rho GTPases are Cdc42 and Rac1 which are 
intimately involved in cell shape and motility, primarily by controlling the 
polymerisation/depolymerisation and branching of actin filaments (Vega and Ridley, 2008). The 
most well characterised downstream effectors of Cdc42 and Rac1 are the p21 activated kinase 
(PAK) family (Bishop and Hall, 2000). PAKs are serine/threonine kinases that consist of 6 
isoforms, separated into two groups according to their sequence homology: group I, containing 
PAK1-3; and group II, containing PAK4-6. PAKs have been shown to be involved in cell cycle 
control, proliferation, cell motility and apoptosis, therefore, it is not surprising to find that this 
family of kinases is thought to play a role in cancer growth and progression (King et al., 2014).  
The overexpression and/or hyperactivation of PAK isoforms have been found in a variety of 
tumours, such as brain (PAK1 hyperactivation), breast (PAK1 and PAK4 overexpression), 
colorectal (PAK5 overexpression) and prostate (PAK6 overexpression) (Dummler et al., 2009; 
Gong et al., 2009). PAK1 and PAK4 are thought to be the most commonly overexpressed 
isoforms in cancer (King et al., 2014). Constitutively activated PAK1 has also been shown in 
previous studies to induce the formation of tumours such as those found in the mammary gland 
(Wang et al., 2006). In addition, the overexpression of activated PAK4 can transform Rat1 and 
NIH3T3 fibroblasts and induce anchorage-independent growth, a pivotal stage in tumour 
progression and metastasis (Qu et al., 2001).  
Studies suggest that PAKs may play a role in invadopodia formation. In a model of rat vascular 
smooth muscle cells, PAK1 can induce the formation of the invadopodia related structures 
known as podosomes (Webb et al., 2005), while a kinase dead PAK1 open conformation mutant 
induces the formation of invadopodia-like protrusions in aortic smooth muscle cells (Furmaniak-
Kazmierczak et al., 2007). The use of an autoinhibitory domain of PAK1 (PAK1-AID), which can 
inhibit endogenous PAK1 protein activation, demonstrated that PAK1 activity is required to 
sustain invadopodia formation and activity during the invasion of the A375MM cell line (Ayala 
et al., 2008). Indeed, PAK1 can phosphorylate cortactin, a protein vital for invadopodia 
formation (Ayala et al., 2008). PAKs are also  activated by Src, which is known to induce 
99 
 
invadopodia formation (Murphy and Courtneidge, 2011). In addition, PAK4  localises to 
podosomes in bone-marrow-derived mouse dendritic cells (Wells and Jones, 2010).  
Many studies have been conducted in which the involvement of PAKs, in different cancer types, 
has been investigated. However, the role of PAKs in cutaneous melanoma has not been well 
studied. In 2006, Pavey and colleagues found that PAK1 overexpression correlated with invasive 
potential in uveal melanoma cell lines (melanoma of the eye) (Pavey et al., 2006). PAK4 mRNA 
overexpression is also found in multiple cutaneous melanoma cell lines, including SK-MEL-2 and 
SK-MEL-28 (Callow et al., 2002). Furthermore, PAK4 is important in the carcinogenesis of 
squamous cell carcinoma (SCC) (Zanivan et al., 2013). These initial studies suggest a possible role 
for PAKs in cutaneous melanoma invasion. As discussed previously, during the early stages of 
metastasis, cells produce the invasive protrusion, invadopodia, to aid matrix degradation and 
invasion. Indeed, many proteins have been implicated in the promotion of invadopodia 
formation and degradation. However, the impact of serine/threonine kinases, especially PAKs, 
is less well studied.  
In addition to investigating cell invasion by quantifying invasive structures such as invadopodia, 
as well as utilising 3D invasion assays, both of which are conducted in vitro, studies in an in vivo 
context are extremely important. However, getting useful quantifiable data using mouse models 
can be quite a challenge. In recent years, the use of zebrafish as an in vivo model has become 
increasingly popular. Single pairs of zebrafish adults can produce many hundreds of embryos in 
a single spawn (which can be repeated weekly), providing sufficient embryos for several 
different treatment conditions and experimental repeats. In addition, zebrafish embryos have a 
very fast developmental process which means that by 5-6 days post-fertilisation (dpf), full 
embryonic cell migration has occurred and major organs are distinguishable (Rubinstein, 2003). 
One such zebrafish in vivo model, the yolk invasion assay, involves the injection of cancer cell 
lines into the yolk of 2 dpf embryos (Eguiara et al., 2011; Jung et al., 2012; Teng et al., 2013). 
The invasiveness of the cancer cell lines can then be quantified by the percentage of embryos 
with tail invasion after 4-7 days post-injection (dpi). This model has shown great promise in 
distinguishing the invasive/metastatic potential of xenografted cell lines. 
This chapter investigates the expression levels of the PAK family of kinases in melanoma cell 
lines and patient derived cell strains. The resulting PAK expression is compared to the invasive 
potential defined in Chapter 3 to identify any correlations. Subsequently, the role of PAKs in 





4.2.1 PAK Isoform Expression in Melanoma Cell Lines 
 
The overexpression of different PAK isoforms has been found in many human tumours 
(Dummler et al., 2009; King et al., 2014). However, PAK protein expression in melanoma cells 
has not been investigated. Thus, PAK isoform expression was quantified in both melanoma cells 
and melanocyte controls.  
As melanoma originates from melanocytes, the latter was used as a wildtype control in this 
study.  In order to determine the best wildtype control for use in western blotting analysis, 
neonatal and adult melanocyte expression of two representative PAK isoforms from each group, 
PAK1 and PAK4, were measured (Figure 4-1). As expected, there was variation in protein 
expression levels between melanocytes from neonatal versus adult origins and in fact, the PAK1 
protein expression was significantly higher in the neonatal melanocytes (2) compared to the 
adult melanocytes (Figure 4-1B). There was, however, no significant difference in PAK4 protein 
expression between the three wildtype cells (Figure 4-1C). To ensure that any changes in protein 
levels observed in the melanoma cell lines and patient derived cell strains were in fact robust, 




Figure 4-1: PAK Protein expression in neonatal and adult melanocytes.  
Western blot of PAK1 and PAK4 expression in neonatal melanocytes (1), neonatal melanocytes (2) and 
adult melanocytes. (B) Analysis of western blot data via densitometry showing PAK1 expression in 
neonatal melanocytes (1) and neonatal melanocytes (2) relative to adult melanocytes. (C) Analysis of 
western blot data via densitometry showing PAK4 expression in neonatal melanocytes (1) and neonatal 
melanocytes (2) relative to adult melanocytes. Significance was calculated relative to adult melanocytes. 
Data are the mean values ± S.E.M., over 3 independent experiments; *= P < 0.05. Densitometric data were 
normalized to GAPDH, which was used as a loading control. 
 
4.2.1.1 Group I PAKs - PAK1 and PAK2 are Overexpressed in Melanoma Cell Lines 
 
The protein expression for each PAK isoform in three invasive cell lines (A-375M2, WM-115 and 
SK-MEL-2) and one non-invasive (SK-MEL-28) cell line was compared to that found in neonatal 
melanocytes (1). Additionally, representative tumour cell lines were also analysed to determine 
how melanoma PAK protein expression levels would compare to levels in human breast (MB-
231), prostate (DU-145) and bladder (T24) cancers. Furthermore, neural crest oligodendrocyte 
progenitor cells (OPCs) were included as a positive control in all PAK screening panels because, 
unlike other cell lines used, they express PAK3 at readily detectable levels (Burbelo et al., 1999).  
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PAK1 protein expression was found to be overexpressed in three melanoma cell lines, A-37M2, 
WM-115 and SK-MEL-2 cells, compared to neonatal melanocyte (1) (Figure 4-2). Interestingly, 
PAK1 was only overexpressed in these melanoma cell lines that were characterised as having an 
invasive phenotype in Chapter 3 (Figure 4-2B). Indeed, the only cell line (SK-MEL-28) that did not 
overexpress PAK1 compared to neonatal melanocytes (1), was classed as having a non-invasive 
phenotype in Chapter 3. Furthermore, the cell line with the most invasive phenotype, WM-115 
(Table 3-1), had the highest PAK1 protein expression level of the four melanoma cell lines. It is 
also interesting to note that PAK1 levels in melanoma cell lines were expressed at similar or 
higher levels than that seen in other tumour cell lines such as breast (MB-231), prostate (DU-
145) and bladder (T24). 
The PAK2 protein was found to be overexpressed in all the melanoma cell lines, compared to 
the neonatal melanocytes (1) (Figure 4-2C). The PAK2 levels were similar to those seen in other 
cancer cell lines such as breast (MB-231), prostate (DU-145) and bladder (T24). There was an 
inverse trend (albeit minor) in PAK2 protein expression compared to cell invasiveness in the 
melanoma cell lines, with the non-invasive SK-MEL-28 cell line having the highest and the three 
invasive cell lines having lower PAK2 protein levels.  
PAK3 is readily detectable in cells of the central nervous system however, is rarely found in other 
cells, normal or tumourous (Burbelo et al., 1999). Therefore, unsurprisingly, PAK3 protein 
expression levels in all melanoma cell lines and neonatal melanocytes (1) were undetectable 
(Figure 4-2D). This suggests that PAK3 is not involved in melanoma cell invasiveness, and is not 
critical for the pathways that promote melanoma. Likewise, no detectable PAK3 protein levels 
were found in MB-231 (breast), DU-145 (prostate) and T24 (bladder) tumour cell lines. As 
expected, high levels of PAK3 were observed in the OPCs, which was used as a positive control.  
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 Figure 4-2: Group I PAK protein expression in melanoma cell lines. 
(A) Western blot of PAK1, PAK2 and PAK3 expression in melanoma cell lines, neonatal melanocytes (1) 
and representative tumour cell lines. (B-C) Analysis of western blot data via densitometry showing PAK1 
(B) and PAK2 (C) protein expression relative to neonatal melanocytes (1). PAK3 protein expression was 
undetectable and therefore densitometry was not performed for this isoform. Significance was calculated 
for melanoma cell lines compared to neonatal melanocytes (1). Data are the mean values ± S.E.M., over 
3 independent experiments; *= P < 0.05. Densitometric data were normalized to GAPDH, which was used 






4.2.1.2 Group II PAKs - PAK4 is Overexpressed in Melanoma Cell Lines 
 
All the melanoma cell lines showed a significant increase in PAK4 protein levels compared to the 
neonatal melanocytes (1) (Figure 4-3). However, there was no correlation with invasive potential 
as measured here. Furthermore, similar PAK4 protein levels were observed in the different 
tumour cell lines.  
The PAK5 and PAK6 protein levels were undetectable in the neonatal melanocytes (1) and many 
of the melanoma cell lines (Figure 4-3). Likewise, levels of both proteins were predominantly too 
low to be quantified in the breast, prostate and bladder tumour cell lines, as well as in OPCs.  
Of the group I PAKs, the protein levels of PAK1 and PAK2 (to a lesser extent) correlated with cell 
invasiveness as characterised in chapter 3 (Table 4-1). In group II, only PAK4 was overexpressed 
in melanoma cell lines. No correlation was apparent between PAK4 expression and invasive 
potential, however, there was a robust overexpression of this protein in melanoma cell lines 
compared to neonatal melanocytes (1). Therefore, PAK4 is clearly important in melanoma, but 
the extent to which this isoform drives invasion is unclear. Given their prevalence in melanoma 
cell lines, PAK1 and PAK4 (representing group I and group II PAKs, respectively) were selected 









Figure 4-3: Group II PAK protein expression in melanoma cell lines. 
(A) Western blot of PAK4, PAK5 and PAK6 expression in melanoma cell lines, neonatal melanocytes (1) 
and representative tumour cell lines. (B) Analysis of western blot data via densitometry showing PAK4 
protein expression relative to neonatal melanocytes (1). PAK5 and PAK6 protein expression was 
unquantifiable and therefore densitometry was not performed for these isoforms. Significance was 
calculated for melanoma cell lines compared to neonatal melanocytes (1). Data are the mean values ± 
S.E.M., over 3 independent experiments; *= P < 0.05. Densitometric data were normalized to GAPDH, 


























PAK1 PAK2 PAK3 PAK4 PAK5 PAK6 
WM-115 Yes +++ +++ +++ ++ + § + § § 
A-375M2 Yes ++ ++ ++ + + § ++ § § 
SK-MEL-2 Yes + + ns + + § ++ § § 




¥ ¥ ¥ ¥ ¥ ¥ § ¥ § § 
Table 4-1: Collation of the trends of invasiveness and the PAK expression of melanoma cell lines. 
The trend in invasion and PAK expression is depicted by the number of + symbols (+ = lowest, +++ = 
highest). The number of + symbols indicates the trend in invasiveness and PAK expression and may not 
necessarily indicate significant differences in invasion and PAK expression to other cell lines with the + 
symbol. ¥ indicates the control cells to which significance was calculated: ns= not significant (P > 0.05). § 
= unquantifiable protein expression. 
 
4.2.2 PAK1 and PAK4 are Overexpressed in Invasive Patient Derived Cell 
Strains 
 
PAK1 and PAK4 protein expression were measured in the patient derived cell strains and 
compared to neonatal melanocytes (1) (Figure 4-4). In addition, A-375M2 and WM-115 were 
used as melanoma cell line representatives (being the two most invasive in this group) such that 
the protein levels in the patient derived cell strains could be compared to that of the melanoma 
cell lines.  
PAK1 was found to be overexpressed in three (M586, M460 and M35) patient derived cell 
strains, compared to neonatal melanocytes (1) (Figure 4-4B) and, interestingly, these were the 
only strains that produced significant numbers of cells with invadopodia (Section 3.2.2.3 and 
Table 4-2). Those patient derived cell strains in which PAK1 was over expressed showed similar 
levels of this protein to that seen in the melanoma cell lines A-375M2 and WM-115. Furthermore 
M133, the non-invasive patient derived cell strain, had significantly lower PAK protein 
expression compared to neonatal melanocytes (1). Therefore, these data show a clear 




Figure 4-4: PAK1 and PAK4 protein expression in patient derived cell strains. 
(A) Western blot of PAK1 and PAK4 protein expression in patient derived cell strains, neonatal 
melanocytes (1) and representative melanoma cell lines (A-375M2 and WM-115). (B-C) Analysis of 
western blot data via densitometry showing PAK1 (B) and PAK4 (C) protein expression relative to neonatal 
melanocytes (1). Significance was calculated for patient derived cell strains and melanoma cell lines 
compared to neonatal melanocytes (1). Data are the mean values ± S.E.M., over 3 independent 




PAK4 protein was overexpressed in four (M133, M586, M460 and M35) patient derived cell 
strains when compared to the neonatal melanocytes (1) (Figure 4-4C), with protein levels in 
these cell strains being similar to that seen in the melanoma cell lines A-375M2 and WM-115. 
M586, M460 and M35 are classed as invasive cell strains (Section 3.2.2.3 and Table 4-2), and all 
showed elevated levels of PAK1 and PAK4. In contrast, the M133 non-invasive patient derived 
cell strain, had significantly lower levels of PAK1 and elevated levels of PAK4.  
 
Cell Strain Invasive phenotype 
Invadopodia 
Invasion 
3D Spheroid Invasion 
(number of invading cells) PAK1 PAK4 
Total >100µm from the spheroid 
M35 Yes +++ Ω Ω ++ ++ 
M460 Yes ++ ++ + + + 
M586 Yes + ++ + + + 
M575 Yes ns +++ ++ ns ns 
M581 Yes ns ++ + ns ns 
M133 No ns + ns - ++ 
Neonatal 
Melanocytes (1) ¥ ¥ ¥ ¥ ¥ ¥ 
Table 4-2: Collation of the patient derived cell strains and neonatal melanocytes (1) invasive phenotypes 
and PAK1 and PAK4 protein expression.  
The trend in invasion and PAK expression is depicted by the number of + symbols (+ = lowest, +++ = 
highest). The number of + symbols indicates the trend in invasiveness and PAK expression and may not 
necessarily indicate significant differences in invasion and PAK expression to other cell lines with the + 
symbol. ¥ indicates the control cells to which significance was calculated: ns= not significant (P > 0.05). 
The Ω symbol shows the assay was not performed for these cells. 
 
4.2.3 siRNA Oligonucleotides can Transiently Reduce PAK1 and PAK4 
Expression in A-375M2 and WM-115 Melanoma Cell Lines 
 
Our data suggests that PAK1 may be involved in melanoma invasiveness, with the picture being 
less clear for PAK4. Therefore, to investigate the involvement (or lack thereof) of these proteins 
in melanoma invasiveness, our established invasion assays were performed with cells that had 
transiently reduced expression of PAK1 and PAK4. As well as the reduction of PAK1 and PAK4 
individually, double knockdown experiments were also performed to simultaneously reduce the 
levels of both proteins in the same cell. Of the melanoma cell lines investigated in this study, 
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WM-115 and A-375M2 had the most consistent invasive phenotype in both the 2D invadopodia 
assay and the 3D spheroid assay (Table 4-1) and were the cell lines chosen for the transient 
depletion of PAK1 and PAK4 expression and subsequent invasion studies. 
In WM-115 cells, PAK1 and PAK4 protein expression was significantly reduced from day four 
when targeted siRNA oligonucleotides were used compared to wildtype and control siRNA cells 
(Figure 4-5). The depletion of PAK1 and PAK4 expression was still present at day seven, with 
>50% reduction for all the oligonucleotides compared to the wildtype and control siRNA cells. 
The double knockdown of PAK1 and PAK4 also showed a protein depletion of >70% at four and 
seven days after siRNA oligonucleotide transfection, compared to wildtype and siRNA control 
cells. The sustained depletion of PAK1 and PAK4 proteins enabled these cells to be used in the 
3D spheroid invasion assay.    
In A-375M2 cells, reduced PAK1 and PAK4 expression was achieved from day four post siRNA 
oligonucleotide transfection and was sustained until day seven for the majority of the 
oligonucleotides (Figure 4-6). The double depletion of PAK1 and PAK4 also showed a protein 
reduction of >40% at four and seven days after siRNA oligonucleotide transfection, compared to 





Figure 4-5: Transient reduction of PAK1 and PAK4 expression in the WM-115 cell line.  
Cells plated at a concentration of 2x104 in a 6 well plate were transiently depleted using siRNA 
oligonucleotides and HiPerfect transfection reagent (2 oligonucleotides for each protein). A double 
knockdown was performed using PAK1 Oligo 1 and PAK4 Oligo 2 oligonucleotides. Control cells were 
transfected with a control siRNA non targeting oligonucleotide. The reduction in protein expression was 
quantified 4 and 7 days after transfection using western blotting and densitometry. The reduction in (A) 
PAK1 and (B) PAK4 protein expression in WM-115 cells. Significance was calculated for protein depleted 
cell lines compared to wildtype and control siRNA transfected cells. Data are the mean values ± S.E.M., 
over 3 independent experiments; *= P < 0.05. Densitometric data were normalized to GAPDH, which was 




Figure 4-6: Transient reduction of PAK1 and PAK4 expression in the A-375M2 cell line.  
Cells plated at a concentration of 2x104 in a 6 well plate were transiently depleted using siRNA 
oligonucleotides and HiPerfect transfection reagent (2 oligonucleotides for each protein). A double 
knockdown was performed using PAK1 Oligo 1 and PAK4 Oligo 2 oligonucleotides. Control cells were 
transfected with a control siRNA non targeting oligonucleotide. The reduction in protein expression was 
quantified 4 and 7 days after transfection using western blotting and densitometry. The reduction in (A) 
PAK1 and (B) PAK4 protein expression in A-375M2 cells. Significance was calculated for protein depleted 
cell lines compared to wildtype and control siRNA transfected cells. Data are the mean values ± S.E.M., 
over 3 independent experiments; *= P < 0.05. Densitometric data were normalized to GAPDH, which was 
used as a loading control. 
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4.2.4 PAK1 and PAK4 Depletion Reduces Invadopodia Formation and 
Degradation 
 
PAK1 and PAK4 were overexpressed in melanoma cell lines and patient derived cell strains that 
were able to produce invadopodia (Table 4-1 and Table 4-2). To investigate this further, the 
invadopodia assay was performed using PAK1 and PAK4 depleted cells (Figure 4-7 and Figure 
4-8).  
WM-115 and A-375M2 cells with reduced PAK1 expression, had a significant decrease in the 
percentage of cells with invadopodia, compared to control and wildtype cells (Figure 4-9A). 
Additionally, the cells that produced invadopodia, had a reduction in the area of degradation 
per invadopodia producing cell compared to wildtype and control invadopodia producing cells 
(Figure 4-9B). A similar phenotype was observed when PAK4 expression was diminished in WM-
115 and A-375M2 cells, with a reduction in the percentage of cells with invadopodia and a 
reduction in the degradation area per invadopodia producing cell compared to wildtype and 
control cells. These data indicate that depleting the expression of PAK1 and PAK4 reduces the 
cell invasiveness not only by decreasing the number of cells with invadopodia but also by 
reducing the ability of the few invadopodia that do form, to degrade gelatin.   
WM-115 and A-375M2 cells in which the expression of PAK1 and PAK4 were simultaneously 
reduced showed a decrease in the percentage of cells with invadopodia and the area of 
invadopodia induced degradation compared to wildtype and control cells. However, this was 






Figure 4-7: Representative invadopodia assay images of WM-115 cells in which PAK1 and PAK4 proteins 
are knocked down (individually and simultaneously). 
Four days after siRNA oligonucleotide transfection the cells were seeded on rhodamine conjugated gelatin 
for 3 hrs and stained for F-actin. Only actin rich dots that corresponded with gelatin degraded dots were 
counted as invadopodia. The degradation was measured using ImageJ software. Scale bars = 10µm. 




 Figure 4-8: Representative invadopodia assay images of A-375M2 in which PAK1 and PAK4 proteins are 
depleted (individually and simultaneously). 
Four days after siRNA oligonucleotide transfection the cells were seeded on rhodamine conjugated gelatin 
for 3 hrs and stained for F-actin. Only actin rich dots that corresponded with gelatin degraded dots were 
counted as invadopodia. The degradation was measured using ImageJ software. Scale bars = 10µm. 




 Figure 4-9: Invadopodia assay with WM-115 and A-375M2 cells in which PAK1 and PAK4 
expression was depleted (individually and simultaneously).  
(A) The percentage of cells with invadopodia. Significance was calculated to wildtype and control cells. 
The double knockdown significance was also calculated to the corresponding single siRNA knockdown 
oligonucleotides. Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * = P < 
0.05. (B) The area of degradation from invadopodia per cell. Significance was calculated to wildtype and 
control cells. The double knockdown significance was also calculated to the corresponding single siRNA 
knockdown oligonucleotides. Data are mean values ± S.E.M. of 90 invadopodia producing cells, over 3 





4.2.5 PAK1 and PAK4 Depletion Reduces 3D Melanoma Invasion 
 
The depletion of PAK1 and PAK4 protein expression revealed a reduction in invadopodia 
formation (Section 4.2.4). To expand the study the cells were subsequently tested in the 
spheroid assay (Figure 4-10 and Figure 4-11). As protein recovery was observed with some of 
the oligonucleotides in A-375M2 cells at day seven, the length of the assay (originally eight days), 
was reduced to seven days in subsequent experiments (one day for the transfection of the siRNA 
oligonucleotides, three days in methylcellulose and three days in the collagen I matrix) to ensure 
that most of the assay was performed in the presence of protein knockdown. 
The depletion of PAK1 expression in WM-115 and A-375M2 cells reduced the total number of 
invading cells and the number that invaded further than 100µm from the spheroid, compared 
to wildtype and control cells. Likewise, when PAK4 expression was depleted in WM-115 and A-
375M2 cells a reduction in the total number of cells as well as the number of cells invading 
further than 100µm was observed, compared to wildtype and control cells. These data show 
that decreasing either PAK1 or PAK4 protein expression reduces the cell invasiveness of 
melanoma cell lines in a 3D collagen matrix.  
Interestingly, the double depletion of PAK1 and PAK4 expression resulted in a further reduction 
in the number of invading cells and the number of cells that invaded further than 100µm, 
compared to when PAK1 or PAK4 expression were decreased individually (Figure 4-11). This is 
in contrast to that which was observed in the invadopodia assay in which there was no additive 
effect in the double knockdown experiments (Figure 4-9). 
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 Figure 4-10: Representative images at day 0 and day 3 of the 3D spheroid invasion assay in WM-115 and 
A-375M2 cells in which PAK1 and PAK4 have been knocked down (individually and simultaneously).  
Spheroids were produced in media containing methylcellulose for 3 days, then submerged in a collagen I 
matrix. Phase contrast images were taken at day 0 and day 3. The cell invasion was measured at day 3, 




 Figure 4-11: 3D spheroid invasion assay of WM-115 and A-375M2 cell lines in which PAK1 and PAK4 
have been knocked down (individually and simultaneously).  
Spheroid were produced in methylcellulose for 3 days, then submerged in a collagen I matrix. The cell 
invasion was measured at day 3, commencing when the spheroids were placed in the collagen I matrix. 
(A) The total number of cell that invaded away from the spheroid mass. Significance was calculated to 
wildtype and control cells. Data are mean values ± S.E.M., of 9 spheroids over 3 independent experiments; 
* = P < 0.05. Control = cells transfected with non-specific siRNA. (B) The number of cells that invaded 
further than 100µm from the spheroid mass. Significance was calculated to wildtype and control cells. 
Data are mean values ± S.E.M., of 9 spheroids over 3 independent experiments; * = P < 0.05. Control = 




4.2.6 Construction of GFPPAK1r Rescue Vector 
 
To verify that the reduction in invasion observed in PAK1 and PAK4 depleted cells was due to 
the specific decrease in PAK1 or PAK4 expression, rescue experiments were performed. The 
GFPPAK4r (PAK4 oligo 2 siRNA resistant) rescue vector was previously created in the Wells lab 
and therefore available for use.   
The GFPPAK1r rescue construct was generated by site directed mutagenesis. The wildtype 
GFPPAK1 construct was used as template DNA in two PCR reactions to create two DNA 
fragments (Figure 4-12A). The first fragment incorporated the 5’ region of the PAK1 cDNA up to 
the desired mutated sequence (PAK1r 5’ primer set) and the second fragment contained the 
mutated sequence and the remaining 3’ sequence of the PAK1 cDNA (PAK1r 3’ primer set). These 
two fragments were purified, mixed and used as template DNA for another PCR reaction using 
primers located at the 5’ and 3’ of the PAK1 cDNA (PAK1 attB primer set) (Figure 4-12B). In this 
PCR reaction the mutated region, located in both PCR fragments, provided a complementary 
sequence to allow for binding, thus producing the full length PAK1 cDNA (including the mutated 
sequence), which was then amplified. The full length PAK1r rescue fragment was also flanked by 
attB sequences to allow for the creation of the GFPPAK1r rescue expression vector via Gateway® 
cloning (Figure 4-12C).   
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 Figure 4-12: Construction of the GFPPAK1r rescue vector. 
The GFPPAK1r (PAK1 oligo 1 siRNA resistant) rescue vector was created using traditional molecular cloning 
techniques and Gateway® cloning. (A) PCR to construct two fragments of PAK1 containing the mutated 
sequence (all using the GFPPAK1 vector as a DNA template). The primer set PAK1r 5’ (PAK1 Fwd and 
PAK1Rescue Rev) produce the 5’ region of the PAK1-mutated site (predicted fragment size = ~100bp). The 
PAK1r 3’ primer set (PAK1Rescue Fwd and PAK1 Rev) produce the 3’ region of PAK1 from the mutated 
sequence (predicted fragment size = ~1.7Kbp). The PAK1 attB primer set (PAK1 Fwd and PAK1 Rev) was 
used as a positive (+ve) control (predicted fragment size = ~1.8Kbp). (B) PCR to create the PAK1r rescue 
construct using the PAK1 attB primer set with the fragments from the PAK1r 5’ and PAK1r 3’ PCR reaction 
as template DNA (predicted fragment size = ~1.8Kbp). (C) PCR screen of PAK1r entry clones produced from 
the Gateway® BP reaction. Primer set PAK1 attB was used for all samples (predicted fragment size = 
~1.8Kbp). A positive (+ve) control was performed using GFPPAK1 as template DNA. For all experiments a 
negative (-ve) control was used containing no DNA. 100bp or 1Kbp DNA ladders were used as a size 
reference (size of fragments are shown in figure).  
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Following the construction of GFPPAK1r, the GFPPAK1r and GFPPAK4r rescue constructs were 
transfected in PAK1 or PAK4 depleted WM-115 cells, respectively, and the rescue of protein 
expression confirmed (Figure 4-13). The rescue construct was 27kDa heavier due to the fused 
GFP biomarker, therefore allowing it to be readily distinguished from the endogenous protein. 
The GFPPAK1r and GFPPAK4r rescue constructs were expressed in cells that had reduced PAK1 
and PAK4 expression, respectively, validating their use in the rescue experiments.  
 
 
Figure 4-13: Confirmation of siRNA resistant proteins in siRNA depleted WM-115 cells.  
Cells were seeded at a concentration of 2x104 in a 6 well plate and transfected with PAK1 oligo 1, PAK4 
oligo 2 or a control siRNA oligonucleotide. After three days, cells were transfected with either GFPPAK1r 
or GFPPAK4r rescue constructs and lysed after 48 hrs. (A) The expression of GFPPAK1r rescue construct in 
WM-115 cells in which PAK1 expression was reduced. (B) The expression of GFPPAK4r rescue construct in 
WM-115 cells in which PAK4 was reduced. GAPDH was used as a loading control in all experiments. 
 
4.2.7 GFPPAK1r Rescues Invadopodia Formation and Degradation in WM-
115 Cells with Reduced PAK4 Expression 
 
PAK1 knockdown in WM-115 cells reduces both the percentage of cells with invadopodia and 
the degradation area per invadopodia producing cell (Figure 4-14). The specificity of this PAK1 
depletion was validated by the expression of the GFPPAK1r siRNA resistant vector in WM-115 
cells with diminished PAK1 expression. The expression of the GFPPAK1r rescue construct in WM-
115 cells with depleted PAK1 was able to rescue the invasive phenotype to levels seen in the 
control cells, both in the percentage of cells with invadopodia and the degradation area. This 




 Figure 4-14: Invadopodia assay of PAK1 depleted WM-115 cells expressing GFPPAK1r. 
Three days after siRNA oligonucleotide transfection, cells were transfected with DNA expression vectors 
and incubated for 48hrs. Following this, the cells were seeded on rhodamine conjugated gelatin for 3 hrs 
and stained for F-actin. Only actin rich dots that corresponded with gelatin degraded dots were counted 
as invadopodia. The degradation was measured using ImageJ software. (A) Representative invadopodia 
assay images of WM-115 depleted cells transfected with GFP alone or GFPPAK1r. Scale bars = 10µm. (B) 
The percentage of cells with invadopodia. Significance was calculated to control siRNA transfected cells. 
Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * = P < 0.05. (C) The area of 
degradation from invadopodia per cell. Significance was calculated to control siRNA transfected cells. Data 
are mean values ± S.E.M. of 90 invadopodia producing cells, over 3 independent experiments; * = P < 0.05. 
Control = cells transfected with non-specific siRNA. 
 




4.2.8 GFPPAK4r Rescues Invadopodia Formation and Degradation in WM-
115 Cells with Reduced PAK4 Expression 
 
The expression of the GFPPAK4r siRNA resistant vector in a PAK4 knockdown background 
rescued both the percentage of cells with invadopodia and the degradation, to values seen by 
the control cells (Figure 4-15). This further validates the importance of PAK4 in invadopodia 
formation and degradation.    
 
Figure 4-15: Invadopodia assay of PAK4 depleted WM-115 cells expressing GFPPAK4r. 
Three days after siRNA oligonucleotide transfection, cells were transfected with DNA expression vectors 
and incubated for 48hrs. Following this, the cells were seeded on rhodamine conjugated gelatin for 3 hrs 
and stained for F-actin. Only actin rich dots that corresponded with gelatin degraded dots were counted 
as invadopodia. The degradation was measured using ImageJ software. (A) Representative invadopodia 
assay images of WM-115 PAK4 depleted cells transfected with GFP alone or GFPPAK4r. Scale bars = 10µm. 
(B) The percentage of cells with invadopodia. Significance was calculated to control siRNA transfected 
cells. Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * = P < 0.05. (C) The 
area of degradation from invadopodia per cell. Significance was calculated to control siRNA transfected 
cells. Data are mean values ± S.E.M. of 90 invadopodia producing cells, over 3 independent experiments; 
* = P < 0.05. Control = cells transfected with non-specific siRNA. 
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4.2.9 Reduction of PAK1 and PAK4 Expression in an In Vivo Zebrafish Yolk 
Invasion Assay 
 
The knockdown of PAK1 and PAK4 reduced the invasion of WM-115 and A-375M2 cells in 2D 
and 3D invasion assays (Section 4.2.4 and Section 4.2.5). To complement these in vitro assays,  
invasion was investigated in an in vivo zebrafish yolk invasion assay.  
 
4.2.9.1 Stable Reduction of PAK1 and PAK4 Expression in A-375M2 cells 
 
The zebrafish yolk invasion assay requires the injection of a high number of fluorescently 
labelled knockdown cells into the zebrafish embryos. To create these stable knockdown A-
375M2 cell lines a bi-cistronic DNA vector containing an shRNA sequence to reduce either PAK1 
or PAK4 expression, and a GFP fluorescence biomarker for cell visualisation in the zebrafish, was 
used.   
The protein expression was reduced with two different shRNA constructs each targeted at either 
PAK1 or PAK4. An off target shRNA construct, with a non-targeting shRNA sequence, was 
transfected for use as a control. Both PAK1 and PAK4 constructs resulted in a significant 
reduction in the expression of the targeted protein compared to wildtype and control shRNA 
cells (Figure 4-16). These PAK1 and PAK4 stable knockdown A-375M2 cells were then used to 
investigate the effects of PAK1 and PAK4 expression on invasive capacity in vivo using the 




Figure 4-16: Stable Reduction of PAK1 and PAK4 in the A-375M2 cell line.  
Stable knockdown A-375M2 cells were created by transfecting cells with shRNA DNA constructs and 
selecting the cells with depleted protein expression using puromycin antibiotic. Protein depletion was 
quantified using western blotting and densitometric analysis. (A) PAK1 and (B) PAK4 reduction in A-375M2 
cells. Significance was calculated for depleted cell lines compared to wildtype cells. Data are the mean 
values ± S.E.M., over 3 independent experiments; *= P < 0.05. Densitometric data were normalized to 
GAPDH, which was used as a loading control. 
 
4.2.9.2 PAK1 and PAK4 Depletion Reduces Invasion of A-375M2 cells In Vivo 
  
A-375M2 cells stably transfected with the control shRNA construct were able to invade through 
the yolk and into the embryo where they lodged in the tail and either proliferated or invaded 
into the surrounding tissue (Figure 4-17). Cell invasion in the head was also seen (Figure 4-17C), 




Figure 4-17: Cell invasion in a zebrafish embryo 4 dpi with A-375M2 control shRNA. 
(A) Diagram of in vivo zebrafish yolk invasion assay. Tumour cells were injected into the yolk sac of 2 dpf 
zebrafish embryos. Tumour cells invade the yolk and intravasate into blood vessels (i), travel through the 
blood system (ii) and lodge in the tail vessels where they can grow or extravasate (iii). (B) A representative 
phase contrast and fluorescent image of a zebrafish (lateral view) 4 dpi with A-375M2 control shRNA cells 
to show cell invasion. Image is a tiled reconstruction of multiple small images. (C-E) The invasion of cells 
was evident in several different parts of the embryo including the head (C), within the yolk sac (D) and in 
the tail (E). Red stars indicate cell mass in yolk sac (original injection site). White arrows indicate invaded 




When the A-375M2 cells with stably depleted PAK1 expression were injected into the zebrafish 
yolk sac the percentage of embryos with tail invasions significantly decreased compared to the 
control (Figure 4-18 and Figure 4-19). A similar reduction was also seen with PAK4 stably 
depleted A-375M2 cells. Therefore, reducing PAK1 or PAK4 expression can inhibit the invasion 
of melanoma cells in vivo, thus validating the work performed in vitro (Section 4.2.4 and Section 
4.2.5) and demonstrating the importance of these proteins in cell invasion.    
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 Figure 4-18: Representative phase contrast and fluorescent images of the In vivo zebrafish yolk invasion 
assay. 
Phase contrast and fluorescent images of zebrafish embryos (lateral view) at 0 and 4 dpi for embryos 
injected with A-375M2 control cells (control shRNA), PAK1 depleted (PAK1 shRNA 1 and PAK1 shRNA2) 
and PAK4 depleted (PAK4 shRNA 1 and PAK4 shRNA 3). Red stars indicate cell mass in yolk sac (original 




 Figure 4-19: In vivo zebrafish yolk invasion assay using PAK1 and PAK4 stably depleted A-375M2 cells. 
2 dpf zebrafish embryos were injected into the yolk sac with approximately 500 cells and incubated at 
35ºC for 4 days. The percentage of embryos with A-375M2 cell tail invasion was measured. Significance 
was calculated for knockdown cell lines compared to the control shRNA cells. Data are the mean values ± 






The PAK family of kinases are the major downstream effectors of Rac1 and Cdc42. PAK isoforms 
(of which there are 6) have been shown to be overexpressed in many human tumours such as 
breast, colon, prostate and ovarian cancer (Radu et al., 2014). This chapter investigated the 
expression of the PAK isoforms in a panel of melanoma cell lines and patient derived cell strains 
(PAK1 and PAK4) compared to melanocyte controls - the aim being to identify any correlating 
trends between PAK protein expression and the invasive capacity, as characterised in chapter 3. 
Following this, the knockdown of PAK1 and PAK4 expression was used as a tool to verify their 
involvement in melanoma cell invasiveness in vitro and in vivo. 
There was a direct correlation between the level of PAK1 expression and the level of 
invasiveness defined in chapter 3. These findings complement previous studies that have linked 
PAK1 overexpression with increased invasiveness of uveal melanoma, a cancer of melanocytes 
located in the eye (Pavey et al., 2006). This suggests a global melanoma requirement for PAK1 
irrespective of the melanocyte origin, be it cutaneous or uveal. Furthermore, melanoma may 
not be the only form of skin cancer in which PAK1 overexpression occurs. Indeed, PAK1  was also 
found to be overexpressed in malignant SCC mouse tissue but not in benign papilloma, in a two 
stage chemically induced tumourigenesis (7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-
tetradecanoylphor- bol-13-acetate (TPA)) mouse model (Zanivan et al., 2013).  
PAK4 was robustly overexpressed in the melanoma cell lines including the invasive cells. An 
increase in PAK4 mRNA in SK-MEL-2 and SK-MEL-28 cells, compared to melanocytes, suggest 
that the upregulation may also be occurring at the transcriptional level (Callow et al., 2002). 
Furthermore, PAK4 is important for the carcinogenesis of SCC, which shows both an increase in 
phosphorylation at Ser181, in a two stage chemically induced tumourigenesis (DMBA and TPA) 
mouse model, and an importance in protein expression for SCC cell line invasion in both a 3D 
collagen invasion assay (A431 cell line) and a 3D organotypic invasion model (SCC9 cell line) 
(Zanivan et al., 2013). This requirement of PAK4 in the invasion of other skin cancers validates 
the choice to investigate PAK4 in melanoma invasion despite overexpression being evident in 
the non-invasive SK-MEL-28 cells. In tumourigenesis and progression, PAK4 can play a role in 
multiple cellular processes including cell cycle progression (Siu et al., 2010a; Zhang et al., 2011; 
Tabusa et al., 2013) and inhibition of apoptosis (Gnesutta and Minden, 2003; Kesanakurti et al., 
2012). Therefore, this protein may enhance other pathways distinct from invasion which may 
mask any correlating trends between PAK4 protein expression and cellular invasion.  
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To complement the results found in melanoma cell lines, PAK1 and PAK4 expression was 
measured in the patient derived cell strains. Both proteins were overexpressed in a variety of 
cell strains, emphasising that PAK1 and PAK4 overexpression is not only observed in melanoma 
cell lines, but also in cells isolated from patient tissue. Furthermore, the invasive strains that 
were able to produce invadopodia (M586, M460 and M35) showed overexpression of PAK1 and 
PAK4. Interestingly, the M35 strain showed the highest expression of both PAK1 and PAK4, 
which correlated with both the high invasion of this strain as characterised in chapter 3 and also 
with the clinical data which revealed that this patient progressed to stage IV metastatic 
melanoma and died 8 months from when the tissue was taken. Similarly, the M460 cell strain 
(derived from primary tissue from a patient with stage IIIA progressive metastatic melanoma) 
had a PAK1 and PAK4 expression profile that matched that of the invasive phenotype.  
Interestingly, the non-invasive patient derived cell strain (M133) did, in fact, overexpress PAK4. 
However, PAK1 levels were significantly lower than that seen for neonatal melanocytes (1). This 
finding phenocopies that seen for the non-invasive SK-MEL-28 cell line that overexpressed PAK4 
but lacked a significant increase in PAK1 expression compared to the neonatal melanocytes (1). 
The inverse combination of high PAK1 with low PAK4 was not detected in any of the melanoma 
cell lines panel or the patient derived cell strains. This suggests that both PAK1 and PAK4 are 
important in melanoma.   
However, a correlation between PAK1 and PAK4 overexpression and invasion was not evident 
in all patient derived cell strains, with the M581 and M575 strains showing no correlation. 
Therefore, the data obtained from the patient derived cell strains show that overexpression of 
both PAK1 and PAK4 is not deleterious to cell invasion, complementing that of the melanoma 
cell lines. However, a larger data set would be required to accurately validate any link between 
these proteins and the invasion potential or clinical data of patient derived cells.  
Our findings of PAK1 overexpression in invasive melanoma cells and in the most invasive patient 
derived cell strain complement published data for other cancer cell types and a study conducted 
using uveal melanoma cell lines (Pavey et al., 2006; Kamai et al., 2010; Siu et al., 2010b). 
However, one contradictory study, using primary melanoma tissue and cell lines found that PAK1 
overexpression was restricted to a  wildtype BRAF subset and was not present in BRAF mutated 
melanomas (Ong et al., 2013). However, the melanoma cell lines used in this current study 
contained the BRAF mutation (A-375M2, WM-115 and SK-MEL-28) and also overexpressed 
PAK1. Of the patient derived cell strains, the BRAF mutational status was only available for M35 
(mutated), M460 (Wildtype) and M581 (wildtype). Once again in contrast to the data presented 
132 
 
in Ong et al M35 showed PAK1 overexpression, while M581 did not. Interestingly, if only the 
primary tissue is taken into account in this study, the data complements that seen by Ong and 
colleagues, with M460 (wildtype BRAF) overexpressing PAK1 and SK-MEL28 (mutated BRAF) 
lacking PAK1 overexpression. Therefore, increased levels of PAK1 may be restricted to wildtype 
BRAF in primary melanoma. However, our study has shown that this is not the case when 
investigating metastatic melanoma, where PAK1 overexpression correlates with invasion (rather 
than BRAF mutational status).      
To further elucidate the role that PAK1 and PAK4 play in melanoma invasion these proteins were 
reduced in the two most invasive melanoma cell lines, WM-115 and A-375M2 and the effect on 
invasive capacity was subsequently assessed. Depleting PAK1 and PAK4 expression resulted in a 
reduction in invasion in both the 2D invadopodia assay and the 3D spheroid invasion assay. 
Reduced expression of PAK1 can inhibit the invasion of colon cancer cell lines (DLD1 and HCT116) 
in a boyden chamber assay (Huynh et al., 2010). In addition, PAK1 inhibition reduces Matrigel 
invasion of the T47D breast cancer cell line (Coniglio et al., 2008). Similarly, the depletion of 
PAK4 expression inhibits the invasion of choriocarcinoma cell lines (JEG3 and JAR cells) (Zhang 
et al., 2011) and endometrial cancer cell lines (AN3CA and Ishikawa cells) (Lu et al., 2013) in 
Matrigel transwell invasion assays. These findings show that the overexpression of PAK1 and 
PAK4 play an important role in invasion in many different tumour types (including melanoma as 
has been shown in this study). PAK4 is important for the invasion of SCC skin cancer (Zanivan et 
al., 2013), while PAK1 is overexpressed and plays a role in uveal melanoma invasion as shown in 
a Matrigel transwell invasion assay (Pavey et al., 2006). Therefore, the data in this study 
complements previously published studies with other cancer types and suggests that PAK1 and 
PAK4 are involved in melanoma invasion in vitro.  
Some evidence has linked PAK1 to the formation of both invadopodia and the invadopodia 
related protrusion, podosomes. PAK1 and kinase dead PAK1 mutants can induce the formation 
of podosomes in rat vascular smooth muscle cells and aortic smooth muscle cells, respectively 
(Webb et al., 2005; Furmaniak-Kazmierczak et al., 2007). Furthermore, PAK1 localises to 
invadopodia (Moshfegh et al., 2014) and the inhibition of endogenous PAK1 via a PAK1 
autoinhibitory domain fragment, can reduce the formation and degradation of invadopodia in 
A375MM cells demonstrating the importance of PAK1 activity for invasive protrusions (Ayala et 
al., 2008). One suggested PAK1 pathway in invadopodia formation is via the phosphorylation of 
cortactin at Ser113 (Ayala et al., 2008). In contrast, an alternate study indicates that PAK1 is 
involved in invadopodia dissolution, with the knockdown of PAK1 increasing matrix degradation 
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of MTLn3 and MDA-MB-231 cells (Moshfegh et al., 2014). The differences found by this study 
may be accounted for by a differing method of matrix degradation quantification, with Mosfegh 
et al quantifying the entire field of view, in contrast to the method used in this study of 
quantifying the degradation under each cell that corresponded with actin puncta. Furthermore, 
this effect may be cell type specific as another tested cell line, MCF10A, had no increase in matrix 
degradation when PAK1 was depleted in this system. Therefore, our findings regarding the role 
of PAK1 in the promotion of invadopodia formation and degradation complements other studies 
and solidifies the hypothesis that PAK1 is important in invadopodia.  
PAK4  localises to podosomes in bone-marrow-derived mouse dendritic cells (Wells and Jones, 
2010) and primary human macrophages (Gringel et al., 2006). Moreover, the kinase activity of 
PAK4 is important in podosome formation as kinase dead and active forms of PAK4 can inhibit 
and enhance respectively, individual podosome size and number in primary human 
macrophages (Gringel et al., 2006). However, this is the first comprehensive study to show that 
PAK4 is involved in invadopodia formation and degradation. 
PAK1 and PAK4 double knockdowns were also performed to identify any additive effects that 
could suggest separate roles/pathways that these PAK isoforms may be involved in. Our findings 
showed no additive reduction in invadopodia percentage or degradation, suggesting that PAK1 
and PAK4 are either: 1) in overlapping pathways, or 2) in different pathways that are equally 
important for invadopodia formation such that the elimination of one pathway reduces the 
invadopodia production to the lowest limit. Interestingly, cells were less invasive in the double 
knockdown 3D spheroid invasion assay compared to single PAK1 and PAK4 depletion, suggesting 
that PAK1 and PAK4 are involved in different pathways in 3D invasion. Where, these different 
PAK1 and PAK4 pathways, each contribute to the total invasive capacity through a 3D collagen I 
matrix. However, this does not indicate that PAK1 and PAK4 are exclusive to these distinct 
pathways, as these proteins may be involved in multiple 3D invasion signalling pathways. This is 
not surprising as invasion of cells through a 3D matrix relies on more than just the matrix 
degradation seen in the invadopodia assay, but also utilises multiple pathways that are involved 
in cell motility and cell-matrix adhesion amongst others (Friedl and Wolf, 2003). Therefore, to 
further elucidate the roles of PAK1 and PAK4 in 3D invasion additional assays could be 
performed with PAK1, PAK4, and PAK1/4 double, knockdown cells, including timelapse 
microscopy on collagen I to investigate cell movement and cell adhesion assays on collagen I to 
investigate cell matrix adhesion. 
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This study not only investigated the role of PAK1 and PAK4 in melanoma cell lines using in vitro 
invasion assays, but in fact, showed that PAK1 and PAK4 are important for invasion in an in vivo 
context as well. This was achieved using the zebrafish yolk invasion assay, in which it was found 
that zebrafish injected with PAK1 or PAK4 knockdown cells had a significantly reduced tumour 
cell invasion.  
Compared to other studies, the percentage of embryos with tail invasion in this assay was low 
(~25% for injection with control A-375M2 cells compared to >75% seen in other studies, in which 
different cell types were injected) (Haldi et al., 2006; Eguiara et al., 2011). This difference could 
be due to the use of different cell types used in this study. 
The zebrafish yolk invasion assay has several advantages over other in vivo models that are used 
to investigate metastasis and invasion, such as the tail vein injection of mice. These advantages 
include, the production of hundreds of zebrafish embryos from each spawn allowing a high 
embryo number for injection and quantification, the transparency of the embryos which means 
that the fluorescently labelled xenografted cells can be easily visualised and the fast zebrafish 
development which means that the entire experiment can be completed within 2 weeks 
(Amatruda et al., 2002; Mimeault and Batra, 2013). Furthermore, the injection of the cells into 
the yolk sac ensures that metastasis into the tail can only occur if the cells invade through the 
yolk into the surrounding blood vessels or tissue, thus providing a representative model of 
tumour cell invasion. In fact, the importance of a functional circulatory system in this assay was 
shown in a recent study in which cells were unable to form tail invasion in cloche mutated 
embryos that lack functional vasculature (Marques et al., 2009).  
The most commonly used mouse metastasis model involves the injection of cells into the tail 
vein and quantification of the number of lung metastases. However, this model is not truly 
representative of metastasis as the initial stages (invasion away from the primary mass and 
intravasation) are bypassed and the injected cells lodge in the next capillary bed, in this case the 
lungs, then simply proliferate (Khanna and Hunter, 2005). Therefore the zebrafish yolk invasion 
assay offers clear advantages over the mouse tail vein injection. However, there are some 
caveats that are associated with the zebrafish yolk invasion assay, the main one being that 
though there is high conservation of genes between fish and humans, little is known about the 
differences in the microenvironment and how this could influence the human cell invasion and 
thus translate to human metastasis (Konantz et al., 2012). Despite this, the zebrafish yolk 
invasion assay provides a good model to investigate the invasive/metastatic capacity of cancer 
cells in vivo.  
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5 Chapter 5 – PAK1 and PAK4 have Converging and Unique 




In the previous chapter reductions in the expression of PAK1 and PAK4 delivered the same 
phenotypes, despite the fact that PAK1 and PAK4 belong to two different groups in this family 
of proteins. This is interesting as pharmaceutical companies are currently developing group or 
isoform specific inhibitors (Viaud and Peterson, 2009; Murray et al., 2010; Zhang et al., 2012). 
However, if both groups contribute to invasion and metastasis, cross reactive inhibitors may be 
particularly beneficial in treating some cancers types. 
 PAK1 and PAK4 are members of the group I and group II subdivision of PAKs, respectively. These 
two proteins, though both PAK isoforms, differ in many ways including the protein sequence. All 
the PAK isoforms contain a conserved N-terminal p21 binding domain (PBD) and a C-terminal 
kinase domain (Dummler et al., 2009). However, the PBD and the kinase domain sequence have 
less than 40% and 54% homology, respectively, between PAKs of group I and II (Jaffer and 
Chernoff, 2002). Furthermore, PAK1 and PAK4 also differ in their kinase activation. Within the 
PBD of PAK1 there is an autoinhibitory domain (AID), which binds to the PBD of another PAK1 
protein, forming a homodimer and blocking protein activation (Lei et al., 2000; Parrini et al., 
2002). PAK1 has a low basal kinase activity which is increased by the binding of Cdc42 and Rac1 
to the PBD, dissociating the inhibitory PAK1 homodimer (Zenke et al., 1999). In contrast, PAK4 
lacks an AID. Recent findings suggest that PAK4 is constitutively phosphorylated and that kinase 
activity is controlled by conformational changes in the N-terminal region by the binding of Cdc42 
(Baskaran et al., 2012; Ha et al., 2012; King et al., 2014). These differences in sequence and 
kinase regulation may suggest that PAK1 and PAK4 could have divergent functions in cells, driven 
by differing substrates (Jaffer and Chernoff, 2002). Moreover, PAK4 knockout mice are 
embryonically lethal while PAK1 knockout mice remain viable, further emphasising that these 
two proteins may have distinct functions (Qu et al., 2003; Arias-Romero and Chernoff, 2008). 
A 2007 positional scanning peptide library study by Rennefahrt and colleagues demonstrated 
differing optimal phosphorylation sequences between PAK1 and PAK4, suggesting differential 
substrate specificities (Rennefahrt et al., 2007). However, despite the structural and biochemical 
differences, PAK1 and PAK4 share the majority of their substrates with little evidence to date 
suggesting that these isoforms are involved in different pathways (Arias-Romero and Chernoff, 
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2008). Furthermore, these two proteins are rarely directly compared in the same cell type which 
poses difficulty in differentiating unique substrates.   
Whilst PAK1 and PAK4 can both bind, phosphorylate and inhibit the function of GEF-H1 (Zenke 
et al., 2004; Callow et al., 2005; Wells et al., 2010; King et al., 2014), the interactions between 
these proteins is not clearly defined with PAK1 and GEF-H1 interactions in particular revealing 
contradictory findings (Zenke et al., 2004; Coniglio et al., 2008; Tian et al., 2014). The PAK4 
interactions are thought to be more consistent, with phosphorylation of GEF-H1 leading to a 
down regulation of RhoA activity (Callow et al., 2005; Wells et al., 2010). The PAK1 and PAK4 
proteins have differential binding to PDZ-RhoGEF - PAK1 does not bind, whilst PAK4 both binds 
and inhibits protein function (Barac et al., 2004; Rosenfeldt et al., 2006). However, this 
interaction with PDZ-RhoGEF has to date not been linked to any distinct PAK4 cellular processes.  








This study, so far has found that both PAK1 and PAK4 protein reduction in melanoma cell lines 
reduced invasion in vitro and in vivo. In the invadopodia assay, no additive reduction in the 
percentage of cells with invadopodia or invadopodia degradation was seen when PAK1 and PAK4 
were simultaneously knocked down (Section 4.2.4). This may suggest that PAK1 and PAK4 are 
involved in the same signalling pathways. To investigate this further, cross rescues were 
performed by expressing GFPPAK1 and GFPPAK4 constructs in cells with reduced expression of 
PAK4 and PAK1, respectively.   
 
5.2.1 GFPPAK4 Can Rescue Invadopodia Degradation in WM-115 Cells with 
Reduced PAK1 Expression 
 
The expression of GFPPAK4 in WM-115 cells with diminished PAK1 expression had no effect on 
the percentage of cells with invadopodia (Figure 5-1). However, GFPPAK4 expression resulted in 
an increase in, and thus a rescue of, the degradation area in these knockdown cells. This result 
suggests, PAK4 may play an important role in degradation. 
In contrast, expression of GFPPAK1 in WM-115 cells that had depleted PAK4 expression did not 
rescue the invasive phenotype, with no increase in either the percentage of cells with 
invadopodia or area of degradation, compared to cells with reduced PAK4 expression (Figure 
5-2). These findings suggest that PAK1 and PAK4 have distinct roles in invadopodia formation 
and degradation.       
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 Figure 5-1: Invadopodia assay of WM-115 cells with diminished PAK1 protein expressing 
GFPPAK4. 
Three days after siRNA oligonucleotide transfection, cells were transfected with DNA expression vectors 
and incubated for 48hrs. Following this, the cells were seeded on rhodamine conjugated gelatin for 3 hrs 
and stained for F-actin. Only actin rich dots that corresponded with gelatin degraded dots were counted 
as invadopodia. The degradation was measured using ImageJ software. (A) Representative invadopodia 
assay images of WM-115 PAK1 knockdown cells transfected with GFP alone or GFPPAK4. Scale bars = 
10µm. (B) The percentage of cells with invadopodia. Significance was calculated to control siRNA 
transfected cells. Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * = P < 
0.05. (C) The area of degradation from invadopodia per cell. Significance was calculated to control siRNA 
transfected cells. Data are mean values ± S.E.M. of 90 invadopodia producing cells, over 3 independent 





Figure 5-2: Invadopodia assay of WM-115 cells with diminished PAK4 protein expressing 
GFPPAK1. 
Three days after siRNA oligonucleotide transfection, cells were transfected with DNA expression vectors 
and incubated for 48hrs. Following this, the cells were seeded on rhodamine conjugated gelatin for 3 hrs 
and stained for F-actin. Only actin rich dots that corresponded with gelatin degraded dots were counted 
as invadopodia. The degradation was measured using ImageJ software. (A) Representative invadopodia 
assay images of WM-115 PAK4 knockdown cells transfected with GFP alone or GFPPAK1. Scale bars = 
10µm. (B) The percentage of cells with invadopodia. Significance was calculated to control siRNA 
transfected cells. Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * = P < 
0.05. (C) The area of degradation from invadopodia per cell. Significance was calculated to control siRNA 
transfected cells. Data are mean values ± S.E.M. of 90 invadopodia producing cells, over 3 independent 




5.2.2 Overexpression of PAK4 Does Not Increase Invadopodia Formation or 
Degradation 
 
As the expression of GFPPAK4 in PAK1 knockdown WM-115 cells rescued the invadopodia 
degradation phenotype, investigations were conducted to determine whether overexpression 
of PAK4 in wildtype WM-115 cells could increase invadopodia formation or degradation. 
The percentage of cells with invadopodia and the area of degradation did not change when 
GFPPAK4 was expressed in WM-115 cells compared to the wildtype and GFP alone control cells 
(Figure 5-3). Therefore, this shows that the expression of GFPPAK4 in WM-115 does not enhance 





 Figure 5-3: Invadopodia assay of WM-115 cells expressing GFPPAK4. 
WM-115 cells were transfected with either GFP alone or GFPPAK4 constructs and incubated for 48hrs. 
Following this, the cells were seeded on rhodamine conjugated gelatin for 3 hrs and stained for F-actin. 
Only actin rich dots that corresponded with gelatin degraded dots were counted as invadopodia. The 
degradation was measured using ImageJ software. (A) Representative invadopodia assay images of WM-
115 cells transfected with no construct (wildtype), GFP alone or GFPPAK4. Scale bars = 10µm. (B) The 
percentage of cells with invadopodia. Significance was calculated to wildtype WM-115 cells. Data are 
mean values ± S.E.M. of 150 cells, over 3 independent experiments; * = P < 0.05. (C) The area of 
degradation from invadopodia per cell. Significance was calculated to wildtype WM-115 cells. Data are 





5.2.3 Depletion of PAK4 Expression Does Not Reduce the Percentage of Cells 
with Actin Puncta on Gelatin 
 
To investigate if PAK1 and PAK4 function in invadopodia development from the early/nascent 
stages to the mature degradative protrusion, the percentage of cells with actin puncta when 
plated on gelatin was calculated. The depletion of PAK1 expression reduced the percentage of 
cells with actin puncta, compared to wildtype and control cells (Figure 5-4), whilst a reduction 
of PAK4 expression had no effect on the percentage of cells with actin puncta. 
 
Figure 5-4: The percentage of WM-115 and A-375M2 cells with actin puncta on gelatin when PAK1 and 
PAK4 expression was depleted (individually and simultaneously).  
Cells were plated on gelatin matrix coated coverslips 4 days post-transfection of siRNA oligonucleotides 
to reduce PAK1 and PAK4. (A) Representative images of WM-115 and A-375M2 cells for each condition. 
Scale bar = 10µm. (B) The percentage of cells with actin puncta on gelatin. Significance was calculated to 
wildtype and control cells. Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * 




5.2.4 Cell Shape is Unaffected by the Depletion of PAK1 and PAK4 
Expression in WM-115 and A-375M2 Cells 
 
All the invasion assays conducted in this study, utilising cells with diminished PAK1 and PAK4 
expression (Section 4.2.4 and Section 4.2.5), found that no phenotypic differences existed 
between these two knockdown groups, with reduced invasion present in both groups. This data 
however, gives little insight into the specific role of PAK1 and PAK4 in melanoma invasion and 
progression. Therefore, to elucidate the role of these proteins additional assays were conducted 
to identify any phenotypic differences between PAK1 and PAK4 knockdown cells. 
As discussed in chapter 3, cell shape may indicate the mode by which cells migrate and invade, 
e.g. a less elongated phenotype may indicate amoeboid migration rather than mesenchymal. 
Therefore, the cell shape was measured in WM-155 and A-375M2 cells in which PAK1, PAK4 and 
both proteins simultaneously, were reduced to identify any differences between these two 
isoforms (Figure 5-5). There was no significant difference in cell area, perimeter or elongation 
when PAK1, PAK4 or both PAK1 and PAK4 simultaneously, were reduced in WM-115 and A-




Figure 5-5: Cell shape analysis of PAK1, PAK4 and PAK1&PAK4 depleted WM-115 and A-375M2 cells.  
Four days post-transfection of siRNA oligonucleotides, cells were seeded on glass coverslips, incubated 
overnight, and stained for F-actin. The cell area (A), cell perimeter (B) and cell elongation (C) were 
calculated for 90 cells, over 3 independent experiments. Cell elongation was represented as a scale from 
0 to 1 where 0 = circular and 1 = straight. Significance was calculated to wildtype and control cells. Data 




5.2.5 Reduced PAK4 Expression Increases Prominent Actin Fibres in WM-
115 and A-375M2 Cells 
 
An increase in prominent actin fibres has been linked to cell rigidity and reduced cell invasion 
(Friedl and Wolf, 2003). Indeed, within this study few prominent actin fibres were found in the 
most invasive WM-115 cell line (Section 3.2.1.1). Furthermore, previous experiments have 
shown an increase in prominent actin fibres in PAK4 diminished DU-145 prostate cancer cells 
and in PAK1 diminished REF-52 rat embryo fibroblast cells (Frost et al., 1998; Wells et al., 2010). 
However, no direct comparison of prominent actin fibre formation in PAK1 and PAK4 depleted 
melanoma cell lines has previously been conducted.  
An increase in prominent actin fibres was detected compared to wildtype and control cells in 
PAK4 depleted cells, whilst a loss of PAK1 expression did not increase the percentage of cells 
with prominent actin fibres (Figure 5-6). The simultaneous reduction of PAK1 and PAK4 also 
increased the percentage of cells with prominent actin fibres. In addition, these different PAK1 





Figure 5-6: Percentage of WM-115 and A-375M2 cells with prominent actin fibres in PAK1 and PAK4 
knockdown (individually and simultaneously) on glass and gelatin. 
Cells were plated on glass or gelatin matrix coated coverslips 4 days post-transfection of siRNA 
oligonucleotides to reduce PAK1 and PAK4. (A) Representative images of WM-115 and A-375M2 cells on 
glass and gelatin for each condition. Scale bar = 10µm (B) Quantification of the percentage of cells with 
prominent actin fibres. Significance was calculated to wildtype and control cells. Data are mean values ± 






5.2.6 GFPPAK4r siRNA Resistant Vector Rescued the Prominent Actin Fibre 
Phenotype in PAK4 Diminished WM-115 Cells 
 
In the previous section, the depletion of PAK4 in WM-115 and A-375M2 cells increased the 
percentage of prominent actin fibres (Section 5.2.5). To validate that this phenotype is PAK4 
specific, the prominent actin fibres were quantified for cells in which the GFPPAK4r siRNA 
resistant construct was expressed. As the wildtype A-375M2 cell line had a higher percentage of 
cells with prominent actin fibres compared to WM-115 cells, and therefore was able to show a 
larger differential in the percentage of cells with prominent actin fibres between wildtype and 
PAK4 knockdown cells, this cell line was used in the rescue experiments.  
The expression of GFPPAK4 in PAK4 knockdown A-375M2 cells rescued the percentage of cells 
with prominent actin fibres back to that seen by the control cells (Figure 5-7). This further 




Figure 5-7: Percentage of cells with prominent actin fibres in PAK4 knockdown A-375M2 cells 
transfected with GFPPAK4r siRNA resistant rescue construct.  
Cells were plated in 6 well plates and transfected with siRNA oligonucleotides to reduce PAK4. Two days 
post-transfection the cells were transfected with GFP alone or GFPPAK4 constructs. After 48 hrs, these 
cells were seeded on glass coverslips and incubated overnight, fixed and stained for F-actin. (A) 
Representative images of A-375M2 cells for each condition. Scale bar = 10µm (B) Quantification of the 
percentage of cells with prominent actin fibres. Significance was calculated to control cells. Data are mean 










5.2.7 A Reduction in PAK4 Protein Expression Leads to an Increase in RhoA 
Activation 
  
An increase in RhoA activity has previously been shown to increase prominent actin fibres 
(Ridley and Hall, 1992). In addition, a reduction of PAK4 leads to an increase in the percentage 
of prominent actin fibres via an increase in RhoA activity in the DU-145 prostate cancer cell line 
(Wells et al., 2010). Therefore, an investigation of the effects of PAK1 and PAK4 knockdown on 
RhoA activation was conducted, using a RhoA biosensor (named A-375M2 RhoA cells) (Fritz et 
al., 2013). 
A-375M2 cells stably expressing the RhoA biosensor (A-375M2 RhoA cells) were generated. 
Initially, the effect of PAK1 and PAK4 knockdown on prominent actin fibre formation was 
measured in A-375M2 RhoA cells to confirm that the presence of the RhoA biosensor does not 
change this phenotype.  
The knockdown of PAK4 increased the percentage of cells with prominent actin fibres in 
agreement with our previous findings (Figure 5-6) whilst, the reduction of PAK1 expression had 







 Figure 5-8: Percentage of cells with prominent actin fibres in PAK1 and PAK4 knockdown (both 
individually and simultaneously) in A-375M2 RhoA cells. 
A-375M2 RhoA cells were plated on glass coverslips four days post-transfection of siRNA oligonucleotides. 
(A) Representative images of A-375M2 RhoA cells for each condition. Scale bar = 10µm. (B) Quantification 
of the percentage of cells with prominent actin fibres. Significance was calculated to wildtype and control 
cells. Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * = P < 0.05. Control = 
cells transfected with non-specific siRNA. 
 
An increase in FRET efficiency was observed in A-375M2 RhoA cells in which PAK4 levels were 
reduced (using either PAK4 oligo 1 or PAK4 oligo 2) compared to the control (Figure 5-9). This 
indicates that an increase in RhoA activation does occur when PAK4 expression is reduced. 
Interestingly, when PAK1 levels were diminished (using either PAK1 oligo 1 or PAK1 oligo 3) in 
A-375M2 RhoA cells there was a decrease in FRET efficiency compared to the control. Therefore, 
the level of RhoA activation differs in PAK1 and PAK4 knockdown A-375M2 RhoA cells. This 





 Figure 5-9: FRET analysis of RhoA activation in A-375M2 RhoA cells in which PAK1 and PAK4 
expression was diminished. 
A-375M2 RhoA cells were plated on glass coverslips four days post-transfection of siRNA oligonucleotides 
and the FRET was measured using a multiphoton, time-correlated single-photon counting (TCSPC) 
fluorescence lifetime imaging microscope (FLIM). FRET efficiency was calculated using TRI2. (A) 
Representative FRET efficiency images of A-375M2 RhoA cells for each condition. (B) Quantification of the 
FRET efficiency of A-375M2 RhoA cells in which PAK1 or PAK4 was reduced. Significance was calculated to 
control cells. Data are mean values ± S.E.M. over 3 independent experiments; * = P < 0.05. Control = cells 
transfected with non-specific siRNA. 
 
5.2.8 PAK4 Does Not Signal Through GEF-H1 in WM-115 Cells 
 
These results suggest PAK4 but not PAK1 signals via inhibition of RhoA. PAK4 has previously been 
shown to inhibit the activation of RhoA via the phosphorylation and inhibition of GEF-H1 at Ser885 
(Callow et al., 2005; Wells et al., 2010). However, the findings regarding PAK1 signalling through 
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GEF-H1 to RhoA are conflicting (Zenke et al., 2004; Coniglio et al., 2008; Tian et al., 2014). To 
date the extent to which PAK1 and PAK4 phosphorylate GEF-H1 has not been directly compared. 
Therefore, the level of pGEF-H1 phosphorylation at Ser885 was quantified using western blot in 
PAK1 and PAK4 knockdown cells. 
There was no significant difference in the phosphorylation of GEF-H1 at Ser885 when PAK1 and 
PAK4 were knocked down (individually and simultaneously) in WM-115 cells when compared to 
control cells (Figure 5-10). This data indicates that the unique signalling of PAK4 to RhoA does 
not occur through the phosphorylation of GEF-H1 at Ser885 in melanoma cells.    
 
Figure 5-10: The expression of p-GEF-H1 (Ser885) in WM-115 cells with reduced expression of PAK1 and 
PAK4 (individually or simultaneously). 
(A) Western blot of p-GEF-H1 (Ser885), total GEF-H1, PAK1 and PAK4 in WM-115 cells in which PAK1 and 
PAK4 expression was reduced (individually and simultaneously). (B) Analysis of western blot data via 
densitometry showing p-GEF-H1 (Ser885) levels compared to the total GEF-H1 protein. Significance was 
calculated compared to control WM-115 cells. Data are the mean values ± S.E.M., over 3 independent 
experiments; *= P < 0.05. Densitometric data were normalized to total GEF-H1. GAPDH was also used as 




5.2.9 PDZ-RhoGEF Dominant Negative Mutant Can Rescue the PAK4 
Knockdown Prominent Actin Fibre Phenotype 
 
The activity of RhoA can be controlled via other GEFs including PDZ-RhoGEF. Interestingly, only 
PAK4 (and not PAK1) can bind to, and inhibit the GEF activity of, PDZ-RhoGEF (Barac et al., 2004; 
Rosenfeldt et al., 2006). Therefore, the inhibition of the activation of RhoA by PAK4 may signal 
via PDZ-RhoGEF in melanoma cells. To investigate this possibility, a dominant negative PDZ-
RhoGEF mutant (myc-PDZ-RhoGEF∆DH) was expressed in cells with reduced PAK4 expression 
and the percentage of cells with prominent actin fibres was subsequently calculated (Figure 
5-11). This myc-PDZ-RhoGEF∆DH mutant, lacks the DH domain essential for GTPase activation 
(Hart et al., 1994), and competes with the wildtype PDZ-RhoGEF to bind Rho, but, is unable to 
activate the GTPase (Driessens et al., 2002; Kasai et al., 2004). If reducing PAK4 expression allows 
increased PDZ-RhoGEF activity, this mutant should repress this effect and deliver a rescue of 
phenotype. The expression of myc-PDZ-RhoGEF∆DH in PAK4 diminished WM-115 cells did 





Figure 5-11: Percentage of cells with prominent actin fibres in PAK4 reduced WM-115 cells expressing 
myc-PDZ-RhoGEF∆DH on gelatin. 
Three days after siRNA oligonucleotide transfection, WM-115 cells were transfected with DNA expression 
vectors and incubated for 48hrs. Following this, the cells were seeded on rhodamine conjugated gelatin 
for 3 hrs and stained for F-actin. (A) Representative images of WM-115 cells for each condition. Scale bar 
= 10µm. (B) Quantification of the percentage of cells with prominent actin fibres. Significance was 
calculated to control cells. Data are mean values ± S.E.M. of 150 cells, over 3 independent experiments; * 








5.2.10 PDZ-RhoGEF∆DH Dominant Negative Mutant Can Rescue the 
Invadopodia Formation and Degradation in PAK4 Diminished Cells 
 
As myc-PDZ-RhoGEF∆DH was able to rescue the PAK4 knockdown prominent actin fibre 
phenotype, the effect of this dominant negative PDZ-RhoGEF mutant on the invasion of WM-
115 PAK4 knockdown cells was investigated. 
The expression of myc-PDZ-RhoGEF∆DH in WM-115 cells in which PAK4 expression levels were 
reduced, rescued the invasive phenotype as measured by the invadopodia assay. In fact, both 
the percentage of cells with invadopodia and the degradation from invadopodia producing cells 





Figure 5-12: Invadopodia assay of PAK4 knockdown WM-115 cells expressing myc-PDZ-RhoGEF∆DH. 
Three days after siRNA oligonucleotide transfection, cells were transfected with DNA expression vectors 
and incubated for 48hrs. Following this, the cells were seeded on rhodamine conjugated gelatin for 3 hrs 
and stained for F-actin. Only actin rich dots that corresponded with gelatin degraded dots were counted 
as invadopodia. The degradation was measured using ImageJ software. (A) Representative invadopodia 
assay images of WM-115 PAK4 knockdown cells for each condition. Scale bars = 10µm. (B) The percentage 
of cells with invadopodia. Significance was calculated to control cells. Data are mean values ± S.E.M. of 
150 cells, over 3 independent experiments; * = P < 0.05. (B) The area of degradation from invadopodia 
per cell. Significance was calculated to control cells. Data are mean values ± S.E.M. of 90 invadopodia 




5.2.11 Overexpression of PDZ-RhoGEF Mimics PAK4 Knockdown in Wildtype 
WM-115 Cells 
 
Given that the dominant negative myc-PDZ-RhoGEF∆DH mutant rescues the invasive phenotype 
(as measured by the invadopodia assay) in PAK4 diminished cells, it was thought that an increase 
in the expression of wildtype myc-PDZ-RhoGEF in WM-115 cells may mimic the PAK4 knockdown 
phenotype. This would further validate the PAK4 signalling pathway via inhibition of PDZ-
RhoGEF. 
 
The overexpression of myc-PDZ-RhoGEF did in fact reduce the percentage of cells with 
invadopodia and the degradation from invadopodia producing cells compared to wildtype and 
GFP Alone transfected cells (Figure 5-13), thus mimicking the PAK4 knockdown phenotype. 
Therefore, this data further validates the conclusion that PAK4 signalling in invadopodia 






Figure 5-13: Invadopodia assay of WM-115 cells expressing myc-PDZ-RhoGEF. 
WM-115 cells were transfected with either GFP alone or myc-PDZ-RhoGEF constructs and incubated for 
48hrs. Following this, the cells were seeded on rhodamine conjugated gelatin for 3 hrs and stained for F-
actin. Only actin rich dots that corresponded with gelatin degraded dots were counted as invadopodia. 
The degradation was measured using ImageJ software. (A) Representative invadopodia assay images of 
WM-115 cells for each condition. Scale bars = 10µm. (B) The percentage of cells with invadopodia. 
Significance was calculated to wildtype WM-115 cells. Data are mean values ± S.E.M. of 150 cells, over 3 
independent experiments; * = P < 0.05. (B) The area of degradation from invadopodia per cell. Significance 
was calculated to wildtype WM-115 cells. Data are mean values ± S.E.M. of 90 invadopodia producing 






5.2.12 PDZ-RhoGEF and PAK4 Localise to Invadopodia 
 
Our findings suggest that PAK4 signals through PDZ-RhoGEF during invadopodia formation and 
degradation. Thus, it might be expected that these proteins are localised to invadopodia. 
Therefore, myc-PDZ-RhoGEF (both wildtype and ∆DH mutant) and GFPPAK4 were overexpressed 
in WM-115 cells and protein localisation was observed using confocal microscopy. 
Both GFPPAK4 and myc-PDZ-RhoGEF (wildtype and ∆DH mutant) localised to invadopodia 
structures (Figure 5-14). Furthermore, the localisation of PDZ-RhoGEF at invadopodia is 
independent of the GEF activity as the myc-PDZ-RhoGEF∆DH dominant mutant retained the 





 Figure 5-14: Co-localisation of GFPPAK4 and myc-PDZ-RhoGEF (wildtype and ∆DH mutant) with F-actin 
and TRITC gelatin degradation. 
WM-115 cells transfected with GFPPAK4 or myc-PDZ-RhoGEF were seeded on TRITC gelatin coated 
coverslips for 3 hrs and then fixed and stained for F-actin. (A) Representative confocal images showing co-
localisation of GFPPAK4 and myc-PDZ-RhoGEF (wildtype and ∆DH mutant) with F-actin and gelatin 
degradation. Scale bar = 10µm. (B) A representative fluorescence intensity plot showing co-localisation of 
GFPPAK4 and myc-PDZ-RhoGEF (wildtype and ∆DH mutant) with F-actin and gelatin degradation. 
Fluorescence intensity was measured at each image pixel along an arbitrary line that crossed through an 





This chapter has identified for the first time a unique PAK4 pathway (not used by PAK1) that 
signals via PDZ-RhoGEF to promote invadopodia formation and degradation, in addition to 
demonstrating a converging PAK1 and PAK4 pathway utilised in invadopodia degradation. These 
findings reveal the importance of both PAK1 and PAK4 in melanoma invasion and invadopodia 
structures.  
The rescue by GFPPAK4 of the degradation area of WM-115 cells in which PAK1 was diminished, 
suggests that PAK4 signals later in the lifecycle of the invadopodia than PAK1. Furthermore, 
when the percentage of cells on gelatin with actin puncta (presumed to be early/nascent 
invadopodia) was analysed, the reduction of PAK4 did not reduce the formation of these puncta. 
This differed from cells with depleted PAK1 levels which had a reduction in the percentage of 
cells with actin puncta. This suggests that PAK1 enhances the formation of invadopodia, which 
is supported by a previous study which found that PAK1 is involved in the early stages of 
invadopodia formation via the phosphorylation of cortactin at Ser113 (Ayala et al., 2008). 
However, the function that cortactin phosphorylation plays in invadopodia is currently in dispute 
with a recent study suggesting a key role for this phosphorylated protein in the disassembly of 
invadopodia (Moshfegh et al., 2014).  In contrast, PAK4 may function during the maturation of 
invadopodia to a degradative protrusion, or during the degradation process.  
Both PAK1 and PAK4 have previously been implicated in pathways involved in matrix 
degradation. Prolactin induced secretion of MMP-1 and MMP-3 by TMX2-28 breast cancer cell 
lines in collagen IV matrix, signals via PAK1, while the expression and secretion of MMP-9 in 
collagen I, and MMP-2 in collagen IV, is down regulated by this PAK isoform (Rider et al., 2013). 
Conversely, the inhibition of PAK1 reduces MMP-9 expression in the PC3 prostate cancer cell 
line (Goc et al., 2013). PAK4 inhibition reduces MMP-2 expression in the 4910 glioma cell line 
and OVCA420 ovarian cancer cell line (Siu et al., 2010a; Kesanakurti et al., 2012). Furthermore, 
PAK4 knockdown down regulates MT1-MMP expression in CCA choriocarcinoma cells (Zhang et 
al., 2011), while its overexpression enhances the expression of MMP-2 (Siu et al., 2010a). Due 
to the key role played by matrix metalloproteinases in matrix degradation and the regulation of 
the expression and secretion of these proteins by PAK4, it is likely that the signalling pathway 
utilised by this isoform in invadopodia degradation occurs via MMPs.   
This study has also found PAK4 to have a unique pathway, not shared by PAK1, in invasion. This 
pathway involves the inhibition of PDZ-RhoGEF by PAK4 in invadopodia. In addition, our findings 
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suggest that it is the RhoA isoform which is involved in this pathway, as PAK4 knockdown 
increases RhoA activity while PAK1 depletion does not.  
PDZ-RhoGEF is classed as a RhoA specific activator and signalling of this protein via the activation 
of RhoA has been widely published (Rumenapp et al., 1999; Rossman et al., 2005; Oleksy et al., 
2006; Wong et al., 2007). However, PDZ-RhoGEF may also play a role in signalling through other 
Rho isoforms, as evidenced by the fact that this protein was able to promote the activation of 
RhoB and RhoC in an in vitro GDP dissociation assay, albeit to a lesser extent than that seen with 
RhoA (Jaiswal et al., 2011). Therefore, further experiments are required to validate that PAK4 
signalling through PDZ-RhoGEF in invadopodia occurs via RhoA. This could be achieved by 
measuring RhoA activity at invadopodia structures (Bravo-Cordero et al., 2011) when expressing 
PAK4, PDZ-RhoGEF or PDZ-RhoGEF∆DH, either using fixed cells or more interestingly, timelapse 
microscopy on live cells. In addition, to confirm the results obtained with the dominant negative 
mutant were specifically due to reduced PDZ-RhoGEF activity, the depletion of PDZ-RhoGEF 
protein expression (using siRNA oligonucleotides) could be performed in PAK4 knockdown cells 
in the invadopodia assay.  
Within this study, both PAK4 and PDZ-RhoGEF were shown to localise to invadopodia structures 
which indicates that Rho activity is spatiotemporally controlled in these structures. This also 
suggests that activation of this GTPase is likely to be required for additional stages of either 
invadopodia formation or dissolution, as the requirement for low levels of Rho activity 
throughout the invadopodia life cycle, could simply be achieved by the localisation of PDZ-
RhoGEF away from the invadopodia structure.  
Other invadopodia proteins exhibit spatiotemporal functions, such as cortactin and cofilin 
(Artym et al., 2006; Oser et al., 2009). In invadopodia cortactin forms an inhibitory complex with 
cofilin, N-WASP, Arp2/3 and other proteins (Oser et al., 2009). During the early formation of 
invadopodia, cortactin is phosphorylated, which results in the release of cofilin, allowing the 
creation of free barbed ends for actin polymerisation (Oser et al., 2009). After the formation of 
invadopodia, cortactin is de-phosphorylated, exerts an inhibitory function on cofilin leading to 
invadopodia stabilisation and matrix degradation.  
RhoC also demonstrates spatiotemperal activity in invadopodia which is controlled by the 
localisation of RhoC GEFs and GAPs (Bravo-Cordero et al., 2011). p190RhoGAP localises to the 
invadopodia core while p190RhoGEF localises around this core in MTLn3 cells, to 
spatiotemporally control RhoC activity in invadopodia, ultimately influencing spatial cofilin 
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phosphorylation. Indeed, a RhoA GAP, ARAP3, also localises to the core of podosomes, an 
invadopodia related structure (Yu et al., 2013). The presence of p190RhoGEF, p190RhoGAP and 
ARAP3 in invadopodia and related structures highlights the importance of GEFs and GAPs in the 
formation of these invasive structures.  
Little is known about the role that PDZ-RhoGEF plays in tumour invasion. Gene amplification of 
PDZ-RhoGEF is evident in gallbladder cancer specimens, compared to normal tissue (Kim et al., 
2008). In addition, PDZ-RhoGEF has higher tissue expression in more advanced stages of breast 
cancer, with this GEF being essential for the spatial activation of RhoA in CXCR4 induced cell 
migration of MDA-MB-231 breast cancer cells (Struckhoff et al., 2013). These findings are in line 
with the results obtained in this current study in which the localisation of PDZ-RhoGEF to 
invadopodia indicates that activity of this protein, is required at some stage of the invadopodia 
life cycle. This study indicates that the spatiotemporal inhibition (via PAK4) of PDZ-RhoGEF is 
essential for the invadopodia function and degradation that promotes cell invasion. Therefore, 
the presence of global PDZ-RhoGEF overexpression in advanced tumours emphasises the 
importance of PAK4 in providing an inhibitory function at invadopodia for successful invasion.  
Studies on the function of RhoA in cell invasion and invadopodia formation have produced 
contradictory results depending on the cell type and experimental technique. RhoA expression 
and activity has been shown to both promote and hinder cell invasion. The depletion of RhoA in 
MDA-MB-231 cells and the prostate cancer cell lines DU-145, PC3 and LnCaP, increased cellular 
invasion both in a 3D Matrigel matrix and in a transwell invasion assay (coated with Matrigel) 
(Vega et al., 2011). Similarly, RhoA protein depletion in the breast cancer cell lines, SUM-159 
and MCF-7, increased cell invasion in a transwell invasion assay (Matrigel coated) (Simpson et 
al., 2004). Moreover, the reduction in β1 integrin in MDA-MB-231 breast cancer cells is 
associated with decreased RhoA activity and increased invasion (Costa et al., 2013). An 
enhancement of cortactin was observed at the invasive front of cells invading through Matrigel 
and a collagen I/Matrigel mix when RhoA expression was diminished in MDA-MB-231 cells. This 
supports the hypothesis that RhoA reduction enhances invasiveness (Vega et al., 2011). 
Contradictory results found that a reduction in RhoA expression in MDA-MB-231 cells reduces 
the lung metastasis in an in vivo murine tail injection assay (Valastyan et al., 2009) and RhoA 
overexpression in rat MM1 hepatoma cells enhances peritoneal invasion (Yoshioka et al., 1999). 
These differing findings suggest that the role of RhoA in invasion is complex and may be 
dependent on the assay itself, and the length of time that is given for invasion. Interestingly, of 
the three Rho isoforms, RhoA is the only isoform that can cause a reduction in cell invasion when 
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overexpressed (Ridley, 2013). This further validates the results of this study which indicate that 
PAK4 inhibition of PDZ-RhoGEF signals downstream to reduce the activation of RhoA in 
invadopodia.  
RhoA is overexpressed in many different tumour types, including breast, colon and lung cancer 
tissue (Fritz et al., 1999; Kamai et al., 2001; Sahai and Marshall, 2002). In invasive melanoma cell 
lines such as A-375M2, the Rho-ROCK-MLC2 pathway is vital for invasion by promoting a highly 
contractile and motile, amoeboid phenotype in both a 3D in vitro assay and in vivo  (Sahai and 
Marshall, 2003; Sanz-Moreno and Marshall, 2010). While this is in line with the findings in the 
current study which suggest that RhoA activity is regulated within invadopodia, a localised lapse 
in cell contractility would be required to allow for the outgrowth of the membrane and the 
formation of these invasive protrusions. This may be achieved through the spatiotemporal 
reduction in RhoA via PAK4 inhibition of PDZ-RhoGEF.   
As with the global impact of RhoA, studies investigating the role played by this protein in 
invadopodia formation provide contradictory results. Bravo-Cordero and colleagues, detected 
no localised variation in RhoA activity at invadopodia structures in the MTLn3 rat mammary 
adenocarcinoma cell line (Bravo-Cordero et al., 2011). However, observation of the published 
FRET timelapse images, reveal the cells to have very high global RhoA activity which may result 
in signal saturation, preventing the observation of subtle changes in RhoA activity. Furthermore, 
a decrease in RhoA expression in these cells reduced invadopodia formation and degradation. 
This is not surprising given that RhoA activity promotes the interaction of the Ras GTPase-
activating-like protein IQGAP1 with Sec3 and Sec8 exocyst subunits to tether cargo, such as 
vesicles containing MMPs, to invadopodia for matrix degradation (Sakurai-Yageta et al., 2008).  
In contrast, other studies using active and dominant negative RhoA indicated that this protein 
had no effect on invadopodia degradation in RPMI7951 melanoma cells (Nakahara et al., 2003), 
while PIP3 induced RhoA inactivation (via the recruitment of ARAP3) resulted in podosome 
formation in rat embryonic fibroblast (REF52) cells (Yu et al., 2013). Furthermore, expression of 
constitutively active RhoA in NIH3T3 cells reduced v-Src induced podosomes (Schramp et al., 
2008) and this was supported by a later study in which a constitutively active RhoA mutant or 
the stimulation of RhoA via LPA eliminated podosome formation (Yu et al., 2013). The 
importance of RhoA in invasive protrusions is further supported by the fact that the stimulation 
of dendritic cells with prostaglandin E2 (PGE2) activates the RhoA-ROCK pathway which 
promotes the dissolution of podosomes (van Helden et al., 2008). Interestingly, the expression 
of a dominant negative RhoA mutant results in disorganisation of v-Src induced podosomes in 
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NIH3T3 cells (Berdeaux et al., 2004). Furthermore, both a constitutively active  and dominant 
negative RhoA mutant reduced the podosome induced degradation by v-Src NIH3T3 cells 
(Berdeaux et al., 2004). These findings suggest that a balance of RhoA activity and inactivation 
may be important for podosome function. Therefore, it is likely that RhoA and its activity, play a 
complex role in invadopodia formation, with differing activation states being present during the 
life cycle of the protrusion.   
Invadopodia formation is controlled by actin polymerisation and microtubule dynamics, which 
are both influenced by RhoA activity (Schoumacher et al., 2010; O'Connor and Chen, 2013). 
RhoA is a central player in membrane protrusions and cell contractility, and thus there are 
multiple pathways that this GTPase may influence in invadopodia formation. One such pathway 
involves the promotion of ROCK phosphorylation by RhoA and subsequent phosphorylation of 
LIMK (Maekawa et al., 1999). LIMK phosphorylates and inhibits cofilin, a protein that binds and 
severs actin filaments, allowing the binding of the Arp2/3 complex to form a nucleation core for 
branched actin polymerisation. This nucleation core also promotes actin depolymerisation to 
provide a pool of free actin for new actin polymerisation (Carlier et al., 1999; Ridley, 2011). The 
importance of cofilin function was recently reported in vivo, using C. elegans (Hagedorn et al., 
2014). In this study, active cofilin was found to be essential for the creation of discrete 
invadopodia-like structures and to promote actin recycling for protrusion turnover. However, 
despite cofilin being a target for RhoA, the depletion of this GTPase did not change the p-Cofilin 
levels in invasive MTLn3 cells (Bravo-Cordero et al., 2011).  
As discussed previously, RhoA is a central protein in controlling cell contractility with RhoA 
activated ROCK  activating MLC by direct phosphorylation and by phosphorylating and inhibiting 
myosin phosphatase (an inactivator of MLC) to enhance myosin induced actin contractility 
(O'Connor and Chen, 2013). Therefore, localised inhibition of this contractility (by inhibiting 
RhoA activity) at invadopodia would allow for the membrane to extend away from the cell body 
to form the protrusion. However, additional investigations, which could include the inhibition of 
myosin II contractility using blebbistatin (Sanz-Moreno et al., 2008) in cells with reduced PAK4 
expression, are needed to elucidate this pathway further.  
This study demonstrates that PAK1 and PAK4 are involved in key pathways in melanoma cell 
invasion, with some of these pathways being shared by both proteins while others are distinct. 
While we have begun to tease out the details of these pathways including signalling through 
PDZ-RhoGEF and RhoA, additional studies are required to provide further insight. However, the 
data obtained so far certainly suggests that PAK1 and PAK4 are potential therapeutic targets for 
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treating metastatic melanoma, with targeting of both isoforms likely to be a more effective 




6 Chapter 6 - Concluding Remarks 
 
The majority of deaths from cancer are as a result of metastasis (>90%) (Valastyan and 
Weinberg, 2011). This is particularly true for melanoma in which a dramatic reduction in patient 
five year survival is evident from primary (98%) to regional (62%) to distant (16%) metastatic 
disease (American Cancer Society, 2014). This considerable drop in survival in melanoma 
patients with metastatic disease highlights the importance of understanding this invasive 
process. This study used the invadopodia assay as an indicator of invasive potential, along with 
a 3D and an in vivo invasion assay, to investigate the role of PAK1 and PAK4 in melanoma 
invasion. Invadopodia are actin rich protrusions that secrete proteases to degrade the ECM and 
are formed by many invasive tumour cell lines in 2D invadopodia assays (Artym et al., 2006; 
Ayala et al., 2008; Schoumacher et al., 2010). However, there is still debate about whether these 
protrusions are formed and used by cells in vivo, and are not therefore artefacts of long term 
cell culture.  
Conflicting views exist over the presence and use of invadopodia in 3D matrices and in vivo, 
primarily due to the difficultly in visualising this protrusion. In 3D, new techniques have been 
utilised to allow the high resolution imaging of invadopodia-like degradative structures in cells, 
embedded in collagen (Yu and Machesky, 2012). In addition, recent studies have visualised 
invadopodia-like protrusions that were positive for cortactin and had local degradation 
(proteolytic activity) in xenografted mammary fat pad tumours (MTLn3 cell line) (Gligorijevic et 
al., 2012). Furthermore, these cells formed invadopodia-like structures that extended into blood 
vessels during intravasation, suggesting a role for this invasive protrusion in vivo (Yamaguchi et 
al., 2005b). In an additional study, glioma cells derived from the tissue of two patients (with 
metastatic disease) had the ability to form invadopodia in vitro (Stylli et al., 2008). Though these 
studies provide some indication that invadopodia do occur in an in vivo setting, they still utilise 
cell lines rather than native tumour cells. However, in a recent study, anchor cells utilising 
invadopodial-like protrusions were imaged invading through the basement membrane in C. 
Elegans (Hagedorn et al., 2014). This study demonstrated that native invasive cells use invasive 
protrusions to cross the basement membrane, thus providing evidence that invasive protrusions 
do occur in vivo. In this study patient derived cell strains were established from both human 
primary and metastatic melanoma tissue and it was demonstrated that melanoma cells from 
patients can produce invadopodia protrusions in culture (Chapter 3). The ability of these patient 
derived cells to form invadopodia in vitro suggests that these cells may also have the capacity to 
do so when in the patient. These findings therefore complement the previous studies described 
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above which suggest a role for invadopodia in vivo and highlight the need for a better 
understanding of these structures as a potential therapeutic target. 
There is some evidence that PAKs are involved in invadopodia function (Ayala et al., 2008; 
Moshfegh et al., 2014). PAK isoforms (of which there are 6) are overexpressed in a wide variety 
of human tumours such as breast, colon, prostate and ovarian cancer (Radu et al., 2014). 
However, the role of these proteins in melanoma invasion is undefined. Therefore, this study 
firstly looked at the PAK isoform protein expression in melanoma, with initial experiments being 
focused on the quantification of protein expression of the six PAK isoforms in melanoma cells 
compared to a melanocyte control. Of the PAK family of proteins, PAK1, PAK2 and PAK4 were 
overexpressed in melanoma cell lines (Chapter 4). These expression levels were subsequently 
compared to the previously characterised invasive potential (Chapter 3) to identify any 
correlations that may suggest a role for these proteins in melanoma invasion. 
PAK1overexpression correlated with melanoma cell line invadopodia formation capacity. A 
correlation with invadopodia capacity was also seen with PAK2, however this was a weaker, 
inverse correlation and thus PAK1 was chosen over PAK2 for further investigation of the group I 
PAKs. PAK4 showed a general overexpression in all melanoma cells. In line with these results, 
PAK1 and PAK4 were also found to be overexpressed in the patient derived cell strains that 
formed invadopodia. Thus, further exploration of the role of PAK1 and PAK4 in invadopodia was 
undertaken. Depletion of PAK1 and PAK4 protein expression in melanoma cell lines reduced the 
percentage of cells with invadopodia and the invadopodial induced matrix degradation, 
suggesting that both proteins are important in promoting invadopodia function (Section 4.2.4). 
The effect of PAK1 and PAK4 on the global invasive capacity was also confirmed in 
complementary 3D invasion and in vivo assays, which showed a reduction in melanoma invasion 
when both proteins were depleted (Chapter 4).  
PAK1 has been previously found to promote the cell invasion of colon cancer (Huynh et al., 2010) 
and breast cancer cell lines (Coniglio et al., 2008). Similarly, PAK4 promotes the cell invasion of 
choriocarcinoma (Zhang et al., 2011) and endometrial cancer (Lu et al., 2013). Moreover, in skin 
cancer specifically, PAK1 and PAK4 promote cell invasion of uveal melanoma (Pavey et al., 2006) 
and SCC (Zanivan et al., 2013) cell lines, respectively. Therefore, the data obtained from this 
study, is in line with that produced in other investigations. This provides key evidence that these 
two proteins are important in melanoma cell invasion and solidifies the data obtained in other 
studies which suggest that these proteins are globally important in cancer invasion.   
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This study suggests that both PAK1 and PAK4 play a role in melanoma invasion. But do these 
proteins function through the same pathway? The PAKs from group I and group II (including 
PAK1 and PAK4, respectively), are activated differently (King et al., 2014). However little is 
known about the unique signalling pathways or the substrates of these two groups and how 
these differences may impact on the effect that these proteins have on the invasive potential of 
tumours (Arias-Romero and Chernoff, 2008). Research into these potential differences could 
help guide the further development of therapeutic drugs. Currently, pharmaceutical companies 
are focused on developing group or isoform specific inhibitors (Viaud and Peterson, 2009; 
Murray et al., 2010; Zhang et al., 2012). Therefore, data indicating whether both groups 
contribute to invasion and metastasis in the same way, may determine whether the use of cross 
reactive inhibitors is more beneficial than isoform specific inhibitors in treating some cancers 
types. This study seeks to help address this question by identifying differences in PAK1 and PAK4 
(representing the group I and group II PAKs respectively) signalling pathways. Our findings 
revealed distinct functional roles for PAK1 and PAK4 in invadopodia, with PAK1 promoting the 
formation of this protrusion while PAK4 functions in the maturation and/or degradation stage 
of the invadopodial lifecycle (Figure 6-1).  
Our hypothesis (Figure 6-1) of a differential function is defined by our specific findings. Depletion 
of PAK1 reduced both the percentage of cells with invadopodia and also the matrix degradation 
for those cells that formed invadopodia (Section 4.2.4). In addition, reduction of PAK1 protein 
expression also reduced the number of nascent invadopodia actin puncta, suggesting an 
important role for this protein in the initial stages of the invadopodial lifecycle (Section 5.2.3). 
Together, our results indicate that PAK1 promotes the initial formation of invadopodia 
protrusions. Several investigations have been conducted into the function of PAK1 in the 
invadopodia-like protrusion, podosomes. Within these studies reduced PAK1 activity resulted in 
a decrease in podosome formation (Furmaniak-Kazmierczak et al., 2007) and increased PAK1 
expression enhanced the formation of this protrusion (Webb et al., 2005). However, while it is 
known that PAK1 localises to invadopodia (Moshfegh et al., 2014), recent findings have 
suggested several contradictory roles for PAK1 in invadopodia function. Some studies suggest 
that PAK1 is important for the formation of invadopodia - inhibition of endogenous PAK1 protein 
(using the PAK1 AID) reduced the formation of invadopodia in the A-375MM melanoma cell line, 
via the phosphorylation of cortactin at Ser113 (Ayala et al., 2008). In contrast a more recent study 
suggests that PAK1 (once again via the phosphorylation of cortactin at Ser113), promotes the 
disassembly of invadopodia protrusions, with a depletion of PAK1 resulting in an increase in 
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matrix degradation (Moshfegh et al., 2014). Therefore, this study strengthens the argument that 
PAK1 is important for the formation of invadopodia protrusions.  
In addition, PAK1 may also contribute to the maturation/degradation stage of the invadopodia 
lifecycle as the depletion of PAK1 also reduced matrix degradation (Section 4.2.4). This 
complements previous studies which suggest that PAK1 promotes MMP-9 expression (Goc et 
al., 2013)  and the secretion of MMP-1 and MMP-3 (Rider et al., 2013). 
 
 
Figure 6-1: Possible functions for PAK1 and PAK4 in the invadopodial lifecycle. 
PAK1 plays a role in the formation of nascent invadopodia. PAK1 and PAK4 both function in the 
maturation/degradation stage of the invadopodial lifecyle.  
 
Findings here suggest that PAK4 does not play a role in the initial stages of invadopodia 
formation, as a reduction in PAK4 protein expression did not reduce the formation of nascent 
invadopodial actin puncta (Section 5.2.3). This study does show for the first time that PAK4 
promotes invadopodia function and is likely to be important in invadopodial maturation and 
degradation (Figure 6-1). These claims are supported by the localisation of PAK4 to invadopodia 
(Section 5.2.12) and the fact that the depletion of PAK4 in melanoma cell lines resulted in a 
reduction in the percentage of cells with invadopodia and invadopodial induced matrix 
degradation (Section 4.2.4). In addition, the overexpression of GFPPAK4 in cells with depleted 
PAK1 expression rescued the matrix degradation capacity of those invadopodia that still formed, 
back to that seen by control cells, further suggesting an important role for PAK4 in invadopodia 
matrix degradation (Section 5.2.1). This complements previous studies in which PAK4 was found 
to promote the expression of proteases involved in matrix degradation such as MMP-2 (Siu et 
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al., 2010a; Kesanakurti et al., 2012) and MT1-MMP (Zhang et al., 2011). Our data is also in line 
with the role of PAK4 in podosomes, in which this kinase was shown to localise to podosomes 
as well as promote their function (Gringel et al., 2006; Wells and Jones, 2010).  
In addition to demonstrating that PAK1 and PAK4 promote invadopodial function, this study has 
identified a signalling pathway, unique to PAK4 (and not shared by PAK1), utilized during the 
invadopodia lifecycle in melanoma cells (Chapter 5). Our findings suggest that PAK4 (localised to 
invadopodia), inhibits the function of PDZ-RhoGEF (a Rho GEF) to promote the formation and 
degradation of invadopodia. This is unique to PAK4 as the binding and inhibition of PDZ-RhoGEF 
by PAK4 is not shared by PAK1 (Barac et al., 2004; Rosenfeldt et al., 2006). In addition, it is 
proposed that this pathway may signal via RhoA (Figure 6-2).  This study is the first time that the 




Figure 6-2: Unique PAK4 pathway in the function of invadopodia protrusions. 
PAK4, localised to the invadopodia protrusion, inhibits the function of PDZ-RhoGEF. This in turn prevents 
the activation of RhoA to promote invadopodial maturation and degradation. This may be through the 
inhibition of membrane contraction. Active RhoA may function in invadopodia to retract the protrusion 
during disassembly. Speculative pathways are labelled in red. PAK1 does not signal through PDZ-RhoGEF 
in invadopodia. It may function via the phosphorylation of cortactin or another substrate.  
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 The unique PAK4/PDZ-RhoGEF pathway was confirmed by the use of a dominant negative 
mutant of PDZ-RhoGEF which could bind, but not activate Rho (Hart et al., 1994; Driessens et 
al., 2002; Kasai et al., 2004). The expression of this mutant in cells with depleted PAK4 protein 
resulted in the rescue of invadopodia formation and degradation back to levels seen by wildtype 
cells (Section 5.2.10). Furthermore, the expression of wildtype PDZ-RhoGEF mimicked a PAK4 
depletion phenotype, reducing the percentage of cells with invadopodia and the invadopodial 
induced matrix degradation (Section 5.2.11). PDZ-RhoGEF, along with PAK4 was found to be 
localised to invadopodia supporting the suggestion that the proposed signalling pathway occurs 
within these protrusions (Section 5.2.12). This localisation also suggests that RhoA activation is 
likely required at some stage during the lifecycle of the protrusion (low levels of Rho activity in 
invadopodia can be easily achieved by the localisation of PDZ-RhoGEF away from the 
protrusion). 
This study proposes that RhoA is the GTPase downstream of the PAK4/PDZ-RhoGEF pathway, in 
invadopodia. Several findings support this proposal including the fact that PAK4 depleted cells 
had an increased RhoA activity while PAK1 depleted cells did not (Section 5.2.7). Furthermore 
PDZ-RhoGEF is known to be specific for Rho, with no binding to Cdc42 or Rac1, with this GEF 
preferentially activating RhoA, over RhoB and RhoC (Jaiswal et al., 2011).  
Investigations into the function of RhoA in invadopodia have yielded contradictory results. Some 
studies have suggested that reduced RhoA expression decreases invadopodia formation and 
degradation (Bravo-Cordero et al., 2011), while others have found no effect on invadopodia 
degradation when RhoA activation is inhibited or activated (Nakahara et al., 2003). However, 
work with podosomes have indicated that RhoA inactivation is required for podosome formation 
(Yu et al., 2013) and that the constitutive activation of this protein reduces podosome formation 
(Schramp et al., 2008; Yu et al., 2013). It has been suggested that a balance of RhoA activation 
and inactivation is important for podosome function with both the constitutive activation and 
reduction of RhoA activity resulting in reduced podosome degradation (Berdeaux et al., 2004). 
Our findings suggest that the same may be true for invadopodia function and provide additional 
evidence that the control of RhoA activity is important in invadopodia function.   
To date, the mechanism by which the PAK4/PDZ-RhoGEF/RhoA pathway functions in 
invadopodia is unknown. RhoA plays a key role in the actin cytoskeletal dynamics and 
actomyosin contractility which is important in the formation of protrusions such as invadopodia 
(Schoumacher et al., 2010; O'Connor and Chen, 2013). Therefore, one potential mechanism by 
174 
 
which the inhibition of RhoA brought about by the PAK4/PDZ-RhoGEF/RhoA pathway can 
function at invadopodia, is through a reduction in the contractile force exerted on the protrusion 
to allow for the extension of the membrane. Furthermore, with RhoA activation being important 
for focal adhesions (incorporation of stress fibres), which is often associated with invadopodia 
dissolution, RhoA inactivation at invadopodia may tip the balance away from focal adhesion 
formation to promote invadopodia formation. 
In conclusion, this study had provided evidence that PAK1 and PAK4 play an important role in 
melanoma cell invasion. In addition it has been demonstrated that these two isoforms have 
distinct pathways in invadopodia function, with PAK4 promoting maturation and/or degradation 
through the localised inhibition of PDZ-RhoGEF. Very crucially, this study suggests a potential 
key role for inhibitors that bind to, and thus block the function of, both the group I and group II 
PAKs, as a treatment for melanoma. One such candidate could be the PF-3758309 inhibitor, 
which has in vitro activity towards both PAK1 (~14nM) and PAK4 (~19nM) (Murray et al., 2010).  
Such inhibitors may reduce the metastasis of this cancer type, thus potentially improving patient 
prognosis.   
 
6.1 Future Work 
 
Based on the findings in this study, PAK1 and PAK4 both promote melanoma cell invasion. To 
further validate the role that these two proteins play in melanoma, staining (using 
immunohistochemistry) of primary and metastatic tissue samples could be performed and 
correlated with patient clinical outcomes. This would give insight into the prognostic 
implications that overexpression of these protein have in melanoma.   
There remains controversy over the function that PAK1 plays in invadopodia formation (Ayala 
et al., 2008; Moshfegh et al., 2014). Further experiments utilising the melanoma cell lines could 
be performed to investigate the effect of PAK1 depletion on cortactin phosphorylation at Ser113. 
Moreover, the use of a PAK1 biosensor, in conjunction with FRET and timelapse microscopy, 
could reveal the extent of PAK1 participation throughout the lifecycle of the invadopodia 
protrusion. This would help determine whether PAK1 activation is important during invadopodia 
formation, disassembly, or even both.  
This study found that PAK4 and PDZ-RhoGEF are localised to invadopodia and that PDZ-RhoGEF 
can rescue the formation and degradation of invadopodia in PAK4 knockdown cells, suggesting 
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an interaction between these proteins. To validate the requirement of RhoA, supplemental 
experiments can be performed, including the depletion of RhoA protein expression to 
investigate the effect on invadopodia function, as well as the quantification of RhoA activity 
through the invadopodia lifecycle using a RhoA biosensor with FRET and timelapse microscopy. 
The FRET experiments could also be performed with cells that have depleted PAK4 expression. 
In addition, the effect of PDZ-RhoGEF protein knockdown on invadopodia function could also 
provide valuable information to validate the role of PDZ-RhoGEF in the activity of this protrusion. 
A significant amount of the data generated in this study point to the importance of PAK4 in the 
maturation and degradation stage of the invadopodia lifecycle. This could be further explored 
by quantifying both the MMP expression levels and the secreted proteins (in cultured media) in 
melanoma cells that have PAK4 depletion, in cells that have expression of PDZ-RhoGEF∆DH in a 
PAK4 depleted background, and in cells overexpressing PDZ-RhoGEF. An investigation into 
whether the PAK4/PDZ-RhoGEF pathway also plays a central role in the 3D spheroid invasion 
assay would provide valuable confirmation as to the importance of this pathway in invasion. This 
can be done by depleting both PDZ-RhoGEF and PAK4 expression simultaneously (using siRNA 
oligonucleotide transfection) and investigating in a 3D spheroid assay, whether this can rescue 
the invasive phenotype of melanoma cells in which only PAK4 is depleted. 
Additional further work would certainly shed more light on, and increase our understanding of 
the signalling pathways involved in invadopodia formation and melanoma invasion. However, 
this current study offers key insights into the role of PAK1 and PAK4 in melanoma invasion and 
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